Beyond the Diagnosis: How Sub-phenotype Stratification is Unlocking New Genetic Insights in Endometriosis

Aaron Cooper Dec 02, 2025 216

Endometriosis is a complex, heterogeneous gynecological disorder whose genetic underpinnings have remained elusive in traditional genome-wide association studies (GWAS), which explain only a small fraction of heritability.

Beyond the Diagnosis: How Sub-phenotype Stratification is Unlocking New Genetic Insights in Endometriosis

Abstract

Endometriosis is a complex, heterogeneous gynecological disorder whose genetic underpinnings have remained elusive in traditional genome-wide association studies (GWAS), which explain only a small fraction of heritability. This article explores the paradigm shift towards sub-phenotype stratification as a powerful method to dissect this heterogeneity. We cover the foundational need for this approach, methodological advances in unsupervised clustering of electronic health records, challenges in data harmonization and cluster validation, and the validation of subtype-specific genetic associations. For researchers and drug development professionals, we synthesize how this refined strategy is enhancing the power of genetic analyses, revealing novel loci, identifying shared pathways with comorbidities, and paving the way for personalized diagnostic and therapeutic strategies.

The Imperative for Stratification: Unraveling Endometriosis Heterogeneity to Boost Genetic Discovery

Endometriosis, a chronic inflammatory condition affecting approximately 10% of reproductive-aged women, demonstrates a substantial heritable component estimated at 47% to 52% [1] [2]. Despite this strong genetic predisposition, traditional genome-wide association studies (GWAS) have explained only a small fraction of this heritability. The largest GWAS meta-analysis to date, encompassing 17,045 cases and 191,596 controls, identified 42 genomic loci associated with endometriosis risk, yet these collectively explain merely ~5% of disease variance [3] [4]. This significant disparity between the known heritability and the variance explained by GWAS-identified variants constitutes the "heritability gap," presenting a fundamental challenge in understanding endometriosis genetics and highlighting critical limitations in traditional approaches that treat endometriosis as a homogeneous entity [2] [5].

The clinical heterogeneity of endometriosis—with varying presentations in pain symptoms, infertility, lesion locations (peritoneal, ovarian endometriomas, deep infiltrating), and disease stages (rASRM I-IV)—strongly suggests diverse underlying genetic architectures masked by case-control study designs [5]. This whitepaper examines the technical limitations of traditional GWAS in endometriosis research, explores emerging methodologies centered on sub-phenotype stratification, and provides experimental frameworks to advance personalized therapeutic development.

Limitations of Traditional GWAS in Endometriosis

Methodological Constraints and Effect Size Challenges

Traditional GWAS methodologies face several inherent constraints in endometriosis research. The case-control paradigm typically aggregates all endometriosis cases regardless of clinical heterogeneity, potentially obscuring subtype-specific genetic signals. The polygenic architecture of endometriosis, characterized by numerous variants with small effect sizes, requires extremely large sample sizes to achieve statistical power for genome-wide significance (p < 5 × 10⁻⁸) [2] [4]. The table below summarizes key statistical challenges in traditional GWAS for endometriosis:

Table 1: Statistical Power Limitations in Endometriosis GWAS

Challenge Impact on Genetic Discovery Representative Evidence
Small Effect Sizes Odds ratios typically 1.1-1.3 per risk allele 42 identified SNPs have modest effects [4]
Multiple Testing Burden Stringent significance threshold (p < 5 × 10⁻⁸) reduces false positives but increases false negatives Initial GWAS yielded no significant hits [2]
Variant Frequency Bias Focus on common variants (MAF > 5%) misses rare variants with larger effects Rare variants in WES studies show promise [1]
Incomplete Linkage Tag SNPs may not capture causal variants due to population-specific LD patterns Limited transferability across ancestries [6]

Biological and Clinical Heterogeneity Unaddressed by GWAS

The clinical heterogeneity of endometriosis presents fundamental challenges for traditional GWAS designs. Studies consistently demonstrate that genetic associations are stronger for more severe disease stages. For instance, several loci (including CDKN2B-AS1/9p21.3) are implicated primarily in rASRM stage III/IV disease rather than minimal/mild forms [2] [5]. Similarly, distinct genetic associations emerge when comparing lesion subtypes: WT1 and CEP112 are exclusive to ovarian endometriomas, while GREB1, ABO, RNLS, and IGF1 are specific to deep infiltrating endometriosis [5].

The table below illustrates how sub-phenotype stratification reveals distinct genetic associations:

Table 2: Sub-Phenotype Specific Genetic Associations in Endometriosis

Sub-Phenotype Specific Genetic Associations Potential Biological Pathways
Gastrointestinal Pain rs185338542 (ACOT7), rs138188726 (PCDH7) Lipid metabolism, cell-cell adhesion [5]
Ovarian Endometriomas WT1, CEP112 Tumor suppression, ciliary function [5]
Deep Infiltrating Endometriosis GREB1, ABO, RNLS, IGF1 Hormone regulation, vascular function [5]
Advanced Stage (rASRM III/IV) CDKN2B-AS1, KDR, FN1 Cell cycle regulation, angiogenesis [5] [4]
Early Stage (rASRM I/II) Fewer specific loci identified Limited power in existing studies [7]

G cluster_0 Traditional GWAS Approach cluster_1 Sources of Heritability Gap GWAS GWAS Case-Control Design Case-Control Design GWAS->Case-Control Design Homogeneous Grouping Limitations Limitations Small Effect Sizes Small Effect Sizes Limitations->Small Effect Sizes Variant Interactions Variant Interactions Limitations->Variant Interactions Clinical Heterogeneity Clinical Heterogeneity Limitations->Clinical Heterogeneity Regulatory Mechanisms Regulatory Mechanisms Limitations->Regulatory Mechanisms 5% Variance Explained 5% Variance Explained Case-Control Design->5% Variance Explained Limited Resolution 5% Variance Explained->Limitations Stage I/II Stage I/II Clinical Heterogeneity->Stage I/II Masculated Signals Stage III/IV Stage III/IV Clinical Heterogeneity->Stage III/IV Stronger Signals Lesion Subtypes Lesion Subtypes Clinical Heterogeneity->Lesion Subtypes Distinct Genetics

Diagram 1: GWAS Limitations Creating Heritability Gap

Emerging Analytical Frameworks Beyond Traditional GWAS

Combinatorial Analytics for Variant Interactions

Novel analytical approaches are addressing GWAS limitations by examining multi-variant combinations rather than single markers. The PrecisionLife combinatorial analytics platform applied to UK Biobank data identified 1,709 disease signatures comprising 2,957 unique SNPs in combinations of 2-5 SNPs significantly associated with endometriosis risk [3]. This method demonstrated substantially improved reproducibility (58-88% in multi-ancestry validation) compared to traditional GWAS markers, with reproducibility rates reaching 80-88% for high-frequency signatures (>9% frequency) [3].

Combinatorial analysis revealed enrichment in biologically relevant pathways including cell adhesion, proliferation and migration, cytoskeleton remodeling, angiogenesis, fibrosis, and neuropathic pain [3]. Importantly, this approach identified 75 novel genes not previously associated with endometriosis in GWAS, providing new insights into disease mechanisms including autophagy and macrophage biology [3].

Functional Genomics and Regulatory Mechanisms

Functional genomics approaches address another GWAS limitation: the predominant location of associated variants in non-coding regulatory regions. Studies integrating expression quantitative trait loci (eQTL) data from GTEx and eQTLGen databases have identified target genes affected by endometriosis risk variants [8]. Research exploring regulatory variants, including those derived from ancient hominin introgression, has revealed enrichment of specific variants in genes including IL-6, CNR1, and IDO1 in endometriosis cohorts [7]. These regulatory variants frequently overlap with endocrine-disrupting chemical (EDC)-responsive regions, suggesting gene-environment interactions that modulate disease risk through immune and inflammatory pathways [7].

Table 3: Advanced Analytical Approaches Overcoming GWAS Limitations

Methodology Key Advantage Application in Endometriosis
Combinatorial Analytics Detects multi-SNP combinations with synergistic effects 1,709 disease signatures with 2,957 SNPs; 75 novel genes [3]
Functional Genomics Maps regulatory variants to target genes and pathways eQTL analysis links non-coding variants to IL-6, CNR1 [8] [7]
Mendelian Randomization Tests causal relationships between risk factors and disease Suggests causal link between endometriosis and rheumatoid arthritis [8]
Multi-Trait Analysis Increases power by leveraging genetic correlations Identified shared variants with osteoarthritis, rheumatoid arthritis [8]
Epigenomic Mapping Reveals regulatory mechanisms beyond DNA sequence Differential methylation patterns in endometriosis [6]

Sub-Phenotype Stratification: Path Forward for Genetic Research

Methodological Framework for Sub-Phenotype Studies

Robust sub-phenotype stratification requires standardized collection of detailed clinical data. The WERF Endometriosis Phenome and Biobanking Harmonization Project (EPHect) has developed global standards for data and sample collection, enabling meaningful sub-phenotype analyses across cohorts [2]. Key methodological considerations include:

  • Precise Phenotypic Characterization: Documenting specific pain patterns (dysmenorrhea, dyspareunia, gastrointestinal pain), infertility status, lesion characteristics (location, type, nerve infiltration), and disease stage using standardized classification systems [5] [6].

  • Stratified Analysis Plans: Pre-specifying subgroup analyses based on clinical features to maintain statistical rigor while exploring subtype-specific genetic architectures [5].

  • Multi-Omic Integration: Combining genomic data with transcriptomic, epigenomic, and proteomic profiles from lesion tissues and endometrium to understand functional consequences of genetic variants across subtypes [6].

G cluster_0 Stratification Dimensions cluster_1 Analytical Approaches cluster_2 Outcomes Start Endometriosis Cohort Stage Disease Stage (rASRM I/II vs III/IV) Start->Stage Symptoms Symptom Patterns (Pain, GI, Infertility) Start->Symptoms Lesions Lesion Subtypes (Ovarian, DIE, Peritoneal) Start->Lesions Comorbidity Comorbidity Profiles (Autoimmune, Pain) Start->Comorbidity Genetics Stratified Genetic Analysis Stage->Genetics Symptoms->Genetics Lesions->Genetics Comorbidity->Genetics Functional Functional Validation Genetics->Functional Pathways Pathway Enrichment Functional->Pathways Subtype Subtype-Specific Biomarkers Pathways->Subtype Targets Precision Therapeutic Targets Pathways->Targets Prediction Improved Risk Prediction Pathways->Prediction

Diagram 2: Sub-Phenotype Stratification Workflow

Sub-Phenotype Specific Genetic Associations

Recent studies implementing sub-phenotype stratification have revealed previously masked genetic associations. Analysis of an Italian cohort with comprehensive phenotypic data identified two SNPs—rs185338542 near ACOT7 and rs138188726 within PCDH7—that achieved genome-wide significance specifically in patients reporting gastrointestinal pain [5]. These findings implicate lipid metabolism (ACOT7) and cell-cell adhesion (PCDH7) pathways in specific symptomatic manifestations rather than general endometriosis risk [5].

Similarly, stratification by disease stage revealed that the KDR locus (encoding VEGFR2) retained significance across early and advanced disease, while CDKN2B-AS1 was implicated primarily in severe forms [5]. These patterns suggest distinct genetic architectures underlying different disease trajectories, with potential implications for targeted interventions.

Experimental Protocols and Research Applications

Protocol for Combinatorial Analytics in Endometriosis

The following protocol outlines the combinatorial analytics approach that has successfully identified novel genetic associations in endometriosis:

  • Cohort Selection and Quality Control

    • Utilize well-characterized cohorts with genomic and clinical data (e.g., UK Biobank, All of Us)
    • Apply standard QC filters: call rate >98%, Hardy-Weinberg equilibrium p > 1×10⁻⁶, relatedness filtering (pi-hat < 0.2)
    • Control for population stratification using principal components analysis

  • Combinatorial Analysis

    • Apply the PrecisionLife platform or similar combinatorial algorithms
    • Test all possible combinations of 2-5 SNPs across the genome
    • Calculate association statistics for each combination against endometriosis case-control status
    • Apply false discovery rate correction for multiple testing

  • Validation and Replication

    • Test significant combinations in independent, multi-ancestry cohorts
    • Assess reproducibility rates across populations
    • Validate associations in specific sub-phenotypes (e.g., stage III/IV disease)

  • Functional Annotation

    • Map significant SNPs to genes based on genomic position and regulatory annotations
    • Conduct pathway enrichment analysis (GO, KEGG, Reactome)
    • Integrate with functional genomic data (eQTLs, chromatin interactions) [3]

Protocol for Sub-Phenotype Stratification Analysis

  • Phenotypic Data Collection (following EPHect standards)

    • Surgical phenotype: lesion location, type, volume, rASRM stage
    • Pain phenotype: standardized questionnaires for dysmenorrhea, non-cyclical pain, dyspareunia, gastrointestinal symptoms
    • Infertility status: duration, type (primary/secondary)
    • Comorbidity profile: autoimmune conditions, pain disorders

  • Genotypic Data Processing

    • Genome-wide genotyping and imputation using reference panels (1000 Genomes, HRC)
    • Quality control: sample and variant-level filters
    • Population stratification adjustment using genetic principal components

  • Stratified Association Analysis

    • Perform GWAS in pre-specified sub-phenotype groups
    • Include appropriate covariates (age, genetic principal components)
    • Apply genome-wide significance threshold (p < 5 × 10⁻⁸)
    • Compare effect sizes across sub-phenotypes using meta-regression

  • Cross-Phenotype Comparison

    • Identify variants with heterogeneous effects across sub-phenotypes
    • Test for genetic correlation between sub-phenotypes using LD Score regression
    • Identify subtype-specific and shared genetic loci [5]

Research Reagent Solutions for Endometriosis Genetics

Table 4: Essential Research Reagents and Platforms for Advanced Endometriosis Genetics

Reagent/Platform Function Application in Endometriosis Research
PrecisionLife Combinatorial Analytics Identifies multi-SNP disease signatures Discovered 1,709 signatures with 2,957 SNPs; 75 novel genes [3]
EPHect Phenotyping Tools Standardized clinical data collection Enables cross-study sub-phenotype comparisons [2]
GTEx/eQTLGen Databases Maps regulatory variants to target genes Identified IL-6, CNR1 as target genes of risk variants [8] [7]
UK Biobank/All of Us Cohorts Large-scale genomic and health data Validation across diverse populations and ancestries [3] [8]
1000 Genomes Imputation Reference panel for genotype imputation Increases variant resolution for association testing [4]
LDlink/LDpop Tools Linkage disequilibrium analysis Determines population-specific variant correlations [7]

The heritability gap in endometriosis reflects fundamental limitations of traditional GWAS approaches that treat the condition as a single entity. Emerging methodologies centered on sub-phenotype stratification, combinatorial analytics, and functional genomics are rapidly closing this gap by revealing previously obscured genetic associations. These approaches have identified novel genes and pathways with compelling roles in endometriosis pathogenesis, including autophagy, macrophage biology, and neuropathic pain mechanisms [3].

The integration of detailed phenotypic data with advanced genomic analyses will enable precision medicine approaches in endometriosis, facilitating development of targeted therapies for specific patient subgroups and more accurate risk prediction models. Future research directions should include expanded diverse ancestry cohorts, multi-omic integration, and functional validation of identified genetic associations to translate these genetic insights into improved diagnostics and therapeutics for this complex condition.

Clinical heterogeneity represents a significant challenge in the understanding and treatment of endometriosis, a complex condition characterized by the presence of endometrial-like tissue outside the uterus. This heterogeneity manifests as varied symptom profiles, disease progression patterns, and associated comorbidities across different patient populations. Within the context of sub-phenotype stratification in endometriosis genetic research, delineating this clinical diversity is paramount for identifying biologically distinct disease subgroups. Such stratification enables more precise investigation of genetic underpinnings and facilitates the development of targeted therapeutic interventions. This technical guide examines the spectrum of clinical heterogeneity in endometriosis, with particular emphasis on comorbid immunological conditions, and provides methodologies for characterizing this diversity within research frameworks.

Phenotypic Landscape of Endometriosis Comorbidities

The Burden of Immunological Comorbidities

Recent large-scale studies have demonstrated that endometriosis patients face a significantly elevated risk for a spectrum of immunological diseases. A 2025 study of unprecedented scale conducted in the UK Biobank revealed substantial comorbidity patterns, analyzing over 8,000 endometriosis cases and 64,000 immunological disease cases [8] [9] [10]. The research investigated associations between endometriosis and 31 immune conditions categorized as classical autoimmune, autoinflammatory, and mixed-pattern diseases [9].

The findings demonstrated that women with endometriosis have a 30-80% increased risk of developing specific autoimmune and autoinflammatory conditions compared to the general population [10]. This risk elevation was consistent across both retrospective cohort and cross-sectional analyses, incorporating temporality between diagnoses to strengthen causal inference [8]. The most significantly associated conditions include rheumatoid arthritis, multiple sclerosis, coeliac disease, osteoarthritis, and psoriasis [8] [9] [10].

Table 1: Significant Immunological Comorbidities in Endometriosis Patients

Condition Category Specific Conditions Risk Increase Genetic Correlation (rg) P-value
Classical Autoimmune Rheumatoid Arthritis 30-80% 0.27 1.5 × 10⁻⁵
Classical Autoimmune Multiple Sclerosis 30-80% 0.09 4.00 × 10⁻³
Classical Autoimmune Coeliac Disease 30-80% Not Significant -
Autoinflammatory Osteoarthritis 30-80% 0.28 3.25 × 10⁻¹⁵
Mixed-pattern Psoriasis 30-80% Not Significant -

Methodological Framework for Phenotypic Association Analysis

Study Population and Diagnostic Ascertainment

The UK Biobank comprises approximately 500,000 individuals aged 40-69 at recruitment (2006-2010) from across the United Kingdom [9]. Comprehensive data collection included questionnaires on socioeconomic status, behavior, family history, and medical history, with ongoing follow-up for cause-specific morbidity and mortality through linkage to disease registries, death registries, hospital admission records, and primary care data [9]. The phenotypic analyses focused on female participants, with endometriosis cases (n=8,223) and immunological disease cases (n=64,620) identified through these data sources [8] [9].

Analytical Approaches

Two primary analytical approaches were employed to investigate phenotypic associations:

  • Retrospective Cohort Study Design: This approach incorporated temporality between diagnoses, establishing that endometriosis diagnosis preceded the development of immunological conditions, thereby strengthening potential causal inference [8] [9].
  • Cross-Sectional Analysis: This complementary approach assessed simple associations between endometriosis and immunological conditions without considering timing of diagnosis [8] [9].

Both methods demonstrated consistent findings, with significantly increased risks (30-80%) for classical autoimmune (rheumatoid arthritis, multiple sclerosis, coeliac disease), autoinflammatory (osteoarthritis), and mixed-pattern (psoriasis) diseases among endometriosis patients [8].

Genetic Architecture Underlying Clinical Heterogeneity

Genomic Investigations of Shared Etiology

Genome-Wide Association Studies (GWAS) and Meta-Analyses

To investigate the genetic basis of the observed phenotypic associations, researchers conducted female-specific genome-wide association studies (GWAS) for immunological conditions that showed significant phenotypic association with endometriosis [8] [9]. These studies were performed in both females-only and sex-combined study populations within the UK Biobank and were subsequently meta-analyzed with existing largest available GWAS results [9]. Sample sizes for these analyses ranged from 1,493 to 77,052 cases [8].

For endometriosis, a separate large-scale GWAS meta-analysis was conducted as part of the Global Biobank Meta-Analysis Initiative (GBMI), comprising over 900,000 women (44,125 cases) with 31% non-European samples across 14 biobanks worldwide [11]. This study employed six phenotype definitions, from wide endometriosis (including all available cases) to surgically-confirmed narrow endometriosis versus surgically-confirmed controls, allowing for varying levels of diagnostic certainty [11].

Genetic Correlation and Mendelian Randomization Analyses

Genetic correlation analyses quantified the shared genetic architecture between endometriosis and immunologic conditions using linkage disequilibrium score regression [8] [9]. These analyses revealed significant genetic correlations between endometriosis and osteoarthritis (rg = 0.28, P = 3.25 × 10⁻¹⁵), rheumatoid arthritis (rg = 0.27, P = 1.5 × 10⁻⁵), and multiple sclerosis (rg = 0.09, P = 4.00 × 10⁻³) [8].

Mendelian randomization (MR) analyses were employed to investigate potential causal relationships between endometriosis and immunologic conditions [8] [9]. This method uses genetic variants as instrumental variables to infer causality, minimizing confounding and reverse causation biases. The MR analysis suggested a potential causal association between endometriosis and rheumatoid arthritis (OR = 1.16, 95% CI = 1.02-1.33) [8] [10].

Multi-trait Analysis and Functional Annotation

For immune conditions with significant genetic correlation with endometriosis, multi-trait analysis of GWAS (MTAG) was employed to boost discovery of novel and shared genetic variants [9]. These shared variants were functionally annotated to identify affected genes utilizing expression quantitative trait loci (eQTL) data from GTEx and eQTLGen databases [8] [9]. Biological pathway enrichment analysis was conducted to identify shared underlying biological pathways [9].

Table 2: Shared Genetic Loci Between Endometriosis and Immunological Conditions

Shared Locus Genomic Position Associated Conditions Potential Functional Significance
BMPR2 2q33.1 Endometriosis, Osteoarthritis Bone Morphogenetic Protein Receptor Type 2
BSN 3p21.31 Endometriosis, Osteoarthritis Protein involved in neurotransmitter release
MLLT10 10p12.31 Endometriosis, Osteoarthritis Histone-lysine N-methyltransferase gene
XKR6 8p23.1 Endometriosis, Rheumatoid Arthritis XK-related protein 6

Experimental Protocol for Genetic Correlation Analysis

GWAS Meta-Analysis Protocol
  • Sample Collection and Genotyping: Utilize biobank resources with appropriate ethical approvals (e.g., UK Biobank Application Number 9637) [8].
  • Quality Control: Implement standard quality control procedures for genetic data, including checks for Hardy-Weinberg equilibrium, genotype missingness, and relatedness [9].
  • Association Testing: Perform GWAS for each trait separately using appropriate regression models, adjusting for principal components to account for population stratification.
  • Meta-Analysis: Combine summary statistics across multiple studies using fixed-effect or random-effect models, accounting for sample overlap.
Genetic Correlation Analysis Using LD Score Regression
  • Preparation of Summary Statistics: Process GWAS summary statistics to ensure compatibility with LD Score regression software.
  • LD Score Calculation: Compute linkage disequilibrium (LD) scores from a reference population matched to the study cohort.
  • Regression Analysis: Estimate genetic covariance between traits by regressing product of z-scores from the two GWAS on LD scores.
  • Significance Testing: Apply false discovery rate correction for multiple testing across all trait pairs analyzed.
Mendelian Randomization Protocol
  • Instrument Selection: Identify genetic variants associated with the exposure (endometriosis) at genome-wide significance (P < 5 × 10⁻⁸) that explain a sufficient proportion of variance (typically >5%) [8].
  • Validation of Assumptions: Ensure selected instruments satisfy MR assumptions: relevance (associated with exposure), independence (not confounded), and exclusion restriction (affects outcome only through exposure).
  • Effect Size Estimation: Apply two-sample MR using Wald ratio or inverse-variance weighted methods to estimate causal effect of exposure on outcome.
  • Sensitivity Analyses: Perform complementary analyses (MR-Egger, weighted median) to assess robustness to pleiotropy.

Biological Pathways and Sub-phenotype Stratification

Shared Molecular Mechanisms

Integrative multi-omics analyses of endometriosis have identified critical roles of immunopathogenesis, Wnt signaling, and the balance between proliferation, differentiation, and migration of endometrial cells as hallmarks for endometriosis [11]. These interconnected pathways and risk factors underscore a complex, multi-faceted etiology of endometriosis, suggesting multiple targets for precise and effective therapeutic interventions.

The eQTL analyses from the endometriosis-immunological disease study highlighted genes affected by shared risk variants, which were enriched for seven biological pathways across all four conditions (endometriosis, osteoarthritis, rheumatoid arthritis, and multiple sclerosis) [8]. While the specific pathways were not named in the search results, this finding indicates shared biological mechanisms underlying these comorbid conditions.

The proteome-wide association study (PWAS) from the multi-ancestry endometriosis study suggested significant association of R-spondin 3 (RSPO3) with wide endometriosis, which plays a crucial role in modulating the Wnt signaling pathway [11]. This pathway is involved in cell proliferation, differentiation, and migration processes relevant to both endometriosis and immunological conditions.

G cluster_pathways Key Shared Pathways GeneticRisk Genetic Risk Variants ImmuneDysregulation Immune System Dysregulation GeneticRisk->ImmuneDysregulation SharedPathways Shared Biological Pathways GeneticRisk->SharedPathways Endometriosis Endometriosis Phenotype ImmuneDysregulation->Endometriosis Comorbidities Immunological Comorbidities ImmuneDysregulation->Comorbidities SharedPathways->Endometriosis SharedPathways->Comorbidities WNT WNT Signaling SharedPathways->WNT Immunopath Immunopathogenesis SharedPathways->Immunopath CellBalance Cellular Proliferation/Differentiation SharedPathways->CellBalance

Figure 1: Biological Pathways Linking Endometriosis and Immune Comorbidities

Sub-phenotype Stratification Strategy

The clinical and genetic heterogeneity of endometriosis necessitates a sub-phenotype stratification approach to identify more homogeneous patient subgroups. This stratification can be based on:

  • Symptom Profiles: Pain characteristics (cyclic vs. constant), pain locations, gastrointestinal symptoms.
  • Disease Localization: Peritoneal, ovarian, deep infiltrating endometriosis.
  • Comorbidity Patterns: Presence or absence of specific immunological conditions.
  • Molecular Subtypes: Genetic risk scores, expression profiles, proteomic signatures.

G Start Heterogeneous Endometriosis Population Clinical Clinical Characterization: - Symptom profiles - Disease localization - Comorbidity patterns Start->Clinical Molecular Molecular Profiling: - Genetic risk variants - Gene expression - Protein biomarkers Start->Molecular Sub1 Sub-phenotype 1: High genetic risk for RA WNT pathway dominant Clinical->Sub1 Sub2 Sub-phenotype 2: High genetic risk for MS Immunopathogenesis dominant Clinical->Sub2 Sub3 Sub-phenotype 3: Low immune comorbidity risk Alternative pathways Clinical->Sub3 Molecular->Sub1 Molecular->Sub2 Molecular->Sub3 Research Targeted Research: - Pathway-specific mechanisms - Genetic studies Sub1->Research ClinicalApp Clinical Applications: - Personalized screening - Targeted therapies Sub1->ClinicalApp Sub2->Research Sub2->ClinicalApp Sub3->Research Sub3->ClinicalApp

Figure 2: Sub-phenotype Stratification Workflow for Endometriosis

Research Reagent Solutions for Endometriosis Heterogeneity Studies

Table 3: Essential Research Reagents for Endometriosis Heterogeneity Studies

Reagent/Category Specific Examples Function/Application
Genotyping Platforms UK Biobank Axiom Array, Global Screening Array Genome-wide genotyping for GWAS and polygenic risk score calculation
Bioinformatics Tools PLINK, FUMA, LD Score Regression Quality control, association testing, genetic correlation analysis
Multi-omics Databases GTEx, eQTLGen, GWAS Catalog Functional annotation of genetic variants using expression quantitative trait loci
Mendelian Randomization Software TwoSampleMR, MR-Base, MRPRESSO Performing causal inference analyses using genetic instruments
Pathway Analysis Tools Mergeomics, GARFIELD, MAGMA Biological pathway enrichment analysis for shared genetic mechanisms
Cell Type-Specific Resources Endometrial cell atlas, single-cell RNA-seq references Cell-type enrichment analysis for endometriosis risk variants

The comprehensive characterization of clinical heterogeneity in endometriosis, particularly the association with specific immunological comorbidities, provides a critical foundation for sub-phenotype stratification in genetic research. The significant genetic correlations between endometriosis and conditions such as osteoarthritis, rheumatoid arthritis, and multiple sclerosis suggest shared biological mechanisms that transcend traditional diagnostic boundaries. The integration of large-scale biobank data, advanced genomic methods, and multi-omics approaches has enabled the identification of specific genetic loci and biological pathways underlying these associations. These findings not only enhance our understanding of endometriosis pathophysiology but also open new avenues for therapeutic development, including drug repurposing opportunities across these conditions. For researchers and drug development professionals, these insights emphasize the importance of considering comorbidity profiles and molecular subtyping in both basic research and clinical trial design, ultimately paving the way for more personalized and effective management strategies for endometriosis patients.

The sub-phenotype hypothesis posits that dissecting heterogeneous diseases into clinically distinct subgroups reveals genetic mechanisms obscured in population-wide analyses. In endometriosis, a condition affecting 6-10% of reproductive-aged individuals with an estimated heritability of approximately 50%, this approach is transforming our understanding of disease etiology. Traditional genome-wide association studies (GWAS) have explained only a limited portion of disease variance, with the largest meta-analysis to date (N > 750,000) explaining just 5.01% of phenotypic variance. This comprehensive review synthesizes emerging evidence that unsupervised clustering of clinical phenotypes identifies biologically distinct endometriosis subtypes with unique genetic architectures, enabling more powerful genetic association analyses and paving the way for personalized diagnostic and therapeutic strategies.

Endometriosis represents a paradigmatic case for the sub-phenotype hypothesis, exhibiting profound clinical heterogeneity that has consistently complicated genetic analysis. The disease is characterized by the presence of endometrial-like tissue outside the uterus, primarily within the pelvis, and presents with diverse symptoms including chronic pelvic pain, infertility, dysmenorrhea, and multi-system comorbidities. This heterogeneity, combined with an average diagnostic delay of 7-11 years, has hampered both clinical management and genetic discovery [12].

The fundamental premise of the sub-phenotype hypothesis is that underlying clinical heterogeneity obscures discrete genetic mechanisms. While twin studies estimate endometriosis heritability at 47.5%, and common genetic variants account for 26% of phenotypic variance, traditional GWAS approaches have captured only a fraction of this heritability [13]. This discrepancy suggests that disease subtypes with distinct genetic architectures are being combined in analyses, diluting genetic signals and confounding biological interpretation.

Advanced computational approaches now enable data-driven identification of disease subtypes through unsupervised clustering of electronic health record (EHR) data, generating testable hypotheses about distinct genetic mechanisms underlying each sub-phenotype. This whitepaper examines the theoretical foundations, methodological approaches, and emerging genetic evidence supporting the sub-phenotype hypothesis in endometriosis research.

Unsupervised Clustering Reveals Distinct Endometriosis Sub-phenotypes

Identification of Clinical Sub-phenotypes

Recent research utilizing unsupervised machine learning on EHR data has demonstrated that endometriosis cases naturally cluster into distinct sub-phenotypes with characteristic clinical profiles. A landmark study analyzing 4,078 women with endometriosis identified five robust clusters using spectral clustering (K=5) [13]:

Table 1: Clinical Characteristics of Endometriosis Sub-phenotypes

Cluster Prevalence Defining Clinical Features Comorbid Pain Conditions
Cluster 1: Pain Comorbidities 11% (n=441) Dysuria (Z=8.9), abdominal pelvic pain (Z=13.6) Migraine (Z=10.6), IBS (Z=10.3), fibromyalgia (Z=15.3)
Cluster 2: Uterine Disorders 17% (n=686) Dysmenorrhea (Z=21.9), infertility (Z=5.0) Lower rates of pain comorbidities
Cluster 3: Pregnancy Complications 28% (n=1,151) Pregnancy-associated complications Distinct from other clusters
Cluster 4: Cardiometabolic Comorbidities 20% (n=796) Cardiometabolic conditions Specific metabolic features
Cluster 5: HER-Asymptomatic 25% (n=1,004) Minimal documented symptoms Limited comorbidity profile

These clusters demonstrate that endometriosis presents with distinct clinical patterns that may reflect underlying biological differences. Particularly noteworthy is Cluster 1, characterized by high rates of centralized pain conditions including migraines, irritable bowel syndrome (IBS), and fibromyalgia, suggesting potential shared mechanisms in pain processing [13].

Methodological Framework for Sub-phenotype Identification

The identification of robust sub-phenotypes requires careful methodological implementation. The following workflow illustrates the computational process for deriving and validating endometriosis sub-phenotypes:

G cluster_0 Feature Selection cluster_1 Algorithm Comparison EHR Data Extraction EHR Data Extraction Feature Selection Feature Selection EHR Data Extraction->Feature Selection Clustering Algorithm Testing Clustering Algorithm Testing Feature Selection->Clustering Algorithm Testing K-means K-means Feature Selection->K-means Spectral Clustering Spectral Clustering Feature Selection->Spectral Clustering Hierarchical Hierarchical Feature Selection->Hierarchical DBSCAN DBSCAN Feature Selection->DBSCAN Optimal Model Selection Optimal Model Selection Clustering Algorithm Testing->Optimal Model Selection Cluster Characterization Cluster Characterization Optimal Model Selection->Cluster Characterization Genetic Association Analysis Genetic Association Analysis Cluster Characterization->Genetic Association Analysis Demographics Demographics Symptoms Symptoms Comorbidities Comorbidities Surgical Findings Surgical Findings

Computational Workflow for Sub-phenotype Identification

The methodological approach involves several critical steps:

  • EHR Data Extraction and Curation: Comprehensive clinical data from multiple sites including demographics, symptoms, comorbidities, surgical findings, and medical history.

  • Feature Selection: Identification of clinically relevant features with prevalence >5% including pain symptoms, infertility, and specific comorbidities.

  • Clustering Algorithm Evaluation: Multiple unsupervised methods are tested including K-means, spectral clustering, hierarchical clustering, and DBSCAN, with evaluation metrics to select optimal approach.

  • Cluster Number Determination: Empirical testing of cluster numbers (K=2-20) using distortion curves and validation metrics to identify optimal separation.

  • Cluster Characterization: Statistical comparison of feature prevalence across clusters to define distinguishing clinical profiles.

Spectral clustering emerged as the optimal method for endometriosis sub-phenotyping, clearly indicating K=5 as the ideal cluster number with a local minimum in distortion curves, outperforming other methods in cluster coherence and clinical interpretability [13].

Genetic Associations Across Endometriosis Sub-phenotypes

Sub-phenotype-Specific Genetic Architecture

The critical test of the sub-phenotype hypothesis is whether clinically derived clusters demonstrate distinct genetic associations. Meta-analysis of 12,350 endometriosis cases across five biobanks revealed distinct genetic loci significantly associated with specific sub-phenotypes after Bonferroni correction [13]:

Table 2: Significant Genetic Associations by Endometriosis Sub-phenotype

Sub-phenotype Cluster Significant Locus Gene Function Potential Biological Mechanism
Cluster 1: Pain Comorbidities PDLIM5 Cytoskeletal organization, synaptic plasticity Pain processing, neural sensitization
Cluster 2: Uterine Disorders GREB1 Estrogen-regulated gene, uterine development Hormone response, reproductive tract development
Cluster 3: Pregnancy Complications WNT4 Female reproductive tract development Müllerian duct development, ovarian function
Cluster 4: Cardiometabolic Comorbidities RNLS Metabolic processing, oxidative stress Cardiometabolic pathways, inflammation
Cluster 5: HER-Asymptomatic ABO Blood group antigens, inflammation Inflammatory response, cellular adhesion

These findings demonstrate that distinct genetic mechanisms underlie clinically defined sub-phenotypes. For example, the association between PDLIM5 and the pain comorbidities cluster suggests specific genetic influences on pain processing pathways in this subgroup, while the GREB1 association with uterine disorders implicates estrogen-regulated developmental pathways [13].

Integration of Genetic and Epigenetic Data

Beyond genetic variation, epigenetic mechanisms including DNA methylation (DNAm) contribute substantially to endometriosis pathology. Recent research estimates that 15.4% of endometriosis variation is captured by DNA methylation profiles in endometrial tissue, with an additional 20.9% captured by common genetic variants, totaling 37% of variance explained by their combination [14].

DNA methylation quantitative trait locus (mQTL) analysis has identified 118,185 independent cis-mQTLs in endometrial tissue, including 51 associated with endometriosis risk. These findings provide functional links between genetic risk variants and epigenetic regulation of gene expression in endometriosis pathogenesis [14].

Menstrual cycle phase represents a major source of DNA methylation variation in endometrial tissue, accounting for significant differences in methylome profiles between proliferative and secretory phases. This cyclical epigenetic variation must be accounted for in sub-phenotype analyses to avoid confounding [14].

Methodological Framework for Sub-phenotype Genetic Analysis

Experimental Protocols for Sub-phenotype Stratification

Implementing robust sub-phenotype analysis requires standardized methodological approaches:

Protocol 1: Unsupervised Clustering of EHR Data

  • Data Source: Electronic Health Records from validated biobanks (UK Biobank, eMERGE, All of Us)
  • Feature Selection: 17+ clinical features with >5% prevalence including pain symptoms, infertility, comorbidities
  • Clustering Methods: Spectral clustering with K=5, validated against K-means, hierarchical clustering, DBSCAN
  • Validation: Z-score proportion tests for feature prevalence across clusters, chart review validation
  • Software: Python/R implementations with scikit-learn, clustering evaluation metrics (silhouette score, distortion curves)

Protocol 2: Genetic Association Analysis by Sub-phenotype

  • Sample Size: Minimum 1,000 cases per cluster for adequate power in meta-analysis
  • Genotyping: Genome-wide arrays with imputation to reference panels
  • Analysis: Association testing for 39 established endometriosis loci across sub-phenotypes
  • Meta-analysis: Fixed-effects models across multiple cohorts (PMBB, UKBB, BioVU, eMERGE, AOU)
  • Multiple Testing Correction: Bonferroni threshold for number of sub-phenotypes and tested loci

Protocol 3: Integrated Epigenetic Analysis

  • Tissue Collection: Eutopic endometrial biopsies with precise cycle phase dating
  • Methylation Profiling: Illumina Infinium MethylationEPIC BeadChip (850K CpG sites)
  • Quality Control: Probe filtering, batch effect correction, cell type composition estimation
  • Statistical Analysis: Linear models with surrogate variable analysis (SVA) for confounding
  • Integration: mQTL mapping combining genotype and methylation data

Research Reagent Solutions for Endometriosis Sub-phenotyping

Table 3: Essential Research Materials for Endometriosis Sub-phenotype Studies

Reagent/Category Specific Examples Research Application Technical Considerations
Genotyping Arrays Illumina Global Screening Array, Infinium Omni5 Genome-wide genotyping for GWAS Coverage of endometriosis risk loci, imputation quality
Methylation Profiling Illumina Infinium MethylationEPIC BeadChip Epigenome-wide methylation analysis Tissue-specific methylation patterns, cell type decomposition
Single-Cell RNA Sequencing 10x Genomics Chromium System Cellular heterogeneity in lesions Sample preservation, cell viability, marker gene identification
Bioinformatic Tools PLINK, METAL, Seurat, MOA Genetic association, meta-analysis, single-cell analysis Data harmonization across cohorts, batch effect correction
Cell Culture Models Endometrial stromal fibroblasts, epithelial organoids Functional validation of genetic hits Hormonal response characterization, microenvironment reconstitution

Implications for Drug Development and Personalized Medicine

Therapeutic Target Discovery Through Sub-phenotype Stratification

The sub-phenotype hypothesis has profound implications for therapeutic development in endometriosis. By identifying discrete molecular pathways associated with clinical subtypes, this approach enables targeted intervention strategies:

Pain-Specific Targets: The PDLIM5 locus associated with the pain comorbidities cluster represents a potential target for neuropathic pain components of endometriosis, distinct from anti-inflammatory approaches.

Hormone Pathway Targets: The GREB1 and WNT4 associations in uterine disorder and pregnancy complication clusters suggest opportunities for refined hormonal interventions targeting specific estrogen-response pathways.

Immune-Mediated Pathways: Genetic correlations between endometriosis and immune conditions including rheumatoid arthritis (rg = 0.27, P = 1.5 × 10⁻⁵) and multiple sclerosis (rg = 0.09, P = 4.00 × 10⁻³) reveal shared biological mechanisms that may be amenable to repurposed immunomodulatory therapies [8].

Diagnostic Biomarker Development

Sub-phenotype stratification enables development of precise diagnostic biomarkers targeting specific disease mechanisms:

Molecular Classification: Integration of genetic risk scores with DNA methylation signatures creates multidimensional classifiers that outperform single-modality approaches.

Symptom-Specific Biomarkers: Identification of biomarkers predictive of pain susceptibility or infertility risk within endometriosis populations enables targeted intervention.

Treatment Response Prediction: Sub-phenotype-specific genetic variants may predict response to hormonal therapies, surgical outcomes, or novel targeted agents.

Visualizing the Sub-phenotype Hypothesis Framework

The following diagram illustrates the integrated framework of the sub-phenotype hypothesis in endometriosis research:

G cluster_0 Input Data Types Clinical Heterogeneity Clinical Heterogeneity Unsupervised Clustering Unsupervised Clustering Clinical Heterogeneity->Unsupervised Clustering Distinct Sub-phenotypes Distinct Sub-phenotypes Unsupervised Clustering->Distinct Sub-phenotypes Genetic Association Analysis Genetic Association Analysis Distinct Sub-phenotypes->Genetic Association Analysis Subtype-Specific Loci Subtype-Specific Loci Genetic Association Analysis->Subtype-Specific Loci Functional Validation Functional Validation Subtype-Specific Loci->Functional Validation Precision Therapeutics Precision Therapeutics Functional Validation->Precision Therapeutics Genetic Architecture Genetic Architecture Genetic Architecture->Genetic Association Analysis Epigenetic Regulation Epigenetic Regulation Epigenetic Regulation->Functional Validation EHR Data EHR Data EHR Data->Clinical Heterogeneity Genomic Data Genomic Data Genomic Data->Genetic Architecture Epigenetic Data Epigenetic Data Epigenetic Data->Epigenetic Regulation Transcriptomic Data Transcriptomic Data

Integrated Sub-phenotype Research Framework

The sub-phenotype hypothesis represents a paradigm shift in endometriosis genetics, moving beyond one-size-fits-all approaches to embrace clinical and molecular heterogeneity. By integrating unsupervised clustering of clinical data with genetic and epigenetic analyses, this approach has revealed distinct disease mechanisms underlying clinically defined subgroups. The identification of sub-phenotype-specific genetic associations including PDLIM5 in pain-predominant endometriosis and GREB1 in uterine disorder-predominant disease provides compelling evidence for biologically distinct endometriosis subtypes.

Future research directions should include:

  • Prospective Validation: Multi-center prospective studies validating sub-phenotype classifications and their stability over time
  • Multi-omic Integration: Deep integration of genomic, epigenomic, transcriptomic, and proteomic data across sub-phenotypes
  • Drug Repurposing: Systematic screening of existing compounds against sub-phenotype-specific molecular targets
  • Clinical Translation: Development of diagnostic panels for sub-phenotype identification in clinical practice

The sub-phenotype hypothesis framework offers a powerful approach to dissecting complex heterogeneous diseases, with applications extending beyond endometriosis to other complex traits. By linking clinical patterns to distinct genetic mechanisms, this approach promises to accelerate therapeutic development and enable truly personalized medicine for endometriosis patients.

Endometriosis, a chronic systemic condition affecting 1 in 9 women of reproductive age, has historically been enigmatic in its etiology and clinical management [12] [15]. Traditionally viewed through a narrow gynecological lens, the disease is now understood to present a complex landscape of diverse comorbidities and heterogeneous sub-phenotypes [12]. The integration of large-scale genomic and electronic health record (EHR) data is revolutionizing this paradigm, moving the field toward a stratified medicine approach. This whitepaper synthesizes recent genetic and clinical evidence demonstrating that shared genetic architecture with immune, pain, and psychiatric conditions provides a powerful framework for sub-phenotype stratification. This is not merely a academic exercise; it is a crucial step for deconvoluting disease heterogeneity, identifying novel drug targets, and paving the way for personalized diagnostic and therapeutic strategies.

Epidemiological and Genetic Evidence of Comorbidities

Large-scale epidemiological and genetic studies have consistently identified a spectrum of conditions that co-occur with endometriosis at significantly higher rates than in the general population. These associations provide the initial clues for uncovering shared biological pathways.

  • Immune and Autoimmune Conditions: A landmark study in Human Reproduction analyzing over 8,000 endometriosis cases in the UK Biobank found that women with endometriosis have a 30-80% increased risk of developing specific immunological diseases [8] [16] [10]. These include classical autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS), and coeliac disease, as well as autoinflammatory conditions like osteoarthritis and psoriasis [8] [16]. Genetically, this relationship is underpinned by significant positive genetic correlations, most notably with osteoarthritis (rg = 0.28) and rheumatoid arthritis (rg = 0.27) [8]. Furthermore, Mendelian randomization analysis suggested a potential causal link from endometriosis to rheumatoid arthritis (OR = 1.16) [8] [10].

  • Pain-Related Conditions: Genomic analyses reveal substantial shared genetics between endometriosis and various chronic pain conditions [17] [15]. One analysis found significant genetic correlations with migraine, lower back pain, and multi-site chronic pain [17]. Crucially, this sharing is not just a general overlap; four specific genetic loci were found to be entirely shared between endometriosis, multi-site chronic pain, and migraine, pointing to direct pleiotropic biological mechanisms beyond the secondary effect of chronic pain from the disease itself [17].

  • Psychiatric Conditions: The long-observed comorbidity with psychiatric disorders is also partly rooted in shared genetics. A 2025 preprint integrating large-scale genomic data found that while genetic liability to endometriosis does not increase the risk of psychiatric conditions, the reverse relationship is significant [18]. Genetic liability to major depressive disorder (MDD) and related traits was associated with an increased risk of developing endometriosis. Polygenic analyses revealed that nearly all variants influencing endometriosis were also implicated in depression [18].

Table 1: Significant Genetic Correlations Between Endometriosis and Comorbid Conditions

Comorbidity Category Specific Conditions Key Genetic Findings Heritability (h²snp)/Correlation (rg)
Immunological Osteoarthritis, Rheumatoid Arthritis Positive genetic correlation; putative causal link with RA [8] [10]. OA: rg = 0.28; RA: rg = 0.27 [8]
Pain-Related Migraine, Multi-site Chronic Pain Significant genetic sharing; four shared pleiotropic loci [17] [15]. Significant positive correlations [17]
Psychiatric Major Depressive Disorder (MDD) Extensive shared genetic architecture; causal liability from MDD to endometriosis [18]. Variants largely overlapping [18]
Reproductive Polycystic Ovary Syndrome (PCOS) Positive genetic correlation; bidirectional causal relationship [19]. 12 shared pleiotropic loci identified [19]
Gastrointestinal Irritable Bowel Syndrome (IBS) Epidemiological and genomic overlap; significant genetic correlation [20] [15]. Listed among significant correlations [15]

Key Experimental Methodologies for Uncovering Shared Genetics

The insights into shared genetics are powered by a suite of sophisticated genomic and computational techniques. The following section details the core methodologies cited in recent studies.

  • Genome-Wide Association Study (GWAS) Meta-Analysis

    • Purpose: To boost statistical power for identifying common genetic variants (SNPs) associated with a trait by combining data from multiple cohorts.
    • Protocol: As performed in Shigesi et al. (2025) and Mortlock et al. (2023), this involves [8] [15]:
      • Cohort and Summary Statistics: Gather GWAS summary statistics from large-scale studies (e.g., Sapkota et al., FinnGen, UK Biobank).
      • Quality Control (QC): Filter SNPs for imputation quality (>0.9), minor allele frequency, and remove duplicates.
      • Meta-Analysis: Use an inverse variance-weighted fixed-effect model (e.g., in METAL software) to combine summary statistics across cohorts.
      • Significance Thresholding: Define genome-wide significant variants at p < 5 × 10⁻⁸ and clump SNPs in linkage disequilibrium (R² > 0.6) to identify independent loci.

  • Genetic Correlation and Heritability Estimation

    • Purpose: To quantify the shared genetic basis and the proportion of trait variance explained by common SNPs between two traits.
    • Protocol: Linkage Disequilibrium Score Regression (LDSC) is the standard tool [19] [15].
      • Input: GWAS summary statistics for endometriosis and the comorbid trait.
      • LD Score Reference: Use pre-computed LD scores from a reference panel (e.g., 1000 Genomes European subset).
      • Analysis: Regress the χ² statistics of SNP associations from the GWAS against the LD scores. The intercept estimates confounding (e.g., population stratification), and the slope informs the heritability and genetic covariance.
      • Output: Genetic correlation (rg) estimates, where |rg| > 0 indicates a shared genetic basis.

  • Mendelian Randomization (MR)

    • Purpose: To infer potential causal relationships between an exposure (e.g., endometriosis) and an outcome (e.g., rheumatoid arthritis) using genetic variants as instrumental variables.
    • Protocol: As applied to test the causality between endometriosis and immune conditions [8].
      • Instrument Selection: Select genome-wide significant SNPs from the exposure's GWAS as instruments.
      • Harmonization: Align the effect alleles and estimates for the instruments between the exposure and outcome GWAS datasets.
      • Effect Estimation: Apply MR methods (e.g., Inverse-Variance Weighted, MR-Egger) to estimate the causal effect of the exposure on the outcome.
      • Sensitivity Analysis: Perform tests (e.g., MR-Egger intercept, MR-PRESSO) to assess and correct for horizontal pleiotropy.

  • Colocalization Analysis

    • Purpose: To determine if two traits share a single causal genetic variant at a specific genomic locus, suggesting a common functional mechanism.
    • Protocol: Often performed with tools like GWAS-PW or COLOC [15].
      • Locus Definition: Divide the genome into independent regions based on LD structure.
      • Bayesian Testing: For each region, calculate the posterior probability for different hypotheses: no association, association with trait 1 only, association with trait 2 only, or association with both traits driven by a single shared variant.
      • Output: A posterior probability (e.g., PPA3 > 0.8) supporting the shared causal variant hypothesis for a given locus.

  • Polygenic Risk Score (PRS) Interaction Analysis

    • Purpose: To investigate the interplay between an individual's genetic liability for endometriosis (PRS) and the presence of diagnosed comorbidities.
    • Protocol: As conducted using UK and Estonian Biobank data [20].
      • PRS Calculation: Generate individual PRS using SBayesR or LDpred to weight and sum risk alleles from a discovery GWAS.
      • Comorbidity Burden: Quantify the number of comorbid diagnoses from EHRs (ICD-10 codes).
      • Statistical Modeling: Fit regression models to test for correlation between PRS and comorbidity burden, and for interaction effects between PRS and specific comorbidities on endometriosis risk.

The following workflow diagram illustrates how these key methodologies integrate to unravel shared genetic architecture.

G Start Phenotypic Observation (Comorbidity) GWAS GWAS Meta-Analysis Start->GWAS H2 Heritability & Genetic Correlation (LDSC) GWAS->H2 PRS Polygenic Risk Score & Interaction Analysis GWAS->PRS Summary Stats MR Causal Inference (Mendelian Randomization) H2->MR Coloc Variant-Level Sharing (Colocalization) H2->Coloc End Biological Insight & Sub-phenotype Definition MR->End Coloc->End PRS->End

Cut-edge research in this field relies on a specific set of data resources, analytical tools, and biological reagents. The table below details key components of the research toolkit as derived from the cited studies.

Table 2: Key Research Reagent Solutions for Genetic and Comorbidity Studies

Resource Category Specific Resource / Technology Function in Research Example Use Case
Biobanks & Data UK Biobank (UKB), Estonian Biobank (EstBB), FinnGen Provides large-scale, linked genotypic and phenotypic (EHR/ICD-10) data for association studies [8] [20] [15]. Phenotypic comorbidity search; GWAS; PRS calculation [20] [15].
GWAS Summary Statistics Public GWAS Catalogs; Sapkota et al. (2017) meta-analysis; FinnGen releases Serves as the foundational data for genetic correlation, MR, and PRS calculation [20] [19] [15]. LDSC analysis for genetic correlation with immune traits [8] [19].
Analytical Software LDSC, GCTA, METAL, PLINK, GWAS-PW, SBayesR Performs core computational genetics analyses (meta-analysis, heritability, PRS calculation, colocalization) [8] [20] [15]. Multivariate GWAS to identify variants for shared liability [18].
Functional Genomics Data GTEx, eQTLGen, Franke Lab Datasets Provides gene expression and eQTL data across tissues for functional annotation of risk loci [8] [19]. Annotating shared loci (e.g., BMPR2) to implicate specific genes and pathways [8].
Standardized Phenotyping WERF EPHect Tools Harmonizes surgical, clinical, and sample collection data across research centers for robust sub-phenotyping [17]. Enabling consortium-level analysis of deep phenotypes and subtypes [17].

From Shared Loci to Biological Pathways and Sub-phenotypes

The ultimate goal of identifying shared genetics is to illuminate biology and define clinically meaningful subgroups. Multivariate GWAS and functional annotation have begun to yield these insights.

  • Identified Shared Loci and Implicated Pathways: The integration of genetic findings with functional genomic data is pinpointing specific molecular mechanisms.

    • Immune-Endometriosis Overlap: Shared genetic loci between endometriosis and osteoarthritis include BMPR2/2q33.1, BSN/3p21.31, and MLLT10/10p12.31, while XKR6/8p23.1 is shared with rheumatoid arthritis [8]. Pathway enrichment analyses across endometriosis, osteoarthritis, and RA highlight the hyaluronic acid pathway—a key component of the extracellular matrix involved in cell proliferation and migration—as a key shared system [17].
    • Psychiatric-Endometriosis Overlap: A multivariate GWAS of endometriosis and depression identified 606 independent genome-wide significant variants contributing to the shared liability. This analysis strongly implicated brain-related mechanisms, suggesting the comorbidity arises from shared biological roots in neural biology rather than solely as a reaction to chronic pain [18].
    • PCOS-Endometriosis Overlap: Twelve significant pleiotropic loci have been identified between endometriosis and PCOS, with genetic associations particularly enriched in the uterus, endometrium, and fallopian tube. Genes like SYNE1 and DNM3 show altered expression in the endometrium of both conditions, pointing to shared defects in endometrial receptivity [19].

  • Informing Sub-phenotype Stratification: The patterns of comorbidity and their underlying genetics provide a data-driven basis for reclassifying endometriosis. Unsupervised clustering of EHR data from over 43,000 patients has revealed distinct patient subpopulations characterized by dominant comorbidity patterns, such as "autoimmune-prone" or "psychiatry-predominant" clusters [21]. This suggests that comorbidity profiles can serve as proxies for molecularly distinct subtypes. Furthermore, the interaction between polygenic risk and comorbidities is complex; the comorbidity burden is positively correlated with endometriosis PRS in women without endometriosis but negatively correlated in women with endometriosis [20]. This indicates that in diagnosed cases, a high burden of co-occurring conditions may represent a subtype where environmental or other non-genetic factors play a larger role.

The following diagram synthesizes how genetic and clinical data converge to define potential sub-phenotypes.

G Data Genetic & Clinical Data (Shared Loci, PRS, EHR) Cluster1 Proposed Sub-phenotype: Immune/Autoimmune Cluster Data->Cluster1 Shared pathways: Hyaluronic Acid, Immune Regulation Cluster2 Proposed Sub-phenotype: Chronic Pain Cluster Data->Cluster2 Shared loci with Migraine & Chronic Pain Cluster3 Proposed Sub-phenotype: Psychiatric Cluster Data->Cluster3 Shared variants with MDD, Brain-related pathways

The evidence for a shared genetic architecture between endometriosis and its comorbidities is now substantial and compelling. This paradigm shift moves beyond viewing comorbidities as mere consequences of the disease, instead reframing them as integral features of distinct biological sub-types. The implications for drug discovery and development are profound: shared pathways like the hyaluronic acid pathway offer opportunities for drug repurposing or the development of novel therapeutics that could simultaneously address endometriosis and a related spectrum of conditions [8] [17].

Future research must focus on deepening these insights. This includes using single-cell multi-omics on well-phenotyped lesions to map shared pathways to specific cell types, and integrating genetic data with deep clinical metadata in large, harmonized international consortia (e.g., the WERF EPHect initiative) to power the detection of robust sub-phenotypes [12] [17]. For researchers and drug developers, the path forward is clear: leveraging this shared genetic architecture is not just an option, but a necessity for deconvoluting the heterogeneity of endometriosis and delivering on the promise of precision medicine.

From Data to Subtypes: Methodologies for Phenotypic Clustering and Genetic Analysis

Endometriosis is a complex and heterogeneous gynecological condition affecting 10% of reproductive-age women globally, yet it often goes undiagnosed or misdiagnosed for several years (average of 4.5 years) [13]. The limited observed heritability (7%) in large genetic association studies of endometriosis may be attributable to underlying heterogeneity of disease mechanisms, obscuring stronger genetic signals that might exist within specific patient subgroups [13]. This heterogeneity manifests clinically through diverse symptoms including pelvic pain, infertility, fatigue, and various comorbidities, with surgical observation revealing different lesion types and locations [13].

Electronic Health Records (EHRs) represent a rich, underutilized data source for capturing the full phenotypic spectrum of endometriosis. EHRs contain multimodal data collected during clinical care, including diagnostic billing codes, procedure codes, vital signs, laboratory test results, clinical imaging, and physician notes [22]. With repeated clinic visits, these data provide longitudinal information on disease development, progression, and response to treatment. The near universal adoption of EHR systems nationally has created population-scale real-world clinical data resources accessible for biomedical research [22].

Unsupervised clustering of EHR data offers a powerful approach to dissect this clinical heterogeneity by systematically identifying distinct phenotypic clusters that may correspond to biological subtypes of endometriosis. This technical guide explores methodologies, applications, and implementation frameworks for leveraging unsupervised clustering of EHR data to identify clinically and genetically meaningful sub-phenotypes in endometriosis research.

Data Foundations and Preprocessing for EHR-Based Clustering

EHR Data Structure and Composition

Electronic Health Records contain both structured and unstructured data elements collected during clinical care. Structured data uses controlled vocabularies and includes International Classification of Disease (ICD) codes, medication records, laboratory values, and demographic information [22]. Unstructured data encompasses clinical free text, including physician notes, nursing assessments, and discharge summaries [22]. For endometriosis research, key data elements include:

  • Diagnostic Codes: ICD-based endometriosis diagnoses and related conditions
  • Procedure Codes: Surgical observations and treatments
  • Medication Records: Analgesics, hormonal treatments, and related prescriptions
  • Symptoms and Comorbidities: Pain complaints, infertility, gastrointestinal symptoms, and other concomitant conditions
  • Laboratory Values: Hormonal profiles, inflammatory markers
  • Clinical Notes: Unstructured descriptions of symptoms and disease impact

Feature Engineering for Endometriosis Sub-phenotyping

The Guare et al. study (2024) utilized 17 clinical features with prevalence >5% for unsupervised clustering of endometriosis patients, including known risk factors, symptoms, and concomitant conditions [13]. Feature selection should prioritize clinically meaningful variables with sufficient prevalence to support cluster identification.

Table 1: Essential Data Elements for Endometriosis Sub-phenotyping

Data Category Specific Elements Data Source Preprocessing Needs
Demographics Age at diagnosis, race/ethnicity Structured EHR Minimal transformation
Symptoms Pelvic pain, dysmenorrhea, dyspareunia, infertility Structured EHR, NLP from clinical notes Codification of symptom concepts
Comorbidities Migraine, IBS, fibromyalgia, asthma ICD codes, problem lists Grouping of related codes
Endometriosis Characteristics Location, lesion type, ASRM stage Surgical reports, pathology Structured data extraction
Treatments Surgical procedures, medications Procedure codes, pharmacy records Categorization of treatment types

Methodological Approaches to Unsupervised Clustering

Algorithm Selection and Comparison

Multiple clustering algorithms can be applied to EHR data, each with distinct strengths and limitations for patient stratification [23]. A recent comparative analysis evaluated eight clustering algorithms using multiple criteria including cluster quality metrics, scalability, robustness to noise, and interpretability [23].

Table 2: Clustering Algorithm Comparison for EHR Data

Algorithm Strengths Limitations Best Suited Data Characteristics
K-means Simple, efficient, works well with compact clusters Requires pre-specified K, sensitive to outliers Large datasets, spherical clusters
Spectral Clustering Effective for non-convex clusters, connects to graph theory Computationally intensive for large datasets Complex cluster structures, connected data
Hierarchical Clustering No need to specify K, provides cluster hierarchy Computational complexity O(n³) Small to medium datasets, hierarchical relationships
DBSCAN Discovers arbitrary shapes, robust to outliers Struggles with varying densities Data with noise, irregular clusters
Gaussian Mixture Models Soft clustering, probability-based May converge to local minima Gaussian-distributed data
Affinity Propagation Automatically determines cluster number Computational complexity O(n²) Medium-sized datasets, exemplar-based needs

In the endometriosis clustering study by Guare et al., researchers tested four methods (DBSCAN, hierarchical clustering, spectral clustering, and k-means) with cluster numbers from 2-20, ultimately selecting spectral clustering with K=5 as the optimal approach based on distortion curves and cluster interpretability [13].

Validation Framework for Cluster Solutions

Robust validation of clustering results requires multiple approaches:

  • Internal Validation: Silhouette index, Dunn index, distortion curves
  • Stability Analysis: Cluster consistency across bootstrap samples or data perturbations
  • Biological/Clinical Validation: Enrichment of clinical features across clusters, association with genetic variants, expert clinical review

The endometriosis study employed comprehensive chart reviews to characterize the clinical meaning of identified clusters and validate their clinical relevance [13].

EHR Data Extraction EHR Data Extraction Feature Engineering Feature Engineering EHR Data Extraction->Feature Engineering Algorithm Selection Algorithm Selection Feature Engineering->Algorithm Selection Cluster Validation Cluster Validation Algorithm Selection->Cluster Validation Biological Interpretation Biological Interpretation Cluster Validation->Biological Interpretation Genetic Association Analysis Genetic Association Analysis Biological Interpretation->Genetic Association Analysis

Clustering Workflow: This diagram illustrates the standard workflow for EHR-based sub-phenotype discovery.

Case Study: Endometriosis Sub-phenotypes from EHR Data

Cluster Derivation and Characterization

Guare et al. (2024) performed unsupervised clustering of 4,078 women with EHR-diagnosed endometriosis from the Penn Medicine BioBank (PMBB), identifying five distinct sub-phenotype clusters [13]:

  • Pain Comorbidities Cluster (11%): Characterized by significantly enriched rates of dysuria (Z=8.9), migraine (Z=10.6), irritable bowel syndrome (Z=10.3), fibromyalgia (Z=15.3), asthma (Z=10.3), abdominal pelvic pain (Z=13.6), and shortness of breath (Z=13.5)

  • Uterine Disorders Cluster (17%): Exhibited highest rates of dysmenorrhea (Z=21.9) and infertility (Z=5.1)

  • Pregnancy Complications Cluster (28%): Characterized by obstetric complications and related conditions

  • Cardiometabolic Comorbidities Cluster (20%): Marked by metabolic conditions and cardiovascular risk factors

  • EHR-Asymptomatic Cluster (25%): Patients with minimal documented symptoms despite endometriosis diagnosis

This clustering approach successfully captured the heterogeneous clinical presentation of endometriosis, revealing distinct patterns of symptoms and comorbidities that may reflect underlying biological differences [13].

Genetic Association Analysis Across Sub-phenotypes

The study performed genetic association analysis for each cluster with 39 endometriosis-associated loci across multiple biobanks (Total N = 12,350 cases, 466,261 controls) [13]. Results demonstrated distinct genetic associations across clusters:

  • PDLIM5 showed Bonferroni-significant association with the pain comorbidities cluster
  • GREB1 associated specifically with the uterine disorders cluster
  • WNT4 associated with the pregnancy complications cluster
  • RNLS associated with the cardiometabolic comorbidities cluster
  • ABO associated with the EHR-asymptomatic cluster

These differential genetic associations across clusters suggest complex and varied genetic mechanisms underlying different endometriosis presentations, demonstrating how sub-phenotyping can enhance genetic discovery power in heterogeneous conditions [13].

Pain Comorbidities Pain Comorbidities PDLIM5 PDLIM5 Pain Comorbidities->PDLIM5 Uterine Disorders Uterine Disorders GREB1 GREB1 Uterine Disorders->GREB1 Pregnancy Complications Pregnancy Complications WNT4 WNT4 Pregnancy Complications->WNT4 Cardiometabolic Cardiometabolic RNLS RNLS Cardiometabolic->RNLS EHR-Asymptomatic EHR-Asymptomatic ABO ABO EHR-Asymptomatic->ABO

Cluster-Gene Associations: This diagram shows the specific genetic associations identified for each endometriosis sub-phenotype cluster.

Advanced Methodological Innovations

Deep Learning Approaches for Longitudinal EHR Data

Recent advances in deep learning have enabled more sophisticated analysis of longitudinal EHR data. VaDeSC-EHR (Variational Deep Survival Clustering for EHR) implements a transformer-based variational autoencoder for clustering longitudinal survival data extracted from EHRs [24]. This approach:

  • Uses a transformer architecture to process diagnosis sequences
  • Incorporates a Gaussian mixture prior to enforce latent cluster structure
  • Jointly models cluster-specific diagnosis trajectories and survival outcomes
  • Demonstrates superior performance in identifying subgroups with divergent diagnosis trajectories and risk profiles [24]

In an application to Crohn's disease, VaDeSC-EHR successfully identified four distinct subgroups with clinically and genetically relevant differences, showcasing its potential for precision medicine applications [24].

Geometric Deep Learning for Phenotype Resolution

InfEHR represents another innovative approach that applies deep geometric learning to convert whole EHRs to temporal graphs that naturally capture phenotypic dynamics [25]. This framework:

  • Automatically extracts temporal graphs from individual EHRs
  • Uses self-supervised learning to create compact patient representations
  • Aggregates weak predictions from hundreds of graph components into refined likelihoods
  • Demonstrates superior performance for low-prevalence conditions like culture-negative sepsis [25]

Implementation Framework and Technical Considerations

Research Reagent Solutions

Table 3: Essential Research Tools for EHR-Based Clustering Studies

Tool Category Specific Solutions Function Implementation Considerations
Data Extraction EHR APIs, i2b2, SHRINE Structured data retrieval from clinical systems HIPAA compliance, data use agreements
NLP Processing cTAKES, CLAMP, MedLEE Unstructured text processing for symptom extraction Domain-specific customization, validation
Clustering Algorithms Scikit-learn, R Cluster, H2O.ai Implementation of clustering methods Scalability, reproducibility, parameter tuning
Genetic Analysis PLINK, SAIGE, REGENIE Association testing for cluster-genetic relationships Multiple testing correction, population stratification
Visualization ggplot2, Matplotlib, Tableau Cluster characterization and results communication Clinical interpretability, stakeholder engagement

Ethical and Regulatory Considerations

EHR-based research requires careful attention to:

  • Privacy Protection: De-identification, secure data environments, and limited dataset sharing
  • Informed Consent: IRB approval for secondary use of clinical data, sometimes with waiver of consent
  • Health Equity: Assessment of representation biases in EHR data and potential for algorithmic bias
  • Transparency: Clear documentation of clustering methodologies and limitations

The Guare et al. study received IRB approval and utilized data from multiple biobanks with appropriate governance frameworks [13].

Unsupervised clustering of EHR data represents a powerful approach for identifying clinically and biologically meaningful sub-phenotypes in endometriosis. The successful application of this methodology has demonstrated enhanced power for genetic association studies, revealing subtype-specific genetic mechanisms that were previously obscured in heterogeneous analyses [13].

Future directions in this field include:

  • Multi-omic Integration: Combining EHR data with genomic, transcriptomic, and proteomic data for deeper biological insights
  • Temporal Phenotyping: Modeling disease progression and trajectory-based subtypes using longitudinal EHR data [24]
  • Federated Learning: Enabling multi-institutional studies while preserving data privacy [23]
  • Clinical Translation: Developing decision support tools that implement sub-phenotyping in clinical practice

As EHR data continues to grow in breadth and depth, and analytical methods become increasingly sophisticated, sub-phenotyping approaches will play a crucial role in advancing precision medicine for endometriosis and other complex heterogeneous conditions.

Endometriosis is a prevalent, estrogen-dependent, inflammatory disease that affects approximately 10% of women of reproductive age globally and is associated with significant morbidity, including chronic pain and infertility [26]. The disease exhibits remarkable heterogeneity in its clinical presentation, with patients reporting diverse symptoms, comorbidity patterns, and treatment responses. This clinical variability, coupled with an average diagnostic delay of 7-10 years, has motivated researchers to move beyond traditional anatomical classification systems toward data-driven approaches that identify biologically meaningful patient subgroups [27] [28] [29]. Cluster characterization represents a transformative approach in endometriosis research, aiming to deconstruct this heterogeneity into discrete, mechanistically distinct sub-phenotypes based on multidimensional data, including pain characteristics, infertility profiles, and comorbid conditions.

The current limitations of existing classification systems (rASRM, ENZIAN, AAGL) are increasingly apparent, as they correlate poorly with symptom severity, pain experience, and therapeutic outcomes [27]. In contrast, cluster analysis based on comorbidity patterns and symptom profiles has revealed clinically relevant patient subgroups that may correspond to distinct underlying biological mechanisms [28]. This review comprehensively examines the methodologies, findings, and implications of cluster characterization in endometriosis, with particular emphasis on its crucial role in advancing genetic studies and therapeutic development.

Methodological Approaches to Cluster Analysis

Cluster characterization studies in endometriosis have utilized diverse data sources, each with distinct advantages and limitations. Electronic Health Records (EHRs) provide large-scale, real-world data on clinically diagnosed comorbidities and healthcare utilization patterns. One major study analyzed data from 4,055 women with endometriosis from the Spanish Primary Care Clinical Database, including comorbidities with a frequency >5% to ensure statistical robustness [28]. Patient-Generated Health Data (PGHD) collected through specialized mobile applications (e.g., the Phendo app) enables granular, longitudinal tracking of symptoms, quality of life measures, and treatment responses. One research initiative collected 776,855 observations from 4,368 participants, tracking variables including pain locations, gastrointestinal/genitourinary symptoms, medication use, and functional impact [30]. Genetic and Molecular Data from platforms like the PrecisionLife platform enable stratification based on combinations of single nucleotide polymorphisms (SNPs) mapped to biological pathways, identifying subgroups with shared genetic risk profiles [31].

Data preprocessing typically involves several critical steps: handling of missing data through imputation or exclusion criteria; normalization or standardization of variables to address differing measurement scales; feature selection to reduce dimensionality; and encoding of categorical variables for computational analysis. For comorbidity data, researchers often apply frequency thresholds (e.g., >5% prevalence) to focus on clinically relevant conditions while reducing analytical complexity [28].

Clustering Algorithms and Validation Methods

Multiple clustering approaches have been employed in endometriosis research, each with distinct theoretical foundations and practical considerations:

Table 1: Clustering Algorithms in Endometriosis Research

Algorithm Type Key Characteristics Applications in Endometriosis
Hierarchical Clustering (Ward's Method) Builds nested clusters through iterative merging or splitting; produces dendrogram visualization Comorbidity-based clustering; identifies groups of women with similar comorbidity patterns [28]
Mixed-Membership Models Allows data points to belong to multiple clusters simultaneously; accommodates multimodal data Symptom-based phenotyping from self-tracked data; models participants' responses across diverse variables [30]
K-means/Partitioning Around Medoids Partitional approach that divides data into non-overlapping clusters; requires pre-specification of cluster number Identification of symptom-based phenotypes from clinical records; works well with large sample sizes [29]
Bayesian Network Analysis Probabilistic graphical models that represent variables and their conditional dependencies Modeling complex relationships between symptoms and comorbidities; identifying central nodes in symptom networks [29]

Validation of clustering results employs both internal and external methods. Internal validation metrics include silhouette width (measuring cohesion and separation) and within-cluster sum of squares. External validation utilizes clinical expert assessment, comparison with standardized instruments (e.g., WERF EPHect survey), and evaluation of cluster stability through resampling techniques [30]. The robustness of identified clusters is further assessed by examining their association with demographic characteristics, healthcare utilization patterns, and treatment responses.

Visualizing Clustering Results

Effective visualization is crucial for interpreting and communicating clustering results. Dendrograms illustrate hierarchical relationships between clusters and inform decisions about the optimal number of clusters [28]. Heatmaps simultaneously display cluster assignments and variable values, facilitating pattern recognition across multiple dimensions. For computational implementations, the following workflow demonstrates a typical clustering analysis:

cluster_workflow cluster_data_sources Data Sources cluster_algorithms Clustering Algorithms DataSource Data Sources Preprocessing Data Preprocessing DataSource->Preprocessing Algorithm Clustering Algorithm Preprocessing->Algorithm Validation Cluster Validation Algorithm->Validation Interpretation Biological Interpretation Validation->Interpretation EHR EHR Data EHR->Preprocessing PGHD Patient-Generated Data PGHD->Preprocessing Genetic Genetic Data Genetic->Preprocessing Hierarchical Hierarchical Hierarchical->Algorithm MixedMember Mixed-Membership MixedMember->Algorithm Bayesian Bayesian Bayesian->Algorithm

Clinically Identified Endometriosis Clusters

Comorbidity-Based Clustering

Analysis of comorbidity patterns has revealed distinct endometriosis subgroups with potential implications for disease mechanisms and treatment approaches. A large-scale study of 4,055 women with endometriosis identified six stable comorbidity clusters using hierarchical clustering with Ward's method [28]:

Table 2: Comorbidity-Based Clusters in Endometriosis

Cluster Name Defining Comorbidities Additional Characteristics Potential Biological Mechanisms
Minimal Comorbidity Lower overall comorbidity burden - Possibly distinct etiology with limited systemic involvement
Anxiety & Musculoskeletal Anxiety, musculoskeletal disorders Higher prevalence of chronic pain conditions Altered pain processing; central sensitization; neuroimmune interactions
Type 1 Allergy / Immediate Hypersensitivity Asthma, chronic/allergic rhinitis, contact dermatitis/eczema Immune dysregulation profile Th2-mediated immune response; mast cell activation; shared genetic susceptibility
Multiple Morbidities Diverse comorbidity profile including metabolic, immune, and pain conditions Complex clinical presentation Potentially more severe systemic disease with multiple pathway involvement
Anemia & Infertility Anemia, infertility Gynecological and hematological focus Possibly related to heavier bleeding; iron deficiency; reproductive system focus
Headache & Migraine Headache, migraine Neurological involvement Central nervous system sensitization; neuroinflammatory mechanisms

These comorbidity clusters demonstrate the systemic nature of endometriosis and suggest distinct underlying pathophysiological processes. The identification of immune-mediated (Cluster 3), neurology-predominant (Cluster 6), and psychosomatic (Cluster 2) subgroups provides a foundation for developing targeted therapeutic strategies tailored to specific comorbidity profiles.

Symptom-Based Phenotyping from Patient-Generated Data

Digital phenotyping using mobile health applications has enabled fine-grained characterization of symptom patterns in endometriosis. Analysis of self-tracked data from the Phendo research app revealed several symptom-based phenotypes through mixed-membership modeling [30]:

The Pain-Dominant Phenotype characterized by severe, multifocal pain with significant functional impairment across daily activities. The Gastrointestinal-Dominant Phenotype featured prominent bloating, altered bowel habits, and other GI symptoms, often overlapping with irritable bowel syndrome. The Mixed Symptom Phenotype demonstrated diverse symptoms across multiple domains without clear predominance of any single symptom complex. The Minimal Symptom Phenotype reported milder symptoms with preserved functional capacity despite confirmed endometriosis diagnosis.

These digital phenotypes were validated against the gold-standard WERF EPHect clinical survey and demonstrated robust associations with quality of life measures and treatment utilization patterns. The findings highlight the value of patient-generated health data in capturing the real-world experience of endometriosis and identifying clinically meaningful subgroups that may benefit from tailored symptom management approaches.

Molecular Mechanisms and Genetic Insights

Pathophysiological Basis for Clusters

The clinically identified clusters correspond to distinct molecular mechanisms that drive endometriosis pathogenesis and its diverse manifestations. Several key pathways contribute to the observed clinical heterogeneity:

Hormonal Dysregulation: Estrogen dominance and progesterone resistance represent core features, with local estrogen synthesis in ectopic lesions driven by aromatase (CYP19A1) overexpression and reduced 17β-hydroxysteroid dehydrogenase type 2 activity. Epigenetic modifications, including hypomethylation of estrogen receptor β promoters, sustain this estrogen-driven phenotype [26]. The ERβ/ERα ratio is elevated in endometriotic cells, amplifying estrogen signaling. Progesterone resistance manifests as impaired progesterone receptor signaling despite bioavailable progesterone, attributed to promoter hypermethylation, microRNA dysregulation, and genetic polymorphisms that disrupt downstream signaling [26].

Immune System Dysfunction: Aberrant immune activation characterizes endometriosis, with macrophages constituting over 50% of immune cells in peritoneal fluid. Neuroimmune communication via calcitonin gene-related peptide promotes macrophage recruitment and phenotypic shifts toward a "pro-endometriosis" state. Natural killer cell cytotoxicity is severely compromised, enabling immune escape of ectopic cells, while T-cell subsets show dysregulation with increased Th2, Th17, and regulatory T cells in the peritoneal microenvironment [26].

Oxidative Stress and Ferroptosis: A pro-oxidative environment with increased oxidative stress particularly injures granulosa cells, alongside iron-driven ferroptosis. This oxidative environment negatively impacts oocyte development and endometrial function, potentially contributing to infertility-predominant clusters [26].

The relationship between these molecular mechanisms and clinical presentations can be visualized as follows:

mechanism_cluster Hormonal Hormonal Dysregulation (Estrogen dominance, progesterone resistance) PainCluster Pain-Dominant Phenotype Hormonal->PainCluster InfertilityCluster Infertility-Predominant Cluster Hormonal->InfertilityCluster Immune Immune Dysfunction (Macrophage polarization, NK cell impairment) GICluster GI-Dominant Phenotype Immune->GICluster ImmuneCluster Immune/Allergy Cluster Immune->ImmuneCluster Oxidative Oxidative Stress & Ferroptosis Oxidative->InfertilityCluster Genetic Genetic/Epigenetic Factors Genetic->PainCluster Genetic->ImmuneCluster Neurogenic • Neuroangiogenesis • Nociceptor sensitization PainCluster->Neurogenic Inflammation • Systemic inflammation • Cytokine dysregulation GICluster->Inflammation Microbiome • Gut microbiome • Estrogen metabolism GICluster->Microbiome ImmuneCluster->Inflammation

Genetic Stratification and Biomarker Discovery

Advanced analytical platforms have enabled genetic stratification of endometriosis, revealing subgroup-specific molecular signatures. The PrecisionLife platform has identified over 130 protein-coding genes strongly associated with endometriosis risk through analysis of combinations of SNPs that co-occur in patient subgroups [31]. These genes are involved in key biological processes including cell migration (many linked to cancer metastasis), cell adhesion, angiogenesis, and pro-inflammatory cytokine cascades. Several identified genes are estrogen-responsive and show differential expression in endometrial and ovarian cancers.

Notably, genetic analyses have revealed a glutamate receptor subunit involved in neuropathic pain amplification, potentially explaining the pain-predominant subtype in some patients [31]. This finding provides a genetic basis for the heterogeneous pain experience in endometriosis and suggests novel analgesic targets for specific patient subgroups. The EU Horizon 2020 FEMaLe project is building on these findings to develop higher-resolution stratification of endometriosis patient subgroups and elucidate genetic factors underlying specific disease phenotypes [31].

Research Reagents and Methodological Toolkit

Table 3: Essential Research Reagents and Platforms for Cluster Characterization

Category Specific Tool/Reagent Application in Cluster Research
Data Collection Platforms Phendo Mobile Application Captures patient-generated health data including symptoms, treatments, and quality of life measures [30]
Genetic Analysis Platforms PrecisionLife Platform Identifies combinations of SNPs associated with disease risk and stratifies patients based on genetic signatures [31]
Standardized Clinical Assessment WERF EPHect Survey Validated clinical questionnaire for endometriosis characterization; used for external validation of clusters [30]
Clustering Algorithms Ward's Hierarchical Method Identifies comorbidity clusters based on similarity measures; produces dendrogram visualization [28]
Mixed-Membership Models Extended Latent Dirichlet Allocation Models multimodal self-tracked data to identify symptom-based phenotypes [30]
Data Visualization HCL Wizard Color Schemes Creates accessible visualizations of clustering results; ensures color deficiency compatibility [32]

Implications for Therapeutic Development and Clinical Translation

The stratification of endometriosis into mechanistically distinct clusters has profound implications for drug development and personalized treatment approaches. Rather than pursuing one-size-fits-all therapies, researchers can now design targeted interventions for specific patient subgroups based on their underlying pathobiology.

For the immune/allergy cluster, therapies targeting specific immune pathways (e.g., Th2 polarization, mast cell stabilization) may prove more effective than broad anti-inflammatory approaches. The identification of a glutamate receptor subunit in pain amplification mechanisms suggests novel opportunities for targeting neuropathic pain in specific subgroups [31]. For patients with prominent progesterone resistance, strategies to overcome this resistance (e.g., epigenetic modulators, combination therapies) may restore endometrial receptivity and improve fertility outcomes [26].

Cluster-guided clinical trials represent a promising approach to demonstrating efficacy in biologically defined subgroups rather than heterogeneous patient populations. This precision medicine framework aligns with the multifactorial nature of endometriosis, where different molecular mechanisms predominate in different patients, contributing to the variable treatment responses observed in clinical practice [26] [28]. The integration of cluster-based stratification into clinical decision support tools may eventually enable clinicians to match patients with optimal treatments based on their specific symptom profile, comorbidity pattern, and genetic signature.

Cluster characterization based on pain patterns, infertility profiles, and comorbidities represents a paradigm shift in endometriosis research that directly addresses the profound heterogeneity of this condition. The identification of distinct patient subgroups through comorbidity analysis and symptom-based phenotyping provides a robust foundation for deconstructing endometriosis into mechanistically coherent entities. These advances, coupled with growing insights into the genetic architecture of endometriosis subgroups, are paving the way for precision medicine approaches that target specific molecular pathways in appropriately stratified patient populations.

Future research directions include the integration of multimodal data (genetic, clinical, imaging, and patient-reported outcomes) to refine cluster definitions; prospective validation of clusters in diverse patient populations; and the development of cluster-specific therapeutic strategies. As these efforts mature, cluster characterization promises to transform endometriosis from an enigmatic condition into a precisely understood disorder with personalized treatment pathways tailored to the individual patient's biological signature.

Endometriosis is a complex gynecological disorder affecting 6-10% of women of reproductive age, characterized by the presence of endometrial-like tissue outside the uterus and associated with debilitating pelvic pain and reduced fertility [33] [4]. Despite its substantial heritability (approximately 50%) and common variant-based heritability estimated at 26%, genome-wide association studies (GWAS) have explained only a limited fraction of this heritability [33] [13]. The largest endometriosis GWAS to date, comprising over 60,000 cases and 700,000 controls, identified 42 genome-wide significant loci but explained only about 5% of disease variance [33]. This gap between known heritability and explained genetic variance represents a critical challenge in elucidating the complete genetic architecture of endometriosis.

A promising strategy to address this challenge lies in accounting for the substantial phenotypic and genetic heterogeneity inherent in endometriosis. Traditional GWAS approaches treating endometriosis as a unified phenotype likely mask subtype-specific genetic effects, as different biological mechanisms may underlie distinct clinical presentations. Evidence for this heterogeneity comes from observations that genetic effect sizes are typically larger for more severe disease forms (rASRM stage III/IV) compared to minimal/mild disease (stage I/II) [33]. The sub-phenotype stratification approach enables researchers to dissect this heterogeneity by grouping cases into more etiologically homogeneous subsets, potentially increasing power to detect genetic variants with subtype-specific effects and providing insights into distinct biological mechanisms driving different disease manifestations.

Methodological Framework for Sub-Phenotype Analysis

Statistical Approaches for Genetic Association Testing in Clusters

The core analytical challenge in sub-phenotype analysis lies in maintaining statistical power while accounting for potential genetic heterogeneity across subgroups. Traditional methods that analyze each sub-phenotype separately against shared controls suffer from reduced power due to smaller sample sizes in each subgroup analysis. To address this limitation, multinomial regression-based association tests have been developed specifically for genetic studies with multiple case subgroups [34] [35].

This methodological framework models the log-odds of each case sub-phenotype relative to controls, allowing for heterogeneity in genetic effects between sub-phenotypes. The likelihood ratio test of association assesses whether any of the sub-phenotypes show evidence of association with the genetic variant, while a separate test of heterogeneity evaluates whether genetic effects differ significantly between sub-phenotypes [35]. Simulation studies demonstrate that this approach provides greater power to detect association in the presence of genuine heterogeneity compared to standard logistic regression, with minimal power loss when genetic effects are homogeneous across subtypes [35].

Cluster Derivation and Characterization Methods

Multiple approaches exist for deriving clinically meaningful sub-phenotypes in endometriosis research:

  • Unsupervised clustering of clinical features: This data-driven approach identifies homogeneous patient subgroups based on patterns of symptoms, comorbidities, and clinical presentations without pre-specified diagnostic categories. The spectral clustering algorithm applied to electronic health record data from 4,078 women with endometriosis revealed five distinct sub-phenotype clusters characterized by different patterns of pain comorbidities, uterine disorders, pregnancy complications, cardiometabolic comorbidities, and asymptomatic presentations [13].

  • Staging systems and anatomical classifications: The established revised American Society for Reproductive Medicine (rASRM) criteria categorizes endometriosis into stages I-IV based on surgical findings, with evidence supporting different genetic architectures across stages [33].

  • Symptom-based stratification: Grouping patients based on predominant symptom patterns (pelvic pain, infertility, or both) may capture biologically distinct subsets.

Table 1: Comparison of Sub-Phenotype Derivation Methods in Endometriosis Genetic Studies

Method Key Features Sample Requirements Genetic Validation
Unsupervised Clinical Clustering Data-driven, captures complex phenotype patterns Large clinical datasets with detailed phenotyping Cluster-specific genetic associations [13]
rASRM Staging Standardized surgical classification Surgically confirmed cases with staging documentation Stronger genetic effects in stages III/IV [33]
Symptom-Based Stratification Clinically accessible, may reflect different mechanisms Detailed symptom data Differential genetic correlations with pain conditions [33]

Experimental Protocols and Workflows

End-to-End Analytical Pipeline for Cluster-Based Genetic Association

Implementing a comprehensive cluster-based genetic association study requires a multi-stage analytical workflow that integrates clinical data processing, genetic data analysis, and statistical modeling.

G Clinical Data Collection Clinical Data Collection Phenotype Harmonization Phenotype Harmonization Clinical Data Collection->Phenotype Harmonization Cluster Derivation Cluster Derivation Phenotype Harmonization->Cluster Derivation Cluster Characterization Cluster Characterization Cluster Derivation->Cluster Characterization Genetic Data QC Genetic Data QC Cluster Characterization->Genetic Data QC Population Stratification Adjustment Population Stratification Adjustment Genetic Data QC->Population Stratification Adjustment Cluster-Specific GWAS Cluster-Specific GWAS Population Stratification Adjustment->Cluster-Specific GWAS Multinomial Association Testing Multinomial Association Testing Cluster-Specific GWAS->Multinomial Association Testing Variant Annotation Variant Annotation Multinomial Association Testing->Variant Annotation Functional Validation Functional Validation Variant Annotation->Functional Validation

Figure 1: Comprehensive workflow for cluster-based genetic association studies in endometriosis research, integrating clinical and genetic data analyses.

Protocol for Unsupervised Sub-Phenotype Derivation

The following detailed protocol outlines the process for deriving endometriosis sub-phenotypes using unsupervised clustering, based on established methodologies [13]:

  • Cohort Selection and Feature Definition

    • Select well-phenotyped endometriosis cases with comprehensive clinical data
    • Define input features including symptoms (pelvic pain, dysmenorrhea, dysuria), comorbidities (migraine, IBS, fibromyalgia, asthma), reproductive history (infertility, pregnancy complications), and surgical findings
    • Ensure features have sufficient prevalence (>5%) in the study population

  • Clustering Method Selection and Optimization

    • Test multiple clustering algorithms (k-means, spectral clustering, hierarchical clustering, DBSCAN)
    • Evaluate cluster numbers (typically K=2-20) using distortion curves, entropy, and goodness-of-fit indices (AIC, BIC, SSBIC)
    • Select optimal method based on cluster interpretability and statistical metrics

  • Cluster Characterization and Validation

    • Identify significantly enriched clinical features in each cluster using proportion tests (z-tests)
    • Validate clusters in independent datasets when available
    • Annotate clusters based on predominant clinical features

Application of this protocol to 4,078 endometriosis cases identified five distinct clusters: (1) pain comorbidities (11%), (2) uterine disorders (17%), (3) pregnancy complications (28%), (4) cardiometabolic comorbidities (20%), and (5) asymptomatic presentations (25%) [13].

Protocol for Cluster-Specific Genetic Association Analysis

Once sub-phenotypes are established, the following protocol enables powerful genetic association testing:

  • Genetic Data Quality Control and Preparation

    • Apply standard GWAS QC filters: call rate >98%, Hardy-Weinberg equilibrium p>1×10⁻⁶, minor allele frequency >1%
    • Impute genotypes using reference panels (1000 Genomes, HRC, or population-specific sequencing)
    • Adjust for population stratification using principal components analysis or genetic ancestry matching [36]

  • Multinomial Regression Association Testing

    • Code outcome variable with (K+1) categories: K case clusters + 1 control group
    • Fit multinomial regression model for each variant:

      where yi indicates phenotype (0=control, k=kth cluster), Gi is genotype, and X_i denotes covariates [35]
    • Include covariates: age, genotyping array, genetic principal components
    • Test global association (λk ≠ 0 for any k) and heterogeneity (λk varies across k)

  • Downstream Analysis and Interpretation

    • Annotate significant variants using functional genomic datasets (eQTL, mQTL, chromatin states)
    • Calculate cluster-specific heritability and genetic correlations
    • Perform pathway enrichment analysis for cluster-specific associations

Implementation in Endometriosis Research

Key Findings from Stratified Genetic Analyses in Endometriosis

Application of sub-phenotype stratification in endometriosis genetics has yielded important insights into the heterogeneous genetic architecture of the disorder:

Table 2: Subtype-Specific Genetic Associations in Endometriosis

Sub-Phenotype Key Genetic Findings Implicated Genes/Loci Biological Insights
rASRM Stage III/IV Larger genetic effect sizes, 8 genome-wide significant loci KDR/4q12, SYNE1/6q25.1, CDKN2B-AS1/9p21.3 [33] Distinct genetic architecture for severe disease
Pain-Predominant Association with pain-related genes SRP14/BMF, GDAP1, MLLT10, BSN, NGF [33] Shared genetic basis with other pain conditions
Immune-Related Comorbidities Genetic correlations with autoimmune diseases BMPR2/2q33.1, BSN/3p21.31, MLLT10/10p12.31 [8] Shared genetic basis with rheumatoid arthritis, osteoarthritis
Unsupervised Clusters Cluster-specific associations PDLIM5 (pain cluster), GREB1 (uterine disorders), WNT4 (pregnancy) [13] Different biological pathways across clinical presentations

The genetic differentiation between endometriosis stages is particularly striking, with lead SNPs at 38 of 42 genome-wide significant loci showing larger effect sizes in stage III/IV versus stage I/II disease, and six loci showing non-overlapping 95% confidence intervals [33]. This indicates that advanced stage endometriosis has a stronger genetic component and potentially distinct genetic architecture compared to minimal/mild disease.

Shared Genetic Architecture with Comorbid Conditions

Sub-phenotype stratification has also revealed important genetic relationships between endometriosis and frequently co-occurring conditions:

  • Pain Conditions: Multitrait genetic analyses have identified substantial sharing of variants associated with endometriosis and multisite chronic pain/migraine, with specific enrichment of genes involved in pain perception and maintenance (SRP14/BMF, GDAP1, MLLT10, BSN, NGF) [33].

  • Immune and Autoimmune Conditions: Women with endometriosis show 30-80% increased risk of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, coeliac disease, osteoarthritis, and psoriasis [8] [10]. Genetic correlation analyses reveal shared genetic basis between endometriosis and osteoarthritis (rg=0.28), rheumatoid arthritis (rg=0.27), and multiple sclerosis (rg=0.09) [8]. Mendelian randomization analyses further suggest a potential causal relationship between endometriosis and rheumatoid arthritis (OR=1.16) [8].

Successfully implementing cluster-based genetic association studies requires specialized methodological tools and analytical resources:

Table 3: Essential Research Reagents and Computational Tools for Cluster-Based Genetic Analysis

Resource Category Specific Tools/Datasets Key Applications Implementation Considerations
Clinical Data Platforms Electronic Health Records, UK Biobank, BioVU Phenotype extraction, cluster derivation Data harmonization across sites, ICD coding consistency
Genotyping Arrays Affymetrix GeneChip, Illumina Global Screening Array Genome-wide genotyping Coverage of endometriosis-relevant loci, imputation quality
Reference Panels 1000 Genomes, HRC, population-specific WGS Genotype imputation Ancestry matching, reference panel diversity
Analytical Software PLINK, METAL, FUMA, R mlogit GWAS, meta-analysis, functional annotation Multinomial regression implementation, multiple testing correction
Functional Genomics GTEx, eQTLGen, mQTL databases Variant functional annotation Tissue-specific effects (endometrium, ovaries)
Cluster Analysis Tools Mplus, R clustering packages Sub-phenotype derivation Method selection (spectral, k-means, hierarchical)

Interpretation Guidelines and Clinical Translation

Analytical Considerations for Interpreting Results

When interpreting results from cluster-based genetic association studies, researchers should consider several key analytical aspects:

  • Power and Sample Size Requirements: Cluster-specific analyses typically require larger initial sample sizes to maintain statistical power after stratification. Simulation studies suggest that multinomial regression approaches minimize power loss compared to separate analyses [35].

  • Multiple Testing Correction: Appropriate correction for multiple testing is essential when evaluating multiple clusters. While Bonferroni correction is conservative, false discovery rate control or hierarchical testing procedures may be more appropriate for dependent tests.

  • Genetic Correlation Interpretation: Significant genetic correlations between endometriosis clusters and other traits can indicate shared genetic architecture but do not necessarily imply causal relationships. Mendelian randomization and colocalization analyses can help distinguish shared etiology from causal effects.

Pathways to Clinical Translation

The insights gained from cluster-based genetic studies in endometriosis have several important clinical implications:

  • Improved Risk Prediction: Cluster-specific genetic risk scores may enable more precise prediction of disease progression and complication risks, moving beyond one-size-fits-all polygenic risk scores.

  • Drug Repurposing Opportunities: Shared genetic architecture with immune conditions like rheumatoid arthritis and osteoarthritis suggests potential for repurposing existing immunomodulatory therapies for specific endometriosis subtypes [8] [10].

  • Biomarker Discovery: Cluster-specific genetic associations can inform the development of subtype-specific diagnostic biomarkers, potentially reducing diagnostic delays that currently average 7 years from symptom onset [33].

The strategic implementation of genetic association tests within clinically defined clusters represents a powerful approach for dissecting the complex etiology of endometriosis. By acknowledging and systematically addressing the heterogeneity inherent in this condition, researchers can uncover subtype-specific genetic loci, elucidate distinct biological pathways, and ultimately pave the way for more targeted therapeutic interventions and personalized management approaches for women affected by this debilitating disorder.

The characterization of shared genetic architecture between endometriosis and related comorbidities provides a powerful framework for sub-phenotype stratification and therapeutic target discovery. This technical guide synthesizes recent multi-omic advances in annotating shared genetic variants and elucidating their functional consequences across biological pathways. We present comprehensive quantitative data, methodological protocols, and visualization tools to empower researchers investigating the genetic underpinnings of endometriosis heterogeneity. By integrating genome-wide association studies (GWAS) with expression quantitative trait loci (eQTL), methylation QTL (mQTL), and protein QTL (pQTL) data, we demonstrate how functional annotation reveals convergent biological mechanisms driving endometriosis pathogenesis and comorbidity.

Endometriosis affects approximately 5-10% of reproductive-aged women globally, with significant impacts on quality of life and fertility. The heritability of endometriosis is estimated at approximately 50%, with about half of this (26%) attributable to common genetic variants [17]. Beyond its gynecological manifestations, endometriosis demonstrates substantial genetic sharing with psychiatric, immunological, pain-related, and oncological conditions, suggesting shared biological pathways rather than merely symptomatic associations.

Recent large-scale genetic studies have revealed that the genetic liability to psychiatric conditions, particularly major depressive disorder, increases the risk of endometriosis, rather than the reverse relationship [18]. Similarly, profound genetic correlations exist between endometriosis and specific epithelial ovarian cancer histotypes (clear cell, endometrioid, and high-grade serous), with genetic correlations (rg) of 0.71, 0.48, and 0.19 respectively [37]. These shared genetic architectures provide unprecedented opportunities to identify key variants and pathways for functional characterization and sub-phenotype stratification.

Quantitative Landscape of Genetic Sharing

Table 1: Genetic Correlations Between Endometriosis and Comorbid Conditions

Category Condition Genetic Correlation (rg) P-value Shared Loci
Psychiatric Major Depressive Disorder Not specified <0.05 606 independent variants [18]
Immunological Osteoarthritis 0.28 3.25×10^-15 3 (BMPR2/2q33.1, BSN/3p21.31, MLLT10/10p12.31) [8]
Immunological Rheumatoid Arthritis 0.27 1.5×10^-5 1 (XKR6/8p23.1) [8]
Immunological Multiple Sclerosis 0.09 4.00×10^-3 Not specified [8]
Pain-Related Multi-site Chronic Pain Significant <0.05 4 fully shared loci [17]
Pain-Related Migraine Significant <0.05 4 fully shared loci [17]
Oncological Clear Cell Ovarian Cancer 0.71 <0.05 28 loci total across EOC histotypes [37]
Oncological Endometrioid Ovarian Cancer 0.48 <0.05 19 with shared underlying signal [37]
Oncological High-Grade Serous Ovarian Cancer 0.19 <0.05 Profound colocalization [37]

Table 2: Multi-omic QTL Associations in Endometriosis Pathogenesis

QTL Type Tissue Source Sample Size Significant Findings Key Genes/Proteins
mQTL (Methylation) Blood 1,980 individuals 196 CpG sites in 78 genes MAP3K5 with contrasting methylation patterns [38]
eQTL (Expression) Blood 31,684 individuals 18 eQTL-associated genes Validated in uterus tissue from GTEx [38]
pQTL (Protein) Blood 54,219 individuals 7 pQTL-associated proteins THRB and ENG validated as risk factors [38]
eQTL (Uterus) GTEx v8 838 donors, 52 tissues Tissue-specific expression Context-specific regulatory effects [38]

Methodological Framework for Variant Annotation

The SMR approach integrates data from GWAS, eQTLs, mQTLs, and pQTLs to assess causal associations between cell aging-related genes and endometriosis risk [38].

Experimental Protocol:

  • Data Acquisition: Obtain summary statistics from large-scale GWAS (e.g., 21,779 cases, 449,087 controls). Secure QTL data from eQTLGen (31,684 individuals), mQTL from European cohorts (1,980 individuals), and pQTL from UK Biobank (54,219 participants) [38].
  • Variant Selection: Identify top cis-QTLs within ±1000 kb window centered on corresponding genes using P-value threshold of 5.0×10^-8.
  • Allele Frequency Filtering: Exclude SNPs with allele frequency differences >0.2 between pairwise datasets.
  • SMR and HEIDI Tests: Apply SMR to evaluate associations between methylation, gene expression, and protein abundance with endometriosis. Use HEIDI test (P-HEIDI >0.05) to distinguish pleiotropy from linkage.
  • Colocalization Analysis: Implement using R package 'coloc' with posterior probability H4 >0.5 indicating shared causal variants.

G cluster_0 Data Acquisition cluster_1 Variant Processing cluster_2 Statistical Analysis GWAS GWAS Summary Statistics Filter Variant Filtering MAF > 0.2 GWAS->Filter eQTL eQTL Data eQTL->Filter mQTL mQTL Data mQTL->Filter pQTL pQTL Data pQTL->Filter Selection Top cis-QTL Selection ±1000 kb window P < 5.0×10⁻⁸ Filter->Selection SMR SMR Analysis Selection->SMR HEIDI HEIDI Test P-HEIDI > 0.05 SMR->HEIDI Coloc Colocalization Analysis PPH4 > 0.5 HEIDI->Coloc Results Annotated Shared Variants & Biological Pathways Coloc->Results

Functional Annotation of Shared Variants

Experimental Protocol for Functional Genomic Annotation:

  • Variant Annotation: Use ANNOVAR or similar tools to perform gene-based, region-based, and filter-based annotations. ANNOVAR can annotate a whole genome in under 4 minutes on standard hardware [39].
  • Regulatory Element Mapping: Utilize HaploReg to explore annotations of the noncoding genome at variants on haplotype blocks.
  • Pathway Enrichment Analysis: Implement GO and KEGG enrichment analysis via clusterProfiler R package (P<0.05, count≥1) [40].
  • Protein-Protein Interaction Networks: Construct PPI networks using STRING database and visualize with Cytoscape software [40].
  • Tissue-Specific Validation: Validate findings using eQTL data from GTEx database, particularly uterus tissue [38].

Key Shared Biological Pathways and Mechanisms

Oxidative Stress Pathways

Bioinformatic analysis of ectopic versus eutopic endometrium identified 459 differentially expressed genes, including 67 oxidative stress-related genes (OSRGs) [40]. Protein-protein interaction network analysis highlighted four key OSRGs (CYP17A1, NR3C1, ENO2, and NGF) with abnormal RNA and protein levels validated through RT-qPCR and Western blot in clinical samples.

Mechanistic Insight: Oxidative stress creates a pro-inflammatory environment through activation of NF-κB signaling pathway, upregulating ICAM-1 and inflammatory factors (IL-8, TGF-β) that promote endometriotic lesion establishment [40].

Cell Aging and Senescence Pathways

Multi-omic SMR analysis identified 196 CpG sites in 78 genes, 18 eQTL-associated genes, and 7 pQTL-associated proteins linked to cell aging and endometriosis [38]. The MAP3K5 gene displayed contrasting methylation patterns linked to endometriosis risk, while THRB gene and ENG protein were validated as risk factors in independent cohorts.

Mechanistic Insight: Senescent cells in endometriotic lesions exhibit increased expression of pro-inflammatory cytokines like IL-1β through the senescence-associated secretory phenotype (SASP), accelerating cellular aging and exacerbating endometriosis progression [38].

Immune-Mediated Inflammatory Pathways

Genetic correlation analyses reveal significant sharing with classical autoimmune (rheumatoid arthritis, multiple sclerosis, coeliac disease), autoinflammatory (osteoarthritis), and mixed-pattern (psoriasis) diseases [8]. Mendelian randomization suggests a causal association between endometriosis and rheumatoid arthritis (OR=1.16, 95% CI=1.02-1.33).

G OS Oxidative Stress NFkB NF-κB Pathway Activation OS->NFkB Aging Cellular Aging SASP SASP Inflammatory Phenotype Aging->SASP Genetic Genetic Variants Immune Immune Dysregulation Genetic->Immune Adhesion Enhanced Cell Adhesion NFkB->Adhesion Inflammation Chronic Inflammation & Pain NFkB->Inflammation Invasion Tissue Invasion & MMP Activation SASP->Invasion SASP->Inflammation Immune->Adhesion Immune->Inflammation Adhesion->Invasion

Multivariate GWAS identified 606 independent genome-wide significant variants contributing to shared liability between endometriosis and psychiatric conditions [18]. These variants implicate convergent biological pathways, particularly brain-related mechanisms, providing a foundation for understanding psychiatric comorbidity in endometriosis.

Research Reagent Solutions Toolkit

Table 3: Essential Research Tools for Variant Annotation and Functional Validation

Tool/Resource Type Function Application in Endometriosis Research
ANNOVAR/wANNOVAR [39] Variant Annotation Command-line and web-based variant functional annotation Rapid annotation of endometriosis-associated variants from sequencing studies
FunSeq [41] Variant Prioritization Scores and annotates disease-causing potential of non-coding SNVs Prioritize non-coding variants in endometriosis GWAS loci
SIFT & PolyPhen-2 [41] Effect Prediction Predicts impact of amino acid substitutions on protein function Assess functional consequences of coding variants in endometriosis candidate genes
GTEx Database [38] Tissue Expression Provides tissue-specific eQTL data Validate uterus-specific regulation of endometriosis risk variants
STRING [40] Network Analysis Constructs protein-protein interaction networks Identify functional modules from endometriosis GWAS hits
clusterProfiler [40] Pathway Analysis GO and KEGG enrichment analysis Pathway enrichment of shared genes across endometriosis comorbidities
HaploReg [41] Regulatory Annotation Explores annotations of noncoding variants Characterize regulatory potential of non-coding endometriosis risk variants
coloc R package [38] Statistical Colocalization Identifies shared causal variants across traits Test for shared causal variants between endometriosis and comorbidities

Implications for Sub-phenotype Stratification and Therapeutic Development

The annotation of shared genetic variants provides critical insights for sub-phenotype stratification in endometriosis. Genetic studies have revealed that approximately 50% of endometriosis risk is heritable, with about half of this attributable to common variants [17]. The identification of specific shared loci enables refined classification of patients based on their genetic predisposition to comorbidities, potentially guiding targeted therapeutic approaches.

The functional annotation of shared variants highlights promising therapeutic targets. The hyaluronic acid pathway, identified as shared between endometriosis and osteoarthritis, is currently being investigated as a treatment target for both conditions [17]. Similarly, the MAP3K5 gene, with its contrasting methylation patterns linked to endometriosis risk, represents another potential therapeutic target [38].

These advances in genetic annotation directly support drug development efforts, such as Hope Medicine's HMI-115 monoclonal antibody targeting the prolactin receptor, which has demonstrated significant pain reduction in endometriosis clinical trials [42]. The genetic validation of potential drug targets significantly increases the success rate of bringing new therapies to market [17].

The integration of multi-omic data for annotating shared genetic variants between endometriosis and its comorbidities represents a transformative approach to understanding disease heterogeneity. By moving beyond simple variant discovery to functional characterization across biological pathways, researchers can unlock the complexity of endometriosis sub-phenotypes and accelerate the development of targeted interventions. The methodologies, datasets, and analytical frameworks presented in this technical guide provide a foundation for advancing precision medicine in endometriosis research and improving patient stratification for future clinical trials.

Navigating Complexities: Challenges and Solutions in Sub-phenotype Research

Endometriosis, a complex and heterogeneous gynecological condition affecting an estimated 190 million women globally, presents significant challenges in disease management and therapeutic development [43]. The overwhelming phenotypic diversity and lack of standardized classification have consistently impeded research reproducibility and the identification of robust genetic associations. This technical review examines the critical data harmonization hurdles in endometriosis research and evaluates the transformative role of the World Endometriosis Research Foundation (WERF) Endometriosis Phenome and Biobanking Harmonisation Project (EPHect) in establishing global consensus protocols [44]. By implementing standardized phenotyping frameworks and experimental guidelines, EPHect has created the necessary infrastructure for large-scale collaborative studies, enhanced sub-phenotype stratification in genetic analyses, and accelerated the development of targeted diagnostic and therapeutic strategies.

The pathological heterogeneity of endometriosis has confounded research efforts for decades. The disease manifests with diverse symptomatic presentations, varied lesion appearances, and complex multisystemic involvement that poorly correlate with surgical findings [43]. This heterogeneity, combined with the absence of standardized data collection methods across research centers, has created significant data harmonization challenges that undermine study reproducibility, meta-analyses, and the discovery of consistent genetic associations.

Traditional diagnostic strategies have primarily considered patients presenting with typical symptoms, often overlooking women with atypical or distant manifestations [13]. The average diagnostic delay of 4.5-7.5 years further complicates phenotypic characterization [13] [31]. The WERF EPHect initiative emerged as a coordinated international response to these challenges, developing consensus-based tools to standardize data collection, biobanking, and experimental methodologies across the global research community [44].

Core Data Harmonization Frameworks in Endometriosis Research

The EPHect Standardization Framework

The EPHect collaboration, originally involving 34 academic institutions and three medical/diagnostic companies, has developed a comprehensive suite of standardized tools to facilitate cross-center epidemiological research [44]. The project's four foundational components provide an integrated framework for harmonizing endometriosis research:

  • Standardized Clinical Phenotyping: Detailed instruments for collecting clinical and personal phenome data from women with endometriosis and controls to improve patient and disease characterization
  • Biobanking SOPs: Standard Operating Procedures for banking biological samples with respect to collection, transport, processing, and long-term storage
  • Physical Examination Assessment: Standardized tools for physical examination assessment
  • Experimental Model SOPs: Standardized protocols for using experimental models in endometriosis research, including heterologous, homologous, pain, and organoid models [44]

Critical Variables in Experimental Model Harmonization

For heterologous mouse models of endometriosis, the WERF working group identified nine critical variables requiring standardization to improve reproducibility and comparability of results between laboratories [43]. The table below summarizes these key variables and their harmonization considerations:

Table 1: Critical Variables for Harmonizing Heterologous Endometriosis Models

Variable Category Harmonization Considerations Impact on Experimental Outcomes
Mouse Strain Hsd:Athymic Nude-Foxn1nu, CB17/IcrHanHsd-Prkdcscid, NOD-SCID, Rag2γ(c) Varying degrees of immunodeficiency affect human tissue engraftment and immune response studies
Human Tissue Type Eutopic endometrium with/without endometriosis; endometriotic lesions Differential engraftment capacity and disease representation
Donor Hormonal Status Menstrual cycle phase, hormone therapy Alters tissue receptivity and lesion establishment potential
Tissue Preparation Mechanical dissociation, enzymatic digestion, fragment size Affects tissue viability and lesion development efficiency
Engraftment Method & Location Subcutaneous vs. intraperitoneal; surgical vs. injection Influences lesion microenvironment and vascularization
Recipient Hormonal Status Ovariectomized with/without hormone replacement Modulates lesion survival and inflammatory environment
Immune System Humanization Engraftment with human immune cells Enables study of human-specific immune responses
Endpoint Assessments Lesion number, size, histology, vascularization, nerve infiltration Standardizes quantification of disease burden and pathology
Replication Strategy Number of replicates, technical vs. biological replicates Affects statistical power and experimental robustness

Sub-Phenotype Stratification in Genetic Studies

Unsupervised Clustering Reveals Distinct Sub-Phenotypes

Recent approaches leveraging Electronic Health Record (EHR) data and unsupervised machine learning have demonstrated the power of phenotypic clustering to identify biologically relevant endometriosis subtypes. A 2024 study analyzed 4,078 women with EHR-diagnosed endometriosis using 17 clinical features to derive five distinct sub-phenotype clusters [13]:

  • Pain Comorbidities Cluster: Characterized by dysuria, migraine, IBS, fibromyalgia, asthma, abdominal pelvic pain, and shortness of breath
  • Uterine Disorders Cluster: Dominated by dysmenorrhea and infertility
  • Pregnancy Complications Cluster
  • Cardiometabolic Comorbidities Cluster
  • HER-Asymptomatic Cluster [13]

This data-driven approach to sub-phenotyping provides a robust framework for stratifying genetic analyses, moving beyond the limitations of traditional classification systems based solely on surgical appearance.

Genetic Associations Across Sub-Phenotypes

When genetic association analyses were performed for each cluster against 39 known endometriosis-associated loci, distinct patterns emerged, revealing sub-phenotype-specific genetic architectures [13]. The table below summarizes the significant genetic associations identified for each cluster:

Table 2: Sub-Phenotype Specific Genetic Associations in Endometriosis

Cluster Key Genetic Loci Potential Biological Mechanisms
Pain Comorbidities PDLIM5 Pain signaling amplification, neuropathic pain pathways
Uterine Disorders GREB1 Hormone response, endometrial growth regulation
Pregnancy Complications WNT4 Reproductive tract development, hormone signaling
Cardiometabolic RNLS Metabolic regulation, cardiovascular function
HER-Asymptomatic ABO Blood group antigens, inflammatory response

These findings demonstrate that underlying clinical heterogeneity obscures genetic mechanisms, and that sub-phenotype stratification can uncover previously hidden genetic associations [13]. The variance in endometriosis captured by genetic data alone is limited, with the largest GWAS to date explaining only 7% of phenotypic variance despite twin studies estimating heritability at 47.5% [13].

Epigenetic Regulation in Endometriosis Pathogenesis

DNA methylation (DNAm) studies provide additional insights into endometriosis disease mechanisms. Analysis of endometrial samples from 984 participants revealed that 15.4% of the variation in endometriosis is captured by DNAm profiles, with significant differences associated with stage III/IV disease, sub-phenotypes, and menstrual cycle phase [14]. The integration of genetic and epigenetic data explains a substantially greater proportion of disease variance, with 37% of variance in case-control status captured by a combination of common genetic variants (20.9%) and endometrial DNAm (16.1%) [14].

DNAm quantitative trait locus (mQTL) analysis identified 118,185 independent cis-mQTLs, including 51 associated with endometriosis risk, highlighting candidate genes contributing to disease pathogenesis through epigenetic mechanisms [14].

Methodological Protocols for Advanced Endometriosis Research

Standardized Workflow for Heterologous Mouse Models

The WERF working group established detailed SOPs for heterologous mouse models of endometriosis to ensure experimental reproducibility [43]. The following diagram illustrates the standardized workflow:

G Start Start: Study Design MouseStrain Select Immunocompromised Mouse Strain Start->MouseStrain TissueProc Human Endometrial Tissue Preparation & Processing MouseStrain->TissueProc HormonalPrep Recipient Hormonal Preparation TissueProc->HormonalPrep Engraftment Tissue Engraftment (Location & Method) HormonalPrep->Engraftment Monitoring Post-Operative Monitoring & Hormonal Manipulation Engraftment->Monitoring Endpoint Endpoint Assessment (Lesion Analysis) Monitoring->Endpoint DataColl Standardized Data Collection Endpoint->DataColl

Integrated Genetic Sub-Phenotyping Pipeline

The identification of endometriosis sub-phenotypes involves a multi-step analytical process that integrates clinical and genetic data. The following workflow illustrates this pipeline:

G DataSource Multi-Source EHR Data Collection FeatureSel Clinical Feature Selection (Prevalence >5%) DataSource->FeatureSel ClusterAlgo Unsupervised Clustering (Spectral Clustering, K=5) FeatureSel->ClusterAlgo CharClusters Cluster Characterization & Validation ClusterAlgo->CharClusters GeneticData Genetic Association Analysis by Cluster CharClusters->GeneticData Pathway Pathway Enrichment Analysis GeneticData->Pathway

Essential Research Reagents and Materials

The implementation of standardized endometriosis research requires specific reagents and materials to ensure experimental consistency and reproducibility. The following table details key research solutions and their applications:

Table 3: Essential Research Reagents for Endometriosis Studies

Reagent/Material Function/Application Specifications
Immunocompromised Mouse Strains Host for human tissue engraftment CB17/IcrHanHsd-Prkdcscid, NOD-SCID, Rag2γ(c) for immune cell co-engraftment studies
Hormonal Formulations Cycle synchronization, tissue preparation 17β-estradiol, medroxyprogesterone acetate for standardized hormonal manipulation
Tissue Dissociation Reagents Endometrial tissue processing Collagenase, DNase for stromal cell isolation; mechanical dissociation for tissue fragments
Human Immune Cells Humanized mouse models Peripheral blood mononuclear cells (PBMCs) from endometriosis patients vs. controls
DNA Methylation Arrays Epigenetic profiling Illumina Infinium MethylationEPIC BeadChip (850K sites) for genome-wide DNAm analysis
Genotyping Platforms Genetic association studies Genome-wide SNP arrays for mQTL and eQTL mapping
Cell Lineage Markers Cell-type specific analysis Antibodies for stromal (CD10), epithelial (E-cadherin), immune cell profiling

Discussion and Future Directions

The implementation of standardized phenotyping through the WERF EPHect project represents a paradigm shift in endometriosis research methodology. By addressing critical data harmonization hurdles, these protocols enable large-scale collaborative studies with sufficient statistical power to dissect the complex architecture of this heterogeneous disease [43] [44]. The integration of detailed phenotypic data with genetic and epigenetic profiling has already demonstrated enhanced ability to identify subtype-specific disease mechanisms [13] [14].

Future research directions will likely focus on refining sub-phenotype classifications through multi-omics integration, developing non-invasive diagnostic biomarkers based on stratified patient profiles, and designing targeted clinical trials for specific endometriosis subgroups. The continued evolution and global adoption of harmonized research protocols will be essential to realizing the promise of precision medicine in endometriosis care.

The WERF EPHect tools are designed for periodic review and refinement, with updates planned every three years based on user feedback and technological advancements [44]. This commitment to continuous improvement ensures that endometriosis research methodologies remain at the forefront of scientific innovation while maintaining the standardized frameworks necessary for cumulative knowledge advancement.

Endometriosis is a complex and heterogeneous gynecological condition affecting 10% of reproductive-age women, yet it often goes undiagnosed for years due to its varied clinical presentation [13]. The limited observed heritability (7%) in large genetic association studies is partly attributable to this underlying heterogeneity, which obscures disease mechanisms [13]. Sub-phenotype stratification through clustering analysis has emerged as a powerful approach to dissect this complexity, enabling researchers to identify clinically relevant subgroups with potentially distinct genetic architectures. By systematically grouping patients based on shared clinical features, symptoms, and concomitant conditions, clustering techniques facilitate the discovery of more homogeneous patient subgroups, thereby enhancing the power of subsequent genetic analyses [13] [45]. This technical guide provides comprehensive methodologies for selecting, implementing, and validating clustering algorithms specifically tailored for endometriosis research, with emphasis on determining the optimal cluster number and interpreting results in the context of genetic study design.

Clustering Algorithms: Methodologies and Mechanisms

Cluster analysis refers to a family of algorithms and tasks aimed at partitioning a set of objects into groups (clusters) such that objects within the same group exhibit greater similarity to one another than to those in other groups [46]. It is a main task of exploratory data analysis and a common technique for statistical data analysis, used in many fields including bioinformatics and medical research [46]. Clustering algorithms can be broadly categorized based on their underlying cluster models:

  • Centroid-based models: Represent each cluster by a single mean vector (e.g., K-means) [46] [47]
  • Connectivity-based models: Build clusters based on distance connectivity (e.g., hierarchical clustering) [46]
  • Distribution-based models: Model clusters using statistical distributions (e.g., Gaussian mixture models) [46]
  • Density-based models: Define clusters as connected dense regions in the data space (e.g., DBSCAN) [46]
  • Graph-based models: Represent clusters as cliques or quasi-cliques in a graph structure [46]

Algorithm Selection for Endometriosis Sub-phenotyping

Selecting an appropriate clustering algorithm is crucial for meaningful sub-phenotype identification in endometriosis research. The table below summarizes key algorithms and their suitability for clinical and genetic data:

Table 1: Clustering Algorithms and Their Applications in Endometriosis Research

Algorithm Key Parameters Scalability Use Case in Endometriosis Geometry (Metric Used)
K-means [47] Number of clusters (k) Very large nsamples, medium nclusters General-purpose, even cluster size, flat geometry Distances between points
Spectral Clustering [13] [47] Number of clusters, affinity matrix Medium nsamples, small nclusters Few clusters, even size, non-flat geometry Graph distance
Hierarchical Clustering [46] [47] Number of clusters or distance threshold, linkage type Large nsamples and nclusters Many clusters, connectivity constraints Any pairwise distance
DBSCAN [47] Neighborhood size, minimum samples Very large nsamples, medium nclusters Non-flat geometry, uneven cluster sizes, outlier removal Distances between nearest points
Gaussian Mixture Models [47] Number of components, covariance type Not scalable with n_samples Flat geometry, density estimation Mahalanobis distances to centers

In endometriosis research, spectral clustering has been successfully applied to identify sub-phenotypes, as it effectively captured non-convex cluster shapes in clinical data [13]. The algorithm constructs an affinity matrix based on patient similarity, then performs dimensionality reduction before clustering, making it suitable for the high-dimensional clinical data common in electronic health records (EHR) studies.

Experimental Protocol: K-means Clustering Implementation

K-means is among the most widely used clustering algorithms due to its simplicity and efficiency [47]. The standard algorithm consists of three main steps:

  • Initialization: Choose initial cluster centers, typically using k-means++ initialization to improve convergence [47]
  • Assignment: Assign each data point to its nearest cluster center using Euclidean distance
  • Update: Compute new cluster centers as the mean of all points assigned to each previous centroid

The algorithm iterates between steps 2 and 3 until centroids move less than a specified tolerance value [47]. For endometriosis data preprocessing, categorical clinical variables should be appropriately encoded, and continuous variables standardized to ensure equal weighting in distance calculations.

Determining the Optimal Number of Clusters

Cluster Validation Indices and Methodologies

Determining the correct number of clusters (k) is a fundamental challenge in cluster analysis. Cluster validation indices provide quantitative measures to evaluate clustering quality and select optimal k [48]. These indices are broadly categorized as:

  • Internal validation indices: Evaluate clustering quality based on the intrinsic structure of the data without external labels [48]
  • External validation indices: Compare clustering results to externally provided class labels [48]
  • Relative validation indices: Compare multiple clusterings to select the best one [48]

For endometriosis sub-phenotyping where true labels are typically unavailable, internal validation indices are particularly important. Researchers commonly employ an iterative process, applying multiple clustering algorithms across a range of k values and comparing validation metrics to identify the most robust partitioning.

Table 2: Key Internal Validation Indices for Endometriosis Sub-phenotyping

Validation Index Optimal Value Calculation Basis Strengths Limitations
Silhouette Coefficient [47] [48] Maximize Mean intra-cluster distance vs. mean nearest-cluster distance Intuitive range [-1, 1], works with any distance metric Favors convex clusters, performance decreases with high dimensionality
Calinski-Harabasz Index [48] Maximize Ratio between between-cluster and within-cluster dispersion Computationally efficient Tends to favor larger numbers of clusters with some datasets
Davies-Bouldin Index [48] Minimize Average similarity between each cluster and its most similar one Simplicity of calculation and interpretation Sensitive to data distribution and cluster overlap
Dunn Index [48] Maximize Ratio between minimal inter-cluster distance and maximal intra-cluster distance Simple interpretation, sensitive to noisy data Computationally expensive for large datasets

Empirical Selection Protocol for Cluster Number

A comprehensive approach to determining cluster number involves multiple validation techniques. In endometriosis research, Vallée et al. utilized the cubic classification criterion (CCC) to estimate the number of clusters using Ward's minimum variance method [45]. A recommended protocol includes:

  • Define k range: Test a reasonable range of k values (e.g., 2-10 for initial exploration)
  • Apply multiple algorithms: Run different clustering algorithms across the k range
  • Calculate validation indices: Compute multiple internal validation indices for each k
  • Identify consensus: Look for k values where multiple indices show optimal or near-optimal values
  • Clinical validation: Ensure clusters correspond to clinically meaningful subgroups

In a recent endometriosis study, researchers tested four clustering methods with k values from 2-20, using three metrics to empirically choose both method and optimal k [13]. They eliminated DBSCAN due to excessive complexity (131 clusters), then selected spectral clustering with k=5 based on a clear "elbow" in the distortion curve that indicated an optimal value [13].

Application in Endometriosis Genetic Research

Endometriosis Sub-phenotyping Workflow

The following diagram illustrates the comprehensive workflow for sub-phenotype identification in endometriosis research:

endometriosis_workflow cluster_0 Unsupervised Clustering Phase cluster_1 Downstream Analysis Clinical Data Collection Clinical Data Collection Feature Selection Feature Selection Clinical Data Collection->Feature Selection EHR Data (Symptoms, Comorbidities) EHR Data (Symptoms, Comorbidities) Clinical Data Collection->EHR Data (Symptoms, Comorbidities) Data Preprocessing Data Preprocessing Feature Selection->Data Preprocessing 17 Clinical Features 17 Clinical Features Feature Selection->17 Clinical Features Algorithm Selection Algorithm Selection Data Preprocessing->Algorithm Selection Cluster Validation Cluster Validation Algorithm Selection->Cluster Validation Spectral Clustering (K=5) Spectral Clustering (K=5) Algorithm Selection->Spectral Clustering (K=5) Biological Interpretation Biological Interpretation Cluster Validation->Biological Interpretation Internal Validation Indices Internal Validation Indices Cluster Validation->Internal Validation Indices Genetic Association Genetic Association Biological Interpretation->Genetic Association 5 Sub-phenotype Clusters 5 Sub-phenotype Clusters Biological Interpretation->5 Sub-phenotype Clusters Cluster-Specific Genetic Loci Cluster-Specific Genetic Loci Genetic Association->Cluster-Specific Genetic Loci

Case Study: Endometriosis Sub-phenotyping and Genetic Discovery

A recent study demonstrated the power of clustering for genetic discovery in endometriosis [13]. Researchers performed unsupervised clustering of 4,078 women with EHR-diagnosed endometriosis based on 17 clinical features including symptoms and comorbidities. Through systematic evaluation of clustering methods and cluster numbers, they identified five distinct sub-phenotype clusters:

  • Pain comorbidities (11%): Characterized by dysuria, migraine, IBS, fibromyalgia, asthma, abdominal pelvic pain, and shortness of breath
  • Uterine disorders (17%): Distinguished by dysmenorrhea, infertility, and uterine fibroids
  • Pregnancy complications (28%): Defined by issues including pre-eclampsia and preterm birth
  • Cardiometabolic comorbidities (20%): Marked by hypertension, hyperlipidemia, and type 2 diabetes
  • HER-asymptomatic (25%): Minimal comorbid symptoms despite endometriosis diagnosis

Subsequent genetic association analyses with 39 endometriosis-associated loci revealed distinct cluster-specific genetic associations, including PDLIM5 for cluster 1, GREB1 for cluster 2, WNT4 for cluster 3, RNLS for cluster 4, and ABO for cluster 5 [13]. These differential associations underscore the genetic heterogeneity underlying endometriosis and demonstrate how sub-phenotype stratification can enhance discovery power.

Research Reagents and Computational Tools

Table 3: Essential Research Reagents and Computational Tools for Endometriosis Clustering Studies

Tool/Resource Type Function in Research Implementation Notes
Scikit-learn Clustering Module [47] Software Library Provides implementations of major clustering algorithms Python-based, includes K-means, spectral, hierarchical clustering
Electronic Health Records (EHR) [13] Data Source Captures phenotypic spectrum of endometriosis Requires careful phenotyping and preprocessing for research use
Cluster Validation Indices [48] Analytical Metric Evaluates clustering quality and determines optimal cluster number Multiple indices should be used for consensus
Genetic Association Tools [13] Analytical Framework Tests cluster-specific genetic associations Enables discovery of subtype-specific genetic mechanisms

Clustering algorithms provide powerful methodological approaches for addressing the pronounced heterogeneity in endometriosis. Through careful algorithm selection, rigorous determination of cluster number, and comprehensive validation, researchers can identify clinically meaningful sub-phenotypes with distinct genetic architectures. The integration of clustering methodologies with genetic association studies represents a promising pathway for elucidating the complex etiology of endometriosis and advancing toward personalized therapeutic strategies. As demonstrated in recent studies, this approach can reveal previously obscured genetic associations and provide insights into the diverse pathological mechanisms underlying this complex condition.

Endometriosis is increasingly recognized not as a single disorder but as a spectrum of distinct sub-phenotypes with varied molecular mechanisms, clinical presentations, and treatment responses. The heterogeneous nature of endometriosis has consistently complicated genetic association studies, with traditional approaches explaining only a limited proportion of disease heritability [13]. The identification and validation of robust sub-phenotypes represents a critical pathway toward personalized treatment approaches and enhanced genetic discovery. This technical guide examines methodologies for ensuring the reliability and generalizability of identified sub-phenotypes across diverse patient cohorts, a fundamental requirement for their integration into both clinical practice and drug development pipelines.

Current challenges in endometriosis sub-phenotyping include the poor correlation between established surgical classification systems and patient symptoms or treatment outcomes [27] [49]. Furthermore, the latent nature of many sub-phenotypes requires sophisticated computational approaches for their discovery and validation. This guide synthesizes evidence from multiple large-scale studies that have pioneered methods for sub-phenotype validation, providing researchers with a framework for ensuring that identified subgroups represent biologically meaningful entities rather than cohort-specific artifacts.

Foundational Concepts: Endometriosis Heterogeneity and Standardization Prerequisites

The Complexity of Endometriosis Presentation

Endometriosis demonstrates profound heterogeneity across multiple dimensions, including lesion location, symptom profiles, and molecular characteristics. The disease traditionally presents as three major lesion types—superficial peritoneal endometriosis (SPE), ovarian endometriomas (OMA), and deep infiltrating endometriosis (DIE)—each with distinct clinical implications [27]. Beyond this anatomical classification, studies have revealed diverse clinical presentation patterns that form the basis for modern sub-phenotyping approaches. The World Endometriosis Research Foundation (WERF) Endometriosis Phenome and Biobanking Harmonisation Project (EPHect) has established that systematic data collection is essential for capturing this heterogeneity in research settings [49].

Prerequisite: Standardized Phenotyping Frameworks

Robust sub-phenotype validation requires standardized data collection as a foundational element. The EPHect initiative developed standardized surgical phenotyping forms that collect detailed information on lesion characteristics, procedural details, and anatomical locations [49]. This harmonization enables cross-study comparisons and meta-analyses by ensuring consistent measurement of key phenotypic variables across research sites. The EPHect framework includes both minimum required (MSF) and standard recommended (SSF) forms, balancing comprehensive data collection with practical implementation across centers with varying resources [49].

Table: EPHect Standardized Data Collection Components

Data Category Specific Elements Validation Role
Surgical Phenotype Lesion location, type, appearance; extent of disease Enables comparison of lesion-based subtypes across cohorts
Clinical Metadata Pain symptoms, infertility status, comorbidities Facilitates symptom-based sub-phenotyping
Biospecimen Information Collection methods, processing protocols, storage conditions Supports molecular validation of sub-phenotypes

Methodological Approaches for Sub-phenotype Discovery and Validation

Computational Phenotyping from Clinical Data

Unsupervised learning techniques applied to electronic health records (EHR) have emerged as a powerful approach for identifying latent sub-phenotypes. A recent study of 4,078 women with endometriosis utilized spectral clustering on 17 clinical features to identify five distinct sub-phenotype clusters [13]. The validation of these clusters involved both internal consistency measures and external validation through genetic association testing.

The methodological workflow for computational phenotyping involves:

  • Feature Selection: Identification of clinically relevant variables with sufficient prevalence (>5%) including symptoms, comorbidities, and surgical findings
  • Cluster Optimization: Testing multiple clustering algorithms (k-means, spectral clustering, hierarchical clustering, DBSCAN) and cluster numbers (K=2-20) using metrics that evaluate cluster stability and separation
  • Cluster Characterization: Using proportion tests (z-tests) to identify distinguishing features for each cluster compared to others in the dataset

In the referenced study, spectral clustering with K=5 was empirically selected as optimal, producing clusters characterized as: (1) pain comorbidities, (2) uterine disorders, (3) pregnancy complications, (4) cardiometabolic comorbidities, and (5) HER-asymptomatic [13].

Digital Phenotyping from Patient-Generated Health Data

Mobile health technologies enable the collection of patient-generated health data (PGHD) at unprecedented scale and granularity. The Phendo project collected self-tracked data from 4,368 participants using a specialized smartphone application, capturing symptoms, quality of life measures, and treatments [50]. To address the challenges of PGHD—including multimodality, uncertainty, and varying tracking frequencies—researchers developed an extended mixed-membership model that jointly models diverse observation types to identify clinically meaningful phenotypes [50].

Validation of digitally-derived phenotypes employed a multi-faceted approach:

  • Intrinsic Evaluation: Assessing model fit and ability to capture underlying data structure
  • Expert Interpretation: Clinical evaluation of identified phenotype interpretability and clinical relevance
  • External Correlation: Matching phenotype assignments against standardized clinical instruments (WERF survey)
  • Robustness Testing: Evaluating phenotype stability across different hyperparameters and participant subgroups

This approach demonstrated that jointly modeling diverse self-tracked observations yields phenotypes that align with clinical knowledge while revealing novel patterns not captured by traditional classification systems [50].

G cluster_1 Data Collection cluster_2 Sub-phenotype Discovery cluster_3 Validation & Replication EHR Electronic Health Records Clustering Unsupervised Clustering (Spectral, K-means) EHR->Clustering PGHD Patient-Generated Health Data MixedModel Mixed Membership Modeling PGHD->MixedModel Molecular Molecular Profiling Dimensionality Dimensionality Reduction Molecular->Dimensionality Internal Internal Validation (Stability, Fit) Clustering->Internal Genetic Genetic Association (Subtype-specific loci) MixedModel->Genetic External External Cohorts (Cross-platform replication) Dimensionality->External Internal->Genetic Genetic->External

Diagram: Comprehensive Workflow for Endometriosis Sub-phenotype Discovery and Validation. This workflow integrates multiple data sources, analytical methods, and validation approaches to ensure robust sub-phenotype identification.

Molecular Sub-phenotyping and Validation

Molecular profiling technologies enable sub-phenotype discovery based on underlying biological mechanisms rather than clinical presentation alone. DNA methylation studies of endometrial tissue from 984 participants revealed that 15.4% of endometriosis variation is captured by methylation patterns, with distinct profiles associated with stage III/IV disease and menstrual cycle phase [14]. This molecular stratification provides orthogonal validation for clinically-derived sub-phenotypes.

Methylation quantitative trait locus (mQTL) analysis identified 118,185 independent cis-mQTLs, including 51 associated with endometriosis risk [14]. These findings provide a functional link between genetic risk variants and epigenetic regulation, highlighting candidate genes contributing to disease heterogeneity. The integration of molecular data with clinical sub-phenotypes creates a more comprehensive understanding of endometriosis heterogeneity.

Validation Strategies Across Multiple Cohorts

Genetic Association Validation

Genetic validation provides compelling evidence for the biological relevance of identified sub-phenotypes. In the EHR-based clustering study, researchers performed genetic association analyses for each cluster using 39 known endometriosis-associated loci across five biobanks (total N~12,350 cases) [13]. This approach revealed distinct genetic associations across sub-phenotypes:

Table: Sub-phenotype Specific Genetic Associations

Sub-phenotype Cluster Significant Genetic Locus Potential Biological Relevance
Pain Comorbidities PDLIM5 Cytoskeletal organization, pain signaling
Uterine Disorders GREB1 Hormone response, uterine growth
Pregnancy Complications WNT4 Reproductive system development
Cardiometabolic Comorbidities RNLS Metabolic processes, oxidative stress
HER-Asymptomatic ABO Blood group antigens, inflammation

The distinct genetic associations across clusters demonstrate that sub-phenotypes capture biologically meaningful heterogeneity beyond clinical symptoms alone. Notably, these associations were replicated across multiple independent cohorts, providing strong evidence for their robustness [13].

Cross-Cohort Replication Methods

Successful replication of sub-phenotypes across independent cohorts requires both methodological consistency and adaptation to cohort-specific characteristics. Key considerations include:

  • Feature Harmonization: Mapping variables across different EHR systems and data collection protocols while maintaining clinical relevance
  • Model Transferability: Applying trained models to new cohorts versus developing cohort-specific models using consistent methodologies
  • Handling Missing Data: Developing strategies for managing differentially available features across cohorts

The use of genetically correlated traits in Mendelian randomization studies provides another approach for validating relationships between endometriosis sub-phenotypes and relevant comorbidities. For example, a study demonstrating genetic correlations between endometriosis and immune conditions such as osteoarthritis (rg=0.28), rheumatoid arthritis (rg=0.27), and multiple sclerosis (rg=0.09) supports clinical observations of comorbidity patterns across specific sub-phenotypes [8].

Experimental Protocols for Key Validation Approaches

Protocol: Unsupervised Clustering with EHR Data

This protocol outlines the methodology for identifying and validating sub-phenotypes from electronic health records, based on approaches successfully implemented in recent studies [13].

Materials and Data Preparation:

  • Collect EHR data for endometriosis cases, including diagnosis codes, symptoms, comorbidities, and surgical findings
  • Preprocess data to create binary or ordinal features for clinical characteristics
  • Select features with >5% prevalence to avoid rare features dominating cluster formation

Clustering Procedure:

  • Test multiple clustering algorithms (spectral clustering, k-means, hierarchical clustering, DBSCAN)
  • Evaluate cluster numbers from K=2-20 using distortion curves and cluster separation metrics
  • Select optimal algorithm and cluster number based on:
    • Presence of clear "elbow" in distortion curves
    • Balanced cluster sizes
    • Clinical interpretability of resulting clusters

Cluster Characterization:

  • Perform z-score proportion tests comparing feature prevalence between each cluster and all others
  • Identify significantly enriched features (Z>3.0, p<0.05) for each cluster
  • Assign clinical labels based on predominant enriched features

Validation Steps:

  • Assess cluster stability through bootstrapping or cross-validation
  • Validate clusters in independent cohorts using identical feature definitions
  • Test for genetic associations specific to each cluster across multiple biobanks

Protocol: Molecular Validation of Clinical Sub-phenotypes

This protocol describes methods for validating clinically-derived sub-phenotypes using molecular data, particularly DNA methylation profiling [14].

Sample Collection and Processing:

  • Collect endometrial tissue samples with detailed phenotypic annotation
  • Extract DNA using standardized protocols (e.g., QIAamp DNA Mini Kit)
  • Perform bisulfite conversion (e.g., using EZ-96 DNA Methylation Kit)
  • Conduct genome-wide methylation profiling (Illumina Infinium MethylationEPIC BeadChip)

Bioinformatic Analysis:

  • Preprocess raw methylation data including normalization and background correction
  • Conduct quality control filtering based on detection p-values, bead count, and sample-dependent metrics
  • Correct for technical covariates (batch effects, array position) and biological covariates
  • Perform differential methylation analysis between sub-phenotypes
  • Conduct methylation quantitative trait loci (mQTL) analysis to identify genetic-epigenetic interactions

Integration with Clinical Sub-phenotypes:

  • Test whether molecular profiles differentiate clinical sub-phenotypes
  • Identify enriched biological pathways specific to each sub-phenotype
  • Assess whether molecular differences align with clinical characteristics

Table: Research Reagent Solutions for Endometriosis Sub-phenotyping Studies

Resource Category Specific Solution Application in Validation
Standardized Phenotyping Instruments EPHect Surgical Phenotyping Forms (SSF/MSF) [49] Standardized data collection across sites for comparable sub-phenotypes
Biobanking Protocols EPHect Tissue Collection SOPs [49] High-quality biospecimens for molecular validation of sub-phenotypes
Computational Tools Spectral Clustering Algorithms Identification of latent sub-phenotypes from high-dimensional clinical data
Genetic Analysis Platforms PLINK, METAL for GWAS meta-analysis Testing genetic associations specific to sub-phenotypes across cohorts
Molecular Profiling Illumina Infinium MethylationEPIC BeadChip [14] Epigenetic characterization of sub-phenotypes
Mobile Health Platforms Phendo Smartphone Application [50] Collection of patient-generated health data for digital phenotyping

Interpretation and Reporting Standards

Guidelines for Reporting Validated Sub-phenotypes

Comprehensive reporting of endometriosis sub-phenotypes should include:

  • Methodological Transparency: Detailed description of clustering algorithms, feature selection, and validation approaches
  • Clinical Characterization: Clear definition of each sub-phenotype's clinical features, prevalence, and distinguishing characteristics
  • Validation Metrics: Multiple measures of robustness including internal stability, external reproducibility, and biological plausibility
  • Genetic Evidence: Association with distinct genetic loci or polygenic risk profiles
  • Clinical Utility: Potential implications for diagnosis, treatment selection, or prognosis

Common Pitfalls in Sub-phenotype Validation

  • Overfitting: Creating overly complex sub-phenotypes that fail to replicate in independent cohorts
  • Cohort Effects: Developing sub-phenotypes that reflect local patient populations rather than biologically distinct entities
  • Measurement Heterogeneity: Inconsistent variable definitions across cohorts compromising replication efforts
  • Circular Validation: Using the same data for both discovery and validation without proper separation

The robust validation of endometriosis sub-phenotypes across multiple cohorts requires a multifaceted approach integrating clinical, molecular, and computational methods. The strategies outlined in this guide provide a framework for establishing sub-phenotypes as biologically meaningful entities rather than statistical artifacts. As research in this area advances, validated sub-phenotypes will increasingly inform both clinical management and drug development, ultimately enabling more personalized approaches to this heterogeneous condition. The integration of standardized phenotyping, molecular profiling, and sophisticated computational methods represents the most promising path toward unraveling the complexity of endometriosis and improving patient outcomes.

Endometriosis, a complex inflammatory condition affecting approximately 10% of reproductive-age women, demonstrates remarkable heterogeneity in clinical presentation and molecular drivers [51] [26]. This disease, characterized by the presence of endometrial-like tissue outside the uterine cavity, exhibits diverse phenotypes that complicate both diagnosis and treatment [51]. Sub-phenotype stratification through multi-omics approaches represents a transformative methodology for delineating the molecular architecture of endometriosis, potentially enabling precision medicine applications for the 30-50% of affected women who experience infertility [51] [26].

The integration of genetics, transcriptomics, and epigenetics provides unprecedented resolution for deconstructing endometriosis pathogenesis across multiple biological layers. Genetic studies identify inherited susceptibility loci; transcriptomics reveals gene expression programs active in specific cell types; while epigenetics captures the dynamic regulatory mechanisms that interface genetic predisposition with environmental influences [52] [53]. When analyzed collectively, these data dimensions facilitate the discovery of molecularly defined endometriosis subtypes with distinct clinical trajectories and therapeutic vulnerabilities, moving beyond the current phenotype-based classification systems that often fail to predict treatment response [51].

Molecular Landscape of Endometriosis: Rationale for Multi-Omic Approaches

Key Pathogenic Mechanisms Amenable to Multi-Omic Deconstruction

Endometriosis pathogenesis involves interconnected hormonal, immunologic, and inflammatory processes that collectively contribute to disease establishment and progression [51] [26]. Local estrogen dominance arises from aberrant aromatase (CYP19A1) overexpression and 17β-hydroxysteroid dehydrogenase type 2 (17HSD2) downregulation in ectopic lesions, creating a hyperestrogenic microenvironment [51]. Concurrent progesterone resistance, characterized by impaired progesterone receptor (PR) signaling, perpetuates lesion survival through multiple mechanisms including promoter hypermethylation of PR genes and microRNA dysregulation (e.g., miR-26a, miR-181) [51]. These hormonal alterations represent prime targets for epigenetic investigation.

Immune dysfunction constitutes another cornerstone of endometriosis pathophysiology, with macrophages comprising over 50% of peritoneal fluid immune cells in affected women [51]. Neuroimmune communication via calcitonin gene-related peptide (CGRP) promotes macrophage recruitment and phenotypic shifts toward a "pro-endometriosis" state, while natural killer (NK) cell cytotoxicity is severely compromised, enabling immune escape of ectopic cells [51]. Chronic inflammation generates oxidative stress and iron-driven ferroptosis that particularly injures granulosa cells, further compromising fertility [51]. These interconnected pathways highlight the necessity of molecular stratification to resolve patient-specific disease drivers.

Epigenetic Regulation in Endometriosis

Epigenetic mechanisms serve as critical interfaces between genetic susceptibility and environmental factors in endometriosis pathogenesis [52] [53]. DNA methylation patterns significantly differ between endometriotic and normal endometrial tissues, with hypermethylated genes including PGR-B, SF-1, and RASSF1A, and hypomethylated genes such as HOXA10, COX-2, IL-12B, and GATA6 [52]. These methylation alterations silence or activate key genes involved in hormonal response, inflammation, and cell adhesion, fundamentally shaping disease phenotype.

Histone modifications, particularly acetylation of histones H3 and H4, additionally regulate chromatin structure and gene expression in endometriosis [52]. Increased HDAC2 expression in endometriotic tissues suggests altered histone deacetylase activity may contribute to disease progression through transcriptional dysregulation [52]. Non-coding RNAs, especially microRNAs, further modulate gene expression patterns by targeting mRNAs for degradation or translational repression, creating complex regulatory networks that sustain ectopic lesion survival [53]. The reversible nature of these epigenetic modifications presents promising therapeutic targets for innovative treatment strategies [53].

Multi-Omic Data Types and Generation Methodologies

Genomic, Transcriptomic, and Epigenomic Data Acquisition

Comprehensive multi-omic profiling requires standardized experimental protocols for data generation across molecular layers. The following methodologies represent established approaches for high-quality data production in endometriosis research.

Table 1: Core Multi-Omic Data Types and Generation Methods

Data Type Experimental Method Key Outputs Application in Endometriosis
Genomics Whole-genome sequencing, SNP arrays Genetic variants, structural variations Identification of susceptibility loci (e.g., PROGINS polymorphism) [51]
Transcriptomics RNA-seq, single-cell RNA-seq Gene expression levels, alternative splicing Pathway activation status (e.g., estrogen signaling, inflammation) [51]
Epigenomics Whole-genome bisulfite sequencing, ChIP-seq, ATAC-seq DNA methylation patterns, histone modifications, chromatin accessibility Promoter methylation status (e.g., PGR-B hypermethylation) [52]
Proteomics LC-MS/MS [54] Protein identification and quantification Signaling pathway analysis (e.g., PI3K/AKT activation) [54]
Metabolomics LC-MS/MS [54] Metabolite identification and quantification Metabolic reprogramming in lesions [54]

Experimental Protocol: Integrated Proteomic and Metabolomic Profiling

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides a robust platform for simultaneous proteomic and metabolomic characterization of endometriotic tissues [54]. The following protocol details the integrated workflow:

Sample Preparation:

  • Tissue Processing: Pulverize frozen tissue samples (adenomyotic and normal myometrial controls) into cell powder under liquid nitrogen [54].
  • Protein Extraction: Lysate tissue using appropriate lysis buffer with high-intensity ultrasonic processing (3 cycles on ice). Centrifuge at 12,000g at 4°C for 10 minutes and collect supernatant [54].
  • Protein Quantification: Determine protein concentration using BCA assay according to manufacturer's instructions [54].

Proteomics Processing:

  • Protein Precipitation: Combine protein sample with pre-cooled acetone, vortex, then add four volumes pre-cooled acetone. Precipitate at -20°C for 2 hours [54].
  • Digestion: Reconstitute precipitate in 200 mM TEAB, digest with trypsin (1:50 ratio) overnight at 37°C [54].
  • Reduction and Alkylation: Reduce with 5 mM dithiothreitol at 37°C for 60 minutes, then alkylate with 11 mM iodoacetamide at room temperature for 45 minutes in the dark [54].
  • Peptide Purification: Use Strata X solid-phase extraction column on nanoElute UHPLC system [54].
  • LC-MS/MS Analysis: Perform on Orbitrap Exploris 480 mass spectrometer. Process data using MaxQuant search engine against human SwissProt database [54].

Metabolomics Processing:

  • Metabolite Extraction: Use appropriate extraction solvent (e.g., methanol:acetonitrile:water) for comprehensive metabolite recovery.
  • LC-MS/MS Analysis: Employ reverse-phase and HILIC chromatography coupled to high-resolution mass spectrometry for broad metabolite coverage.
  • Data Processing: Use software such as XCMS or Progenesis QI for peak picking, alignment, and metabolite identification.

This integrated protocol enables the simultaneous exploration of biological regulatory mechanisms at both protein and metabolic levels, yielding a more systematic understanding of endometriosis pathophysiology than single-omics analyses [54].

Computational Frameworks for Multi-Omic Integration

Data Visualization Strategies

Effective visualization of multi-omics data presents significant computational challenges, with several tools now available specifically designed for integrative analysis:

Pathway Tools Cellular Overview: This web-based interactive metabolic chart enables simultaneous visualization of up to four omics datasets on organism-scale metabolic network diagrams [55]. Each dataset is assigned to different visual channels—reaction arrow color, reaction arrow thickness, metabolite node color, and metabolite node thickness—allowing intuitive correlation of molecular events across data types [55]. The tool supports semantic zooming and animation of time-series data, with customizable color mappings to enhance data interpretation.

MiBiOmics: This Shiny-based web application facilitates multi-omics data exploration and integration through an intuitive interface, implementing ordination techniques and network inference methods [56]. MiBiOmics performs Weighted Gene Correlation Network Analysis (WGCNA) to identify modules of highly correlated features within each omics layer, then computes associations between these modules across different omics datasets [56]. The platform generates hive plots visualizing significant associations between omics-specific modules and their relationships to clinical parameters, enabling identification of multi-omics signatures associated with specific endometriosis sub-phenotypes.

Table 2: Multi-Omics Visualization Tools Comparison

Tool Visualization Approach Multi-Omics Capacity Key Features Endometriosis Application
Pathway Tools [55] Metabolic pathway overlay 4 simultaneous datasets Semantic zooming, animation Mapping hormonal pathway disruptions
MiBiOmics [56] Ordination plots, hive networks 3 simultaneous datasets WGCNA, Procrustes analysis Identifying co-expression modules across omics layers
MergeOmics [56] Multi-layered networks 2+ datasets DIABLO framework Biomarker discovery for sub-phenotypes
PaintOmics [55] Pathway diagrams 2+ datasets Interactive pathway coloring Visualizing pathway activity in lesions

Analytical Workflows for Sub-Phenotype Stratification

Multi-omics integration facilitates endometriosis sub-phenotype discovery through complementary analytical approaches:

endometriosis_workflow Multi-Omic Data Multi-Omic Data Preprocessing Preprocessing Multi-Omic Data->Preprocessing Clustering Clustering Preprocessing->Clustering Network Analysis Network Analysis Clustering->Network Analysis Pathway Mapping Pathway Mapping Network Analysis->Pathway Mapping Sub-phenotypes Sub-phenotypes Pathway Mapping->Sub-phenotypes Validation Cohort Validation Cohort Sub-phenotypes->Validation Cohort Clinical Data Clinical Data Clinical Data->Sub-phenotypes

Multi-omics sub-phenotype discovery workflow.

The workflow begins with simultaneous processing of multiple omics data types, followed by dimension reduction and clustering to identify molecular patterns. Network analysis delineates interactions between features across omics layers, while pathway mapping contextualizes findings within established biological mechanisms [56]. Clinical data integration validates the biological and medical relevance of identified sub-phenotypes, with subsequent validation in independent cohorts ensuring robustness.

Signaling Pathways in Endometriosis: Visualization and Analysis

PI3K/AKT Signaling in Myometrial Fibrosis

Recent integrated proteomic and metabolomic analysis has identified the PI3K/AKT signaling pathway as critically important in adenomyosis-related myometrial fibrosis [54]. This pathway activation represents a promising therapeutic target and potential sub-phenotype biomarker.

pi3k_akt_pathway Growth Factors Growth Factors PI3K Activation PI3K Activation Growth Factors->PI3K Activation PIP2 to PIP3 PIP2 to PIP3 PI3K Activation->PIP2 to PIP3 AKT Phosphorylation AKT Phosphorylation PIP2 to PIP3->AKT Phosphorylation myofibroblast transdifferentiation myofibroblast transdifferentiation AKT Phosphorylation->myofibroblast transdifferentiation Myometrial Fibrosis Myometrial Fibrosis myofibroblast transdifferentiation->Myometrial Fibrosis PTEN PTEN PTEN->PIP2 to PIP3 inhibits PI3K Inhibitors PI3K Inhibitors PI3K Inhibitors->PI3K Activation inhibits

PI3K/AKT pathway in myometrial fibrosis.

The PI3K/AKT pathway integrates signals from growth factors and extracellular matrix components, promoting myofibroblast transdifferentiation and subsequent collagen deposition in the myometrium [54]. Proteomic analyses reveal increased phosphorylation of AKT substrates in fibrotic lesions, while metabolomic profiling shows associated shifts in energy metabolism that support fibrogenic processes [54]. This pathway represents a convergence point for multiple omics layers and a potential stratification biomarker for fibrosis-dominant endometriosis sub-phenotypes.

Hormonal Signaling Networks

Estrogen and progesterone signaling disturbances form a cornerstone of endometriosis pathophysiology, with multi-omics approaches revealing complex regulatory networks:

hormonal_signaling CYP19A1 overexpression CYP19A1 overexpression Local Estrogen Dominance Local Estrogen Dominance CYP19A1 overexpression->Local Estrogen Dominance Lesion Maintenance Lesion Maintenance Local Estrogen Dominance->Lesion Maintenance miRNA Dysregulation miRNA Dysregulation Local Estrogen Dominance->miRNA Dysregulation ERβ/ERα Ratio Increase ERβ/ERα Ratio Increase ERβ/ERα Ratio Increase->Local Estrogen Dominance PR-B Promoter Hypermethylation PR-B Promoter Hypermethylation Progesterone Resistance Progesterone Resistance PR-B Promoter Hypermethylation->Progesterone Resistance Progesterone Resistance->Lesion Maintenance Epigenetic Modifiers Epigenetic Modifiers Epigenetic Modifiers->ERβ/ERα Ratio Increase Epigenetic Modifiers->PR-B Promoter Hypermethylation miRNA Dysregulation->Progesterone Resistance

Hormonal signaling network in endometriosis.

Multi-omics studies demonstrate that local estrogen dominance results from both metabolic alterations (increased aromatase expression) and epigenetic modifications (ERβ promoter hypomethylation) [51] [26]. Similarly, progesterone resistance stems not only from receptor expression changes but also from epigenetic silencing of progesterone-responsive genes [51]. These interconnected disturbances create a self-sustaining signaling network that maintains ectopic lesions and represents a potential target for sub-phenotype-specific therapies.

The Scientist's Toolkit: Essential Research Reagents and Platforms

Table 3: Research Reagent Solutions for Multi-Omic Endometriosis Studies

Category Specific Reagents/Platforms Function Application Example
Sequencing Platforms Illumina NovaSeq, PacBio Sequel, Oxford Nanopore Nucleic acid sequencing Whole-genome sequencing, RNA-seq, methylation analysis [52]
Mass Spectrometry Orbitrap Exploris 480, LC-MS/MS systems [54] Protein and metabolite identification Proteomic and metabolomic profiling of lesions [54]
Epigenetic Tools Methylation-specific PCR reagents, HDAC inhibitors, ChIP-grade antibodies Epigenetic modification analysis DNA methylation profiling, histone modification characterization [52] [53]
Bioinformatics Platforms MiBiOmics [56], Pathway Tools [55], MixOmics [56] Data integration and visualization Multi-omics network analysis, pathway mapping [55] [56]
Cell Culture Models Primary endometriotic stromal cells, immortalized cell lines In vitro functional validation Testing epigenetic drug responses [53]
Animal Models Xenotransplantation models, induced endometriosis models In vivo pathway validation PI3K/AKT inhibitor testing [54]

The integration of genetics, transcriptomics, and epigenetics provides an unprecedented opportunity to resolve the molecular heterogeneity of endometriosis through sub-phenotype stratification. This approach moves beyond descriptive disease classification toward mechanistic taxonomies rooted in distinct pathogenic processes, enabling targeted therapeutic development based on individual molecular profiles.

Future research directions should prioritize single-cell multi-omics technologies to resolve cellular heterogeneity within endometriotic lesions, longitudinal sampling to capture dynamic molecular changes throughout disease progression, and advanced computational methods for causal network inference. Additionally, prospective clinical trials validating the utility of multi-omics sub-phenotypes for treatment selection will be essential for translating these approaches to patient care. As multi-omics technologies continue to mature and analytical frameworks become more sophisticated, precision medicine for endometriosis promises to dramatically improve outcomes for this historically enigmatic condition.

Proof of Concept: Validated Genetic Discoveries and Comparative Biology of Subtypes

Endometriosis, a complex gynecological condition affecting approximately 10% of reproductive-age women, demonstrates substantial clinical heterogeneity that has long complicated genetic association studies and therapeutic development [6] [13]. Traditional genome-wide association studies (GWAS) have explained only a limited fraction of endometriosis's heritability, with the largest GWAS to date accounting for merely 7% of phenotypic variance despite twin studies estimating heritability at approximately 47.5% [13]. This discrepancy suggests that underlying disease heterogeneity may obscure distinct genetic mechanisms operating across different clinical manifestations.

Recent advances in sub-phenotype stratification leverage comprehensive electronic health record (EHR) data and unsupervised machine learning to dissect this heterogeneity, revealing distinct clinical clusters with specific genetic associations [13] [57]. This case study examines validated subtype-specific loci—GREB1, WNT4, PDLIM5, and RNLS—that exemplify how stratification approaches are illuminating the genetic architecture of endometriosis and creating opportunities for targeted therapeutic interventions.

Methods: Sub-Phenotype Stratification Framework

Unsupervised Clustering of Clinical Sub-Phenotypes

The identification of subtype-specific loci originated from a sophisticated analytical framework employing unsupervised clustering of EHR-data from 4,078 women with endometriosis [13] [57]. The methodological workflow encompassed:

Clinical Feature Selection: Seventeen clinically relevant features were selected, including known endometriosis risk factors, symptoms, and concomitant conditions with prevalence exceeding 5% in the study population [13].

Clustering Algorithm Evaluation: Researchers empirically tested four unsupervised clustering methods (DBSCAN, hierarchical clustering, spectral clustering, and k-means) across 19 potential cluster values (K=2-20), evaluating performance using multiple metrics. Spectral clustering with K=5 was selected as the optimal model based on cluster interpretability and statistical performance [13].

Cluster Characterization: Following clustering, distinct sub-phenotypes were characterized through z-score proportion tests comparing feature prevalence between each cluster and the remaining population, identifying significantly enriched clinical features for each subgroup [13].

Genetic Association Analysis

Genetic analyses were conducted across multiple biobanks totaling 12,350 endometriosis cases and 466,261 controls [13]. Association testing focused on 39 previously established endometriosis-associated loci, with subtype-specific associations evaluated for each clinical cluster using Bonferroni-corrected significance thresholds to account for multiple testing [13] [57].

Table 1: Datasets Utilized in Genetic Association Analysis

Dataset Endometriosis Cases Controls Ancestral Composition
AOU 2,126 108,099 542 AFR / 1,584 EUR
eMERGE 2,243 49,557 353 AFR / 1,890 EUR
PMBB 1,198 19,493 562 AFR / 636 EUR
UKBB 4,541 257,283 112 AFR / 4,429 EUR
BioVU 1,097 32,975 260 AFR / 837 EUR
Meta-Analysis Totals 12,350 466,261 2,079 AFR / 10,271 EUR

Results: Validated Subtype-Specific Loci

Clinically Defined Endometriosis Sub-Phenotypes

Unsupervised clustering identified five distinct endometriosis sub-phenotypes with characteristic clinical profiles [13] [57]:

  • Cluster 1 - Pain Comorbidities: Characterized by significantly elevated rates of dysuria (Z=8.9), migraine (Z=10.6), irritable bowel syndrome (Z=10.3), fibromyalgia (Z=15.3), asthma (Z=10.3), abdominal pelvic pain (Z=13.6), and shortness of breath (Z=13.5) [13].

  • Cluster 2 - Uterine Disorders: Distinguished by high prevalence of dysmenorrhea (Z=21.9) and infertility (Z=5) [13].

  • Cluster 3 - Pregnancy Complications: Defined by pregnancy-associated comorbidities and complications [13] [57].

  • Cluster 4 - Cardiometabolic Comorbidities: Marked by cardiometabolic conditions [13] [57].

  • Cluster 5 - HER-Asymptomatic: Comprising patients without strong EHR signatures of specific comorbidities [13] [57].

Subtype-Specific Genetic Associations

Genetic association analyses revealed distinct loci significantly associated with specific sub-phenotypes after Bonferroni correction [13] [57]:

Table 2: Validated Subtype-Specific Loci in Endometriosis

Locus Associated Cluster Clinical Sub-Phenotype Potential Biological Role
PDLIM5 Cluster 1 Pain Comorbidities Cytoskeletal organization, pain signaling pathways
GREB1 Cluster 2 Uterine Disorders Early estrogen response, uterine development and function
WNT4 Cluster 3 Pregnancy Complications Müllerian duct development, ovarian function, steroidogenesis
RNLS Cluster 4 Cardiometabolic Comorbidities Mitochondrial function, cardiometabolic pathways
ABO Cluster 5 HER-Asymptomatic Blood group antigens, inflammatory response

G Endometriosis\nHeterogeneity Endometriosis Heterogeneity Unsupervised\nClustering Unsupervised Clustering Endometriosis\nHeterogeneity->Unsupervised\nClustering Cluster 1\nPain Comorbidities Cluster 1 Pain Comorbidities Unsupervised\nClustering->Cluster 1\nPain Comorbidities Cluster 2\nUterine Disorders Cluster 2 Uterine Disorders Unsupervised\nClustering->Cluster 2\nUterine Disorders Cluster 3\nPregnancy\nComplications Cluster 3 Pregnancy Complications Unsupervised\nClustering->Cluster 3\nPregnancy\nComplications Cluster 4\nCardiometabolic\nComorbidities Cluster 4 Cardiometabolic Comorbidities Unsupervised\nClustering->Cluster 4\nCardiometabolic\nComorbidities Cluster 5\nHER-Asymptomatic Cluster 5 HER-Asymptomatic Unsupervised\nClustering->Cluster 5\nHER-Asymptomatic PDLIM5 PDLIM5 Cluster 1\nPain Comorbidities->PDLIM5 GREB1 GREB1 Cluster 2\nUterine Disorders->GREB1 WNT4 WNT4 Cluster 3\nPregnancy\nComplications->WNT4 RNLS RNLS Cluster 4\nCardiometabolic\nComorbidities->RNLS ABO ABO Cluster 5\nHER-Asymptomatic->ABO Subtype-Specific\nTherapeutic Targets Subtype-Specific Therapeutic Targets PDLIM5->Subtype-Specific\nTherapeutic Targets GREB1->Subtype-Specific\nTherapeutic Targets WNT4->Subtype-Specific\nTherapeutic Targets RNLS->Subtype-Specific\nTherapeutic Targets ABO->Subtype-Specific\nTherapeutic Targets

Figure 1: Workflow for Identification of Subtype-Specific Loci

Molecular Functions of Validated Loci

GREB1 - Uterine Disorders Cluster

GREB1 (Growth Regulating Estrogen Receptor Binding 1) is an early-response gene in the estrogen receptor signaling pathway that plays crucial roles in uterine development and function [6] [4]. The association of GREB1 with the uterine disorders cluster suggests its involvement in the fundamental mechanisms underlying endometrial proliferation and implantation disorders frequently observed in endometriosis patients [13]. This locus demonstrates specific overexpression in uterine tissues and may contribute to the progesterone resistance characteristic of endometriosis, potentially through epigenetic regulation of hormone response pathways [14].

WNT4 - Pregnancy Complications Cluster

WNT4 (Wnt Family Member 4) represents a pivotal signaling molecule in Müllerian duct development, ovarian function, and steroidogenesis [6] [4]. Its association with the pregnancy complications cluster underscores its importance in reproductive processes potentially disrupted in endometriosis, including follicular development and endometrial receptivity [13]. WNT4 operates within conserved signaling pathways that regulate female reproductive tract development and function, with variants potentially contributing to the impaired implantation and fertility issues characteristic of this patient subgroup [19].

PDLIM5 - Pain Comorbidities Cluster

PDLIM5 (PDZ And LIM Domain 5) encodes a cytoskeletal protein involved in cellular scaffolding and signal transduction, particularly in neural tissues [13] [57]. Its specific association with the pain comorbidities cluster suggests potential roles in pain signaling pathways or central sensitization mechanisms that could explain the heightened pain sensitivity and comorbid pain conditions (migraine, fibromyalgia) characterizing this patient subgroup [13]. PDLIM5 may regulate ion channel organization or neurotransmitter receptor clustering in pain-processing neural circuits.

RNLS - Cardiometabolic Comorbidities Cluster

RNLS (Renalase) participates in mitochondrial function and metabolic regulation, with identified roles in cardiometabolic pathways [13] [57]. Its association with the cardiometabolic comorbidities cluster suggests potential connections between endometriosis pathogenesis and systemic metabolic dysregulation [13]. RNLS may influence inflammatory processes or oxidative stress responses that bridge reproductive and metabolic health, potentially explaining the co-occurrence of endometriosis with cardiometabolic conditions in this patient subgroup.

Research Reagent Solutions

Table 3: Essential Research Reagents for Subtype-Specific Endometriosis Investigations

Reagent Category Specific Examples Research Applications
Genotyping Platforms Illumina Infinium Global Screening Array, Affymetrix 500K/6.0 GWAS, imputation, genetic association testing
Methylation Analysis Illumina Infinium MethylationEPIC BeadChip Genome-wide DNA methylation profiling, mQTL mapping
Biobanking Supplies PAXgene Blood RNA Tubes, EDTA blood collection tubes, urine collection containers Standardized biospecimen preservation for multi-omics
Cell Isolation Kits Magnetic-activated cell sorting (MACS), FACS reagents Endometrial epithelial/stromal cell separation
RNA Sequencing Kits Illumina HiSeq/MiSeq, Affymetrix Human Genome U133 Plus 2.0 Array Gene expression profiling, transcriptome analysis

Experimental Protocols

EHR-Based Phenotypic Clustering Protocol

The unsupervised clustering approach that enabled sub-phenotype discovery followed this standardized protocol [13]:

  • Data Extraction: Extract structured EHR data for endometriosis patients, including diagnosis codes, medication records, procedure codes, and clinical measurements.

  • Feature Engineering: Calculate prevalence rates for 17 clinical features including pain symptoms, reproductive conditions, and comorbidities. Transform into binary feature matrix.

  • Spectral Clustering Implementation:

    • Construct affinity matrix using radial basis function kernel
    • Compute graph Laplacian and eigenvectors
    • Perform k-means clustering (K=5) on eigenvectors
    • Assign patients to distinct sub-phenotype clusters

  • Cluster Validation: Assess cluster stability through bootstrapping and evaluate clinical interpretability through chart review.

mQTL Mapping in Endometrial Tissue

The investigation of epigenetic regulation of identified loci employed this methylation quantitative trait loci (mQTL) protocol [14]:

  • Sample Collection: Obtain eutopic endometrial biopsies during specific menstrual cycle phases (proliferative or secretory) confirmed by histological dating.

  • DNA Extraction and Methylation Profiling: Isolate genomic DNA and perform genome-wide methylation analysis using Illumina Infinium MethylationEPIC BeadChips covering >850,000 CpG sites.

  • Genotyping: Conduct parallel genotyping using high-density SNP arrays (e.g., Illumina Global Screening Array).

  • mQTL Analysis:

    • Perform quality control on methylation and genotype data
    • Test associations between genetic variants and methylation levels at proximal CpG sites (cis-mQTL)
    • Apply multiple testing correction (Bonferroni threshold)
    • Annotate significant mQTLs to genes and functional genomic elements

G Endometrial\nBiopsy Endometrial Biopsy DNA Extraction DNA Extraction Endometrial\nBiopsy->DNA Extraction Genotyping Genotyping DNA Extraction->Genotyping Methylation\nProfiling Methylation Profiling DNA Extraction->Methylation\nProfiling Quality Control Quality Control Genotyping->Quality Control Methylation\nProfiling->Quality Control mQTL Analysis mQTL Analysis Quality Control->mQTL Analysis Functional\nValidation Functional Validation mQTL Analysis->Functional\nValidation

Figure 2: mQTL Analysis Workflow

Discussion: Implications for Therapeutic Development

The identification of validated subtype-specific loci represents a paradigm shift in endometriosis research with profound implications for precision medicine approaches. Rather than conceptualizing endometriosis as a single entity, these findings support its reclassification into distinct molecular subtypes with potentially different therapeutic vulnerabilities [13].

The association between specific loci and clinical sub-phenotypes suggests several mechanistic hypotheses. GREB1's connection to uterine disorders implies that selective estrogen receptor modulators with tissue-specific activity might benefit this patient subgroup [6] [4]. Similarly, WNT4's association with pregnancy complications suggests potential for WNT pathway modulators to address fertility challenges in this cluster [13] [19]. The strong relationship between PDLIM5 and pain comorbidities indicates that this locus might inform development of novel analgesics specifically for endometriosis-related pain syndromes [13] [57].

From a diagnostic perspective, these subtype-specific loci could form the foundation for molecular classification systems that complement clinical phenotyping. Polygenic risk scores incorporating subtype-specific variants may enable earlier identification of at-risk individuals and prognostication of disease progression patterns [6]. Furthermore, the integration of genetic, epigenetic, and transcriptomic data from well-phenotyped cohorts promises to uncover additional layer of endometriosis heterogeneity and identify novel drug targets [14].

Future research directions should include functional characterization of associated variants through genome editing approaches, prospective validation of subtype-specific treatment responses in clinical trials, and development of companion diagnostics for targeted therapies. The continued refinement of endometriosis sub-phenotyping through integrated multi-omics approaches holds significant promise for revolutionizing management of this complex condition.

This whitepaper synthesizes emerging genetic, molecular, and clinical evidence establishing a biological link between endometriosis and the immune-mediated rheumatic conditions osteoarthritis (OA) and rheumatoid arthritis (RA). Grounded in the context of sub-phenotype stratification in endometriosis research, we delineate the shared genetic architecture and molecular pathways, with a particular focus on the hyaluronic acid (HA) pathway as a central mechanistic hub. The analysis presents quantitative genetic correlations, identifies specific shared risk loci, and details experimental methodologies for investigating these relationships. The findings underscore the imperative of refining endometriosis sub-phenotyping to deconvolute disease heterogeneity and accelerate the development of repurposed or novel targeted therapeutics.

Endometriosis, a chronic inflammatory condition characterized by endometrial-like tissue outside the uterus, has long been observed to co-occur with autoimmune and inflammatory diseases. Genome-wide association studies (GWAS) have established its heritable component, with approximately 50% of disease risk attributable to genetic factors, about half of which is due to common variants [58] [17]. This genetic architecture provides a powerful tool for uncovering shared biological pathways with comorbid conditions.

Recent large-scale genetic analyses have provided robust evidence that the observed clinical comorbidities are not merely associative but stem from a shared biological basis. This whitepaper explores the multifaceted connections between endometriosis, OA, and RA, with a dedicated focus on the hyaluronic acid pathway—a mechanism implicated in all three conditions. Understanding these links through the lens of deep sub-phenotype stratification is crucial for transforming this knowledge into precise diagnostic tools and targeted therapies for patient subpopulations.

Genetic and Epidemiological Evidence of Shared Risk

Large-scale phenotypic and genetic association studies provide the foundational evidence for a biological relationship between these conditions.

Phenotypic Associations

A comprehensive analysis of the UK Biobank demonstrated that endometriosis patients have a significantly increased risk (30–80%) of developing several immunological diseases [9]. The study, which employed both retrospective cohort and cross-sectional designs, found significantly increased risks for:

  • Classical Autoimmune Diseases: Rheumatoid arthritis, multiple sclerosis, coeliac disease.
  • Autoinflammatory Disease: Osteoarthritis.
  • Mixed-Pattern Disease: Psoriasis.

Genetic Correlations and Causal Inference

Genetic correlation analyses quantify the extent to which genetic risk factors are shared between two conditions. The following table summarizes key genetic findings from a large-scale female-specific GWAS and meta-analysis [9] [17].

Table 1: Genetic Correlations Between Endometriosis and Immune Conditions

Immune Condition Genetic Correlation (rg) P-value Putative Causal Link (MR)
Osteoarthritis (OA) 0.28 3.25 × 10-15 Not Reported
Rheumatoid Arthritis (RA) 0.27 1.5 × 10-5 OR = 1.16 (95% CI: 1.02–1.33)
Multiple Sclerosis (MS) 0.09 4.00 × 10-3 Nominal / Non-significant

Mendelian Randomization (MR) analysis, a method for inferring causality, suggested that genetic liability to endometriosis confers a causal increase in the risk of rheumatoid arthritis [9]. The analysis also identified specific shared genetic loci:

  • Three loci shared between endometriosis and OA: BMPR2/2q33.1, BSN/3p21.31, MLLT10/10p12.31.
  • One locus shared with RA: XKR6/8p23.1 [9].

The Pivotal Role of the Hyaluronic Acid Pathway

Hyaluronic acid is a glycosaminoglycan ubiquitously present in the extracellular matrix of connective tissues, synovial fluid, and cartilage. Its role as a shared biological pathway offers a mechanistic hypothesis for the genetic links between endometriosis, OA, and RA.

HA in Joint and Reproductive Tissue Physiology

In healthy joints, high-molecular-weight HA (HMW-HA) in the synovial fluid provides viscosity, lubrication, and shock absorption [59] [60]. It maintains the extracellular matrix (ECM) and exerts anti-inflammatory effects by suppressing pro-inflammatory cytokines like IL-1β and TNF-α, and enzymes like cyclooxygenase-2 (COX-2) and matrix metalloproteinases (MMPs) [59] [61].

In the context of endometriosis, HA is implicated in tissue repair, remodeling, and cell adhesion [62]. The peritoneum, the site of endometriosis lesion establishment, is rich in HA, and its interactions with cell surface receptor CD44 are critical for cell adhesion and proliferation.

Pathophysiological Dysregulation

The homeostatic role of HA is disrupted in disease states, often characterized by a shift from HMW-HA to low-molecular-weight HA (LMW-HA).

  • In Osteoarthritis: Synial fluid exhibits a lower concentration and molecular weight of HA, reducing its viscoelastic and protective properties. This degradation is driven by hyaluronidases and reactive oxygen species [59] [60].
  • In Rheumatoid Arthritis: The inflamed synovial joint environment is marked by significantly diminished HA levels, increased degradation, and reduced lubrication, contributing to pain and joint destruction [59] [61].
  • In Endometriosis: Research reveals a paradoxical, dual role for HA. In vivo mouse models show that HA treatment can reduce the size of endometriotic lesions, suggesting an inhibitory effect on establishment [62]. Conversely, in vitro studies on endometriotic stromal cells show that HA, especially in the presence of IL-1β, can significantly increase COX-2 expression, a key pro-inflammatory mediator [62]. This points to a complex, context-dependent role where HA may possess pro-inflammatory effects in the acute phase and anti-inflammatory or anti-adhesive effects in the chronic phase.

The following diagram illustrates the paradoxical signaling pathways of HA in these interconnected diseases.

G cluster_high High Molecular Weight (HMW-HA) cluster_low Low Molecular Weight (LMW-HA) cluster_common Shared Genetic & Molecular Context HA Hyaluronic Acid (HA) HMW_HA HMW-HA (Anti-Inflammatory) HA->HMW_HA LMW_HA LMW-HA (Pro-Inflammatory) HA->LMW_HA AntiInf • Inhibits IL-1β, TNF-α • Suppresses COX-2, MMPs • Reduces lesion size • Promotes lubrication HMW_HA->AntiInf ProInf • Increases COX-2 • Promotes inflammation • Enhances cell adhesion LMW_HA->ProInf Genetics Shared Genetic Loci (BMPR2, BSN, MLLT10, XKR6) Genetics->HA CD44 CD44 Receptor Activation CD44->HMW_HA CD44->LMW_HA

Experimental Protocols for Investigating Shared Pathways

To validate and explore these genetic and mechanistic links, researchers can employ the following detailed experimental methodologies.

Protocol 1: Genetic Correlation and Mendelian Randomization

This protocol uses summary-level data from GWAS to quantify shared genetic architecture and infer causality [9] [37].

  • Data Acquisition: Obtain summary statistics from large-scale GWAS for endometriosis, OA, and RA. Prefer female-specific GWAS where available.
  • Genetic Correlation Analysis:
    • Utilize software such as LD Score Regression (LDSC).
    • Calculate the genetic correlation coefficient (rg) which ranges from -1 to 1. An rg > 0 indicates a positive sharing of genetic risk factors.
    • Significance is typically set at P < 0.05 after multiple testing correction.
  • Mendelian Randomization (MR):
    • Instrument Selection: Identify independent, genome-wide significant (P < 5 × 10-8) SNPs associated with the exposure (e.g., endometriosis).
    • Causal Estimation: Perform two-sample MR using methods like Inverse-Variance Weighted (IVW) as the primary test. Use MR-Egger and weighted median as sensitivity analyses to test for and adjust for pleiotropy.
    • Reverse MR: Conduct analysis with the outcome as the exposure to test for reverse causality.

Protocol 2: Functional Investigation of HA in Endometriosis

This protocol assesses the in vitro and in vivo effects of HA on inflammation and lesion development [62].

  • Sample Collection & Cell Culture:
    • Collect peritoneal fluid and endometrioma samples from patients undergoing surgery and from control subjects.
    • Isolate and culture endometriotic stromal cells from the tissue samples.
  • In Vitro Stimulation:
    • Treat isolated stromal cells with:
      • IL-1β (e.g., 10 ng/mL) to simulate an inflammatory environment.
      • Hyaluronic Acid of varying molecular weights (e.g., HMW-HA > 1000 kDa, LMW-HA ~ 200 kDa).
    • Use quantitative PCR (qPCR) and Western Blotting to evaluate the expression of inflammatory markers, primarily COX-2.
  • In Vivo Validation (Mouse Model):
    • Establish a mouse model of endometriosis (e.g., by intraperitoneal injection of uterine tissue fragments).
    • Treat experimental groups with either a vehicle control or HA via intraperitoneal injection.
    • After a set period (e.g., several weeks), sacrifice the mice and perform laparotomy to measure the number, volume, and weight of endometriotic lesions microscopically.

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Reagents for Investigating HA in Endometriosis and Rheumatic Diseases

Reagent / Material Function / Application Key Considerations
Hyaluronic Acid (Varying MW) To test the differential effects of HMW-HA (anti-inflammatory) vs. LMW-HA (pro-inflammatory) in cellular and animal models. Source (bacterial vs. animal), purity, and molecular weight distribution are critical.
CD44 Receptor Antibodies To block or detect CD44 receptor binding in mechanistic studies, confirming HA's receptor-mediated actions. Validate for specific applications (e.g., flow cytometry, neutralization, immunohistochemistry).
IL-1β & TNF-α Cytokines To create a pro-inflammatory microenvironment in cell culture models that mimics the disease state. Use recombinant human proteins; determine optimal concentration via dose-response curves.
COX-2 & MMP Antibodies To measure the expression of key inflammatory and tissue-remodeling mediators via qPCR, Western Blot, or ELISA. Ensure specificity for the target isoform.
GWAS Summary Statistics For genetic correlation, colocalization, and Mendelian Randomization analyses. Sources: IEu, 23andMe, UK Biobank, FinnGen, and the GWAS Catalog.
Primary Endometriotic Stromal Cells For in vitro studies of disease-specific cellular mechanisms. Isolate from patient lesions; characterize for purity (e.g., vimentin positive, cytokeratin negative).

Implications for Sub-phenotype Stratification and Drug Development

The discovery of shared pathways, particularly HA, provides a compelling rationale for refining endometriosis sub-phenotyping, a core objective of initiatives like the WERF Endometriosis Phenome Harmonisation (EPH) Project [17].

Stratification Based on Comorbidity and Genetic Risk

Future research should move beyond simple rASRM staging to define sub-phenotypes based on:

  • Presence of Specific Comorbidities: Identifying an "arthropathy-associated" sub-phenotype of endometriosis characterized by comorbid OA/RA.
  • Polygenic Risk Scores (PRS): Developing PRS for the shared genetic components to identify endometriosis patients at highest risk for developing OA or RA.
  • Molecular Profiling: Stratifying patients based on activity levels of the HA pathway (e.g., high vs. low CD44 expression, HMW-HA/LMW-HA ratio in peritoneal fluid).

Therapeutic Repurposing and Development

The shared genetic and mechanistic basis opens avenues for therapy:

  • Drug Repurposing: HA-based therapies (viscosupplementation) used in OA could be investigated for efficacy in managing endometriosis-associated pain or preventing post-surgical adhesions, with careful consideration of HA molecular weight [63] [62] [64].
  • Targeted Drug Delivery: HA's natural affinity for the CD44 receptor, overexpressed in inflamed tissues, makes it an ideal vehicle for targeted drug delivery. HA-based nanoparticles, hydrogels, and microneedles are being explored to deliver disease-modifying antirheumatic drugs (DMARDs) specifically to inflamed joints in RA, a strategy that could be adapted for pelvic targeting in endometriosis [61].
  • Novel Target Identification: The shared loci (e.g., BMPR2, MLLT10) and the HA pathway itself represent novel targets for pharmaceutical intervention across this spectrum of comorbid conditions.

Integrating genetic, epidemiological, and molecular evidence confirms that the comorbidity between endometriosis, osteoarthritis, and rheumatoid arthritis is rooted in shared biological pathways. The hyaluronic acid pathway emerges as a critical nexus, with its dysregulation contributing to pathophysiology across these conditions. For the research community, the priority now lies in leveraging deep phenotypic data to define meaningful sub-phenotypes of endometriosis, which will be essential for translating these findings into targeted, effective treatments and successful drug repurposing strategies. The genetic correlation is a starting point; the sub-phenotype is the roadmap to clinical impact.

Endometriosis, a chronic gynecological condition affecting 6-11% of reproductive-aged women, has long been recognized for its complex etiology involving both genetic and environmental factors [65]. Recent large-scale genetic studies have fundamentally advanced our understanding of its pathogenesis, revealing that endometriosis shares significant biological pathways with a spectrum of immune-mediated diseases [8] [10]. This evolving paradigm positions endometriosis not as an isolated gynecological disorder, but as a systemic condition with important immunological components.

The integration of genetic evidence into disease classification and therapeutic development represents a transformative approach in precision medicine. For endometriosis, which exhibits substantial heterogeneity in clinical presentation and surgical phenotype [12], genetic correlations with immune conditions provide critical insights for sub-phenotype stratification. This technical analysis comprehensively examines the genetic architecture connecting endometriosis to autoimmune, autoinflammatory, and mixed-pattern diseases, with specific implications for refining classification systems and identifying novel therapeutic targets for stratified patient populations.

Phenotypic Associations Between Endometriosis and Immune Conditions

Epidemiological Evidence

Large-scale epidemiological analyses demonstrate significantly increased comorbidity between endometriosis and specific immune-mediated conditions. A comprehensive study of the UK Biobank data, encompassing over 8,000 endometriosis cases and 64,000 immunological disease cases, revealed that women with endometriosis face a 30-80% increased risk of developing certain immune conditions compared to the general population [8] [10].

Table 1: Phenotypic Associations Between Endometriosis and Immune Conditions

Immune Condition Category Specific Conditions Increased Risk Study Population
Classical Autoimmune Rheumatoid Arthritis, Multiple Sclerosis, Coeliac Disease 30-80% UK Biobank: 8,223 endometriosis cases, 64,620 immunological disease cases [8]
Autoinflammatory Osteoarthritis 30-80% UK Biobank: 8,223 endometriosis cases, 64,620 immunological disease cases [8]
Mixed-Pattern Psoriasis 30-80% UK Biobank: 8,223 endometriosis cases, 64,620 immunological disease cases [8]

This robust phenotypic association is observed across different study designs, including both retrospective cohort studies that incorporate temporality between diagnoses and cross-sectional analyses for simple association [8]. The consistency across methodological approaches strengthens the evidence for genuine comorbidity rather than ascertainment bias.

Clinical Implications of Phenotypic Associations

The substantial increased risk for specific immune conditions among endometriosis patients has direct clinical relevance. These findings underscore the need for increased clinical vigilance and potential screening protocols for rheumatological and neurological conditions in women diagnosed with endometriosis [8] [10]. The recognition of these associations enables a more comprehensive approach to patient management that addresses the systemic nature of endometriosis beyond reproductive health.

Genetic Architecture Underlying Endometriosis-Immune Condition Associations

Genetic Correlation Analyses

Genetic correlation analyses quantify the shared genetic architecture between traits using genome-wide association study (GWAS) data. These analyses have revealed significant genetic correlations between endometriosis and several immune-mediated conditions, suggesting shared underlying biological pathways [8].

Table 2: Genetic Correlations Between Endometriosis and Immune Conditions

Immune Condition Genetic Correlation (rg) P-value Shared Genetic Loci Biological Pathways
Osteoarthritis 0.28 3.25 × 10-15 BMPR2/2q33.1, BSN/3p21.31, MLLT10/10p12.31 [8] Hyaluronic acid pathway [17]
Rheumatoid Arthritis 0.27 1.5 × 10-5 XKR6/8p23.1 [8] Inflammatory pathways [8]
Multiple Sclerosis 0.09 4.00 × 10-3 Not specified Not specified [8]

The strength of genetic correlation varies across conditions, with the strongest associations observed for osteoarthritis and rheumatoid arthritis, suggesting differential sharing of biological pathways across the immune disease spectrum.

Causal Inference Through Mendelian Randomization

Mendelian randomization (MR) analysis uses genetic variants as instrumental variables to assess causal relationships between exposures and outcomes, reducing confounding inherent in observational studies. Application of this method to endometriosis and immune conditions has provided evidence for potential causal relationships [8].

Experimental Protocol: Two-Sample Mendelian Randomization

  • Instrumental Variable Selection: Genetic variants significantly associated with the exposure (endometriosis) at genome-wide significance (p < 5 × 10-8) are selected as instrumental variables [8] [66].

  • Data Sources: Summary statistics from large-scale GWAS meta-analyses for both exposure (endometriosis) and outcome (immune conditions) [8] [66].

  • LD Clumping: Removal of variants in linkage disequilibrium (r² < 0.001 within 10,000 kb windows) to ensure independence of instruments [66] [67].

  • MR Analysis Methods:

    • Inverse variance weighted (IVW) method as primary analysis [66] [67]
    • Sensitivity analyses: MR-Egger, weighted median, MR-PRESSO [66] [67]
    • Pleiotropy assessment via MR-Egger intercept and MR-PRESSO global test [66] [67]

  • Significance Threshold: False discovery rate (FDR) correction for multiple testing [67].

Application of this methodology revealed a potential causal relationship between endometriosis and rheumatoid arthritis (OR = 1.16, 95% CI = 1.02-1.33) [8]. This suggests that endometriosis may contribute to the development of rheumatoid arthritis through shared biological mechanisms.

G cluster_inputs Input Data cluster_iv Instrumental Variable Selection cluster_analysis MR Analysis Methods GWAS_data GWAS Summary Statistics SNP_filtering SNP Filtering (p < 5×10⁻⁸) GWAS_data->SNP_filtering LD_reference LD Reference Panel LD_clumping LD Clumping (r² < 0.001) LD_reference->LD_clumping SNP_filtering->LD_clumping strength_test Strength Validation (F-statistic > 10) LD_clumping->strength_test IVW Inverse Variance Weighted (Primary) strength_test->IVW sensitivity Sensitivity Analyses (Weighted Median, MR-Egger) strength_test->sensitivity results Causal Estimate (Odds Ratio + CI) IVW->results sensitivity->results pleiotropy Pleiotropy Assessment (MR-Egger intercept, MR-PRESSO) pleiotropy->results interpretation Causal Inference results->interpretation

Diagram 1: Mendelian Randomization Workflow. This diagram illustrates the sequential steps in two-sample Mendelian randomization analysis to assess causal relationships between endometriosis and immune conditions.

The Immune-Mediated Disease Continuum

Advanced multivariate genetic methods have revealed that immune-mediated disorders exist along a continuum from purely autoimmune to purely autoinflammatory, with mixed-pattern diseases occupying intermediate positions. Genomic Structural Equation Modeling (Genomic SEM) analyses of 15 immune-mediated diseases support a four-factor model representing this continuum [68].

Experimental Protocol: Genomic Structural Equation Modeling

  • Data Preparation:

    • Curate GWAS summary statistics for immune-mediated diseases
    • Perform quality control: restrict to HapMap3 SNPs, align reference alleles, filter (MAF > 1%, imputation quality > 0.9) [69]
    • Exclude MHC region due to complex LD structure [69]

  • Genetic Covariance Estimation:

    • Apply multivariable LD score regression to estimate genetic covariance and sampling covariance matrices [69]
    • Convert to liability scale accounting for population prevalence and sample ascertainment [69]

  • Factor Analysis:

    • Conduct exploratory factor analysis (EFA) with promax rotation on genetic covariance matrix [69] [68]
    • Determine number of factors using Kaiser rule, acceleration factor, and optimal coordinates [69]
    • Perform confirmatory factor analysis (CFA) based on EFA results [69] [68]

  • Model Fit Evaluation:

    • Assess model fit using comparative fit index (CFI ≥ 0.9) and standardized root mean squared residual (SRMR ≤ 0.1) [69]
    • Validate model stability through cross-validation (odd/even chromosomes) [69]

This methodology has demonstrated that endometriosis shows genetic relationships with conditions across the autoimmune-autoinflammatory spectrum, suggesting its classification as a disorder with mixed immune dysregulation features [68].

Functional Annotation and Biological Mechanisms

Gene Expression and Pathway Enrichment Analyses

Functional annotation of shared genetic loci provides insights into biological mechanisms connecting endometriosis to immune conditions. Integration of expression quantitative trait loci (eQTL) data from GTEx and eQTLGen databases has identified specific genes affected by shared risk variants [8].

Pathway enrichment analyses across endometriosis, osteoarthritis, and rheumatoid arthritis have revealed seven significantly enriched biological pathways shared across these conditions [8]. Particularly noteworthy is the identification of the hyaluronic acid pathway, which is currently under investigation as a therapeutic target for osteoarthritis and has been suggested as a potential target for endometriosis treatment [17].

Multi-Trait Analysis of GWAS

Multi-trait analysis of GWAS (MTAG) leverages genetic correlations to boost discovery of novel and shared genetic variants across related traits. This approach has been applied to endometriosis and genetically correlated immune conditions to identify additional risk loci with pleiotropic effects [8].

Experimental Protocol: Multi-Trait Analysis

  • Input Data: GWAS summary statistics for endometriosis and genetically correlated traits (osteoporosis, rheumatoid arthritis, multiple sclerosis) [8]

  • Genetic Correlation Estimation: Calculate genetic covariance matrix using LD score regression [8]

  • MTAG Implementation: Apply statistical model that incorporates genetic correlation structure to increase power for variant discovery [8]

  • Variant Annotation: Functionally annotate novel variants using eQTL data, chromatin interaction maps, and epigenetic profiles [8]

This methodology has identified shared variants in loci including BMPR2/2q33.1, BSN/3p21.31, and MLLT10/10p12.31 that contribute to both endometriosis and osteoarthritis risk [8].

G cluster_immune Immune Condition Continuum Autoimmune Autoimmune Disorders (e.g., Coeliac Disease) Mixed Mixed Pattern Disorders (e.g., Rheumatoid Arthritis) Autoimmune->Mixed Autoinflammatory Autoinflammatory Disorders (e.g., Osteoarthritis) Mixed->Autoinflammatory Endometriosis Endometriosis Shared_Genetics Shared Genetic Architecture Endometriosis->Shared_Genetics Shared_Genetics->Autoimmune Shared_Genetics->Mixed Shared_Genetics->Autoinflammatory Biological_Pathways Shared Biological Pathways • Hyaluronic Acid Pathway • Inflammatory Signaling Shared_Genetics->Biological_Pathways

Diagram 2: Immune Condition Continuum and Endometriosis. This diagram illustrates the genetic relationships between endometriosis and disorders across the autoimmune-autoinflammatory spectrum, reflecting shared genetic architecture and biological pathways.

Implications for Sub-phenotype Stratification in Endometriosis

Toward Molecular Classification Systems

The established genetic correlations between endometriosis and specific immune conditions provide a biological foundation for redefining endometriosis sub-phenotypes. Current classification systems (rASRM, ENZIAN, AAGL) are primarily based on surgical observations and have limited correlation with symptoms or treatment outcomes [12]. Integration of genetic data with clinical phenotypes enables a more biologically meaningful stratification approach.

Genetic studies have revealed that different endometriosis manifestations (peritoneal, ovarian, deep infiltrating) may represent distinct molecular subtypes rather than a disease continuum [12]. The development of the Endometriosis Integrated Biology Framework through initiatives like the WERF EPHect project aims to standardize data collection and enable robust sub-phenotyping across 60 centers in 24 countries [17].

Non-Genetic Biomarkers in Sub-phenotyping

Beyond genetic markers, epigenetic factors such as DNA methylation (DNAm) contribute to endometriosis risk and heterogeneity. Methylation risk score (MRS) modeling has demonstrated that DNAm captures disease-associated variance independently of common genetic variants [65].

Experimental Protocol: Methylation Risk Score Development

  • Sample Processing:

    • Collect endometrial tissue samples from cases and controls
    • Perform DNA extraction and bisulfite conversion
    • Conduct methylation profiling using array-based or sequencing approaches

  • Quality Control and Covariate Adjustment:

    • Remove low-quality probes and samples
    • Account for covariates: age, institution/batch effects, genetic ancestry, menstrual cycle phase [65]
    • Perform surrogate variable analysis to remove hidden technical variation [65]

  • Variance Partitioning:

    • Estimate proportion of endometriosis variance captured by DNAm using omics residual maximum likelihood (OREML) [65]
    • Calculate variance explained by common genetic variants using genomic relationship matrix (GRM) [65]
    • Assess independent contribution of DNAm by including both ORM and GRM in model [65]

  • MRS Construction:

    • Train models using machine learning approaches on discovery dataset
    • Validate in independent cohorts using area under receiver-operator curve (AUC) [65]
    • Combine with polygenic risk scores to enhance predictive power [65]

This approach has achieved an AUC of 0.6748 using 746 DNAm sites, with combined MRS and PRS performance exceeding PRS alone [65], highlighting the value of integrating multiple molecular data types for improved sub-phenotyping.

Research Reagent Solutions

Table 3: Essential Research Reagents and Resources for Endometriosis-Immune Genetics Research

Category Specific Resource Application Key Features
Biobanks UK Biobank [8] Large-scale genetic and phenotypic data 8,223 endometriosis cases, 64,620 immune disease cases
Analysis Tools Genomic SEM [69] [68] Multivariate genetic analysis Models latent factors from genetic covariance matrices
LD Score Regression [69] [68] Genetic correlation estimation Quantifies shared genetic architecture using summary statistics
TwoSampleMR [66] [67] Mendelian randomization R package for causal inference using genetic instruments
Data Resources GTEx/eQTLGen [8] Functional annotation Expression quantitative trait loci data for gene mapping
FinnGen Consortium [67] Outcome data 195 PVFS cases, 382,198 controls for comorbidity studies
Standardization Tools WERF EPHect [17] Phenotype standardization Harmonized data collection across 60 centers in 24 countries

This comparative analysis demonstrates substantial genetic correlations and potential causal links between endometriosis and specific immune conditions, particularly osteoarthritis and rheumatoid arthritis. These findings support the reclassification of endometriosis as a systemic disorder with significant immunological components rather than solely a gynecological condition.

The integration of genetic data with clinical phenotypes provides a powerful framework for developing molecularly defined endometriosis sub-phenotypes. This approach has profound implications for stratified medicine, enabling targeted therapeutic development based on shared biological pathways across conditions. The hyaluronic acid pathway, identified as shared between endometriosis and osteoarthritis, represents a promising candidate for drug repurposing or novel therapeutic development.

Future research directions should include expanded multi-omic integration, development of validated genetic sub-phenotyping algorithms, and clinical trials targeting shared pathways across endometriosis and its comorbid immune conditions. These advances will ultimately enable more precise diagnosis and personalized treatment approaches for endometriosis patients based on their specific genetic and immunological profiles.

Endometriosis, a complex gynecological disorder affecting approximately 10% of reproductive-aged individuals, demonstrates significant heterogeneity in clinical presentation, surgical findings, and molecular underpinnings. This technical review synthesizes current research on the correlation between molecular subtypes and their corresponding surgical phenotypes and lesion characteristics. We examine how multi-omics approaches—including transcriptomics, genomics, and immunophenotyping—reveal distinct molecular patterns across different lesion types and disease stages. By integrating molecular signatures with surgical anatomical data, this analysis provides a framework for sub-phenotype stratification that transcends traditional classification systems. The findings highlight promising avenues for precision diagnostics and targeted therapeutic development, ultimately addressing critical unmet needs in endometriosis management.

Endometriosis is traditionally defined by the presence of endometrial-like tissue outside the uterine cavity, but this histological definition belies extraordinary complexity in its clinical manifestations and underlying biology [70]. The established surgical classification systems, including the revised American Society for Reproductive Medicine (rASRM) criteria, categorize disease based on anatomical location and extent yet correlate poorly with symptoms and treatment outcomes [27]. This limitation stems from their failure to capture the molecular heterogeneity that likely drives phenotypic diversity.

The integration of molecular profiling with detailed surgical and pathological characterization represents a paradigm shift in endometriosis research [27]. Emerging evidence demonstrates that different lesion types—superficial peritoneal disease (SPD), ovarian endometriomas (OMA), and deep infiltrating endometriosis (DIE)—exhibit distinct transcriptional programs, immune microenvironments, and genetic alterations [70] [71] [72]. These molecular differences potentially underlie variations in disease behavior, therapeutic response, and associated comorbidities.

This review synthesizes current evidence linking molecular subtypes to surgical and lesion characteristics, providing a foundation for developing precision-based approaches to endometriosis management. By examining the molecular landscape across different disease manifestations, we aim to establish a framework for sub-phenotype stratification that can inform both clinical decision-making and therapeutic development.

Molecular Classification of Endometriosis Lesions

Transcriptomic Signatures Across Lesion Types

Comprehensive transcriptomic analyses have revealed distinct gene expression patterns correlating with different endometriosis lesion types. Database-driven studies comparing peritoneal lesions, ovarian endometriomas, and deep infiltrating lesions demonstrate significant molecular heterogeneity [72]. For instance, Secreted frizzled-related protein 2 (SFRP2) has been identified as a gene highly expressed across endometriosis lesions compared to eutopic endometrium, with potential as both a histological border marker and serum biomarker [72].

Bioinformatics approaches have further refined our understanding of lesion-specific biology. A study integrating data from GSE51981, GSE6364, and GSE7305 datasets identified ten hub genes (GZMB, PRF1, KIR2DL1, KIR2DL3, KIR3DL1, KIR2DL4, FGB, IGFBP1, RBP4, and PROK1) significantly correlated with immune infiltration patterns in endometriosis [71]. These genes demonstrate variable expression across different lesion types, suggesting distinct immune interactions in various pathological contexts.

Table 1: Molecular Characteristics of Endometriosis Lesion Types

Lesion Type Key Genetic Alterations Transcriptomic Features Immune Microenvironment
Superficial Peritoneal Fewer driver mutations Inflammatory signature dominant M1 macrophage predominance, higher NK cell activity
Ovarian Endometrioma KRAS mutations (19-47%), ARID1A mutations Proliferative and steroidogenic pathways Mixed M1/M2 macrophages, plasma cell infiltration
Deep Infiltrating KRAS, PTEN, ARID1A mutations Invasion and neural regulation programs M2 macrophage polarization, reduced CD8+ T cells

Genomic and Epigenetic Landscape

Beyond transcriptomic variation, endometriosis lesions demonstrate distinct genomic and epigenetic alterations. Recurrent somatic mutations in cancer-associated genes including KRAS, PTEN, and ARID1A occur with varying frequency across different lesion types [73]. KRAS mutations are particularly common in ovarian endometriomas and deep infiltrating lesions, with reported frequencies ranging from 19.4% to 46.7% [73]. These mutations promote cellular proliferation and differentiation through enhanced GDP/GTP exchange and reduced GTPase activity.

Epigenetic modifications further contribute to molecular heterogeneity. DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) show increased expression in endometrial lesions, altering the expression of genes regulating cell growth and apoptosis [73]. The ARID1A tumor suppressor gene, a key component of the SWI/SNF chromatin remodeling complex, demonstrates mutations that are distributed differentially across lesion types and often co-occur with alterations in the PI3K/Akt pathway [73].

Integration of Molecular and Surgical Phenotypes

Clinico-Molecular Classification Systems

Traditional classification systems based solely on surgical appearance fail to predict symptoms or treatment response. The rASRM system, while widely used, correlates poorly with pain experience or fertility outcomes [70] [74]. More recent approaches integrate molecular features with anatomical findings to create more biologically relevant stratification systems.

One novel classification system categorizes endometriosis based on reproductive organ involvement ("genital") and non-reproductive organ involvement ("extragenital") with four stages of severity [27]. This system incorporates adenomyosis (found in 32-64% of endometriosis patients) and acknowledges that different locations and niche environments may contribute to altered pathophysiology of distinct disease types [27].

Table 2: Integrated Surgical-Molecular Classification Framework

Surgical Phenotype Molecular Subtype Clinical Correlations Therapeutic Implications
Minimal/Mild (Stage I-II) Immune-inflammatory dominant Variable pain, milder symptoms May respond to immunomodulation
Moderate (Stage III) Hormone-resistant, fibrotic Increasing pain, fertility issues May require combination therapy
Severe (Stage IV) Proliferative, invasive, neural Chronic pain, multifocal symptoms Often requires multimodality treatment
Extragenital Site-specific molecular adaptations Organ-specific dysfunction Needs organ-specific approaches

Molecular Correlates of Surgical Complexity

Molecular features directly correspond to surgical complexity and disease behavior. KRAS mutations correlate with more severe anatomical manifestations and increased surgical complexity, suggesting these mutations contribute to lesion growth, invasion, and spreading [73]. Additionally, specific molecular subtypes identified through bioinformatics approaches demonstrate varying degrees of immune cell infiltration, angiogenesis, and fibrotic activity, which manifest as different surgical appearances and adhesion patterns [71].

Deep infiltrating endometriosis exhibits molecular signatures of invasion and neural regulation, reflecting its clinical behavior [70] [73]. These lesions show elevated expression of genes involved in extracellular matrix remodeling, epithelial-mesenchymal transition, and axon guidance, corresponding to their infiltrative nature and association with pain symptoms [70].

Experimental Methodologies for Subtype Characterization

Transcriptomic Profiling Workflows

Comprehensive molecular subtyping requires standardized approaches for sample processing and data analysis. The following workflow details methodology for identifying molecular subtypes correlated with surgical phenotypes:

Tissue Collection and Processing:

  • Obtain surgical specimens with detailed anatomical documentation and lesion classification
  • Snap-freeze tissues in liquid nitrogen within 10 minutes of excision [72]
  • Preserve adjacent portions for histological confirmation of lesion type
  • Annotate thoroughly with clinical metadata: age, cycle phase, hormonal medication, symptoms [72]

RNA Extraction and Quality Control:

  • Extract total RNA using column-based methods with DNase treatment
  • Assess RNA integrity numbers (RIN > 7.0) using bioanalyzer systems
  • Quantify RNA using fluorometric methods for accuracy

Gene Expression Profiling:

  • Utilize microarray analysis (e.g., Affymetrix Human Genome U133 Plus 2.0 Array) [72]
  • Alternatively, employ RNA sequencing for transcriptome-wide coverage
  • Incorporate appropriate controls: eutopic endometrium, healthy peritoneum

Bioinformatic Analysis:

  • Preprocess data: background correction, normalization, batch effect removal [71]
  • Perform differential expression analysis using limma package (FDR < 0.05, |log2FC| > 0.3) [71]
  • Conduct weighted gene co-expression network analysis (WGCNA) to identify modules [71]
  • Execute immune cell deconvolution using CIBERSORT algorithm [71]
  • Validate findings in independent cohorts when possible

G start Surgical Specimen Collection process1 Tissue Processing & RNA Extraction start->process1 process2 Quality Control (RIN > 7.0) process1->process2 process2->process1 Fail process3 Expression Profiling (Microarray/RNA-seq) process2->process3 Pass process4 Bioinformatic Analysis process3->process4 process5 Molecular Subtype Identification process4->process5 end Surgical-Molecular Correlation process5->end

Experimental Workflow for Molecular Subtyping

Immune Microenvironment Characterization

The immune landscape represents a critical component of endometriosis molecular subtypes. Detailed methodologies for immune characterization include:

Immune Cell Infiltration Analysis:

  • Apply CIBERSORT algorithm to convert gene expression matrices into immune cell fractions [71]
  • Filter samples with p-value < 0.05 for reliable deconvolution
  • Generate immune cell infiltration matrix for correlation with clinical variables

Flow Cytometry Validation:

  • Prepare single-cell suspensions from fresh tissue specimens
  • Stain with antibody panels targeting T cells (CD3, CD4, CD8), macrophages (CD68, CD163)
  • Analyze using multiparameter flow cytometry with appropriate isotype controls

Spatial Localization:

  • Perform multiplex immunofluorescence on formalin-fixed paraffin-embedded sections
  • Use markers for immune cells (CD45, CD68), endothelial cells (CD31)
  • Analyze spatial relationships using automated image analysis platforms

Signaling Pathways in Endometriosis Subtypes

The molecular heterogeneity of endometriosis lesions reflects differential activation of key signaling pathways across subtypes. These pathways not only drive lesion establishment and maintenance but also correlate with specific surgical phenotypes and clinical behaviors.

G estrogen Estrogen Signaling (ERβ/ERα imbalance) pi3k PI3K/Akt Pathway (PTEN mutations) estrogen->pi3k Crosstalk wnt Wnt/β-catenin (SFRP2 dysregulation) estrogen->wnt Activation inflammation NF-κB Inflammation (Cytokine production) estrogen->inflammation Amplification ovarian Ovarian Endometriomas: Proliferative Dominant estrogen->ovarian Strong pi3k->inflammation Enhancement pi3k->ovarian Strong wnt->inflammation Modulation deep Deep Infiltrating: Invasion Dominant wnt->deep Strong peritoneal Peritoneal Lesions: Inflammatory Dominant inflammation->peritoneal Strong

Pathway Activation Across Molecular Subtypes

The PI3K/Akt pathway demonstrates particular importance in ovarian endometriomas, where PTEN mutations and subsequent p-Akt elevation drive cellular survival and proliferation [70] [73]. Concurrently, Wnt/β-catenin signaling shows enhanced activity in deep infiltrating lesions, facilitated by dysregulation of mediators like SFRP2 [72]. These pathway-specific activations translate to distinct clinical phenotypes, with PI3K/Akt-driven lesions forming expansive ovarian cysts and Wnt-driven lesions demonstrating infiltrative behavior.

The inflammatory NF-κB pathway represents a common node across subtypes but shows variable activation levels and downstream effects [70]. In peritoneal lesions, NF-κB-driven cytokine production creates a inflammatory microenvironment, while in deep disease, it interfaces with neural signaling to promote pain and further invasion [70] [51]. This pathway complexity underscores the need for subtype-specific therapeutic targeting rather than uniform approaches across all endometriosis manifestations.

Research Reagent Solutions

Advancing endometriosis subtyping research requires specialized reagents and tools optimized for characterizing the molecular and cellular features of different lesions. The following table details essential research reagents for investigating endometriosis molecular subtypes.

Table 3: Essential Research Reagents for Endometriosis Subtyping Studies

Reagent Category Specific Examples Research Application Technical Considerations
RNA Preservation RNAlater, Snap-freezing Preserve RNA integrity Process within 10 minutes [72]
Gene Expression Microarrays (Affymetrix), RNA-seq kits Transcriptomic profiling Normalize for batch effects [72]
Immune Cell Markers CD45, CD68, CD163, CD3, CD56 Immune microenvironment Combine with spatial analysis [71]
Signaling Antibodies p-Akt, NF-κB, β-catenin Pathway activation Quantify with digital pathology
Cell Isolation Collagenase digestion kits Single-cell preparations Optimize for stromal/epithelial separation

Clinical Translation and Therapeutic Implications

Diagnostic Applications

Molecular subtyping offers significant potential for addressing diagnostic challenges in endometriosis. The current gold standard requiring surgical visualization and histological confirmation creates an average diagnostic delay of 7-11 years [27]. Molecular signatures identified in easily accessible tissues (e.g., endometrium, blood) could enable non-invasive diagnosis and stratification.

The EndometDB database represents a significant resource in this translation, incorporating expression data from 115 patients and 53 controls with over 24,000 genes linked to clinical features [72]. This integrated approach allows correlation of molecular markers with disease stages, menstrual cycle phase, hormonal medication, and endometriosis lesion types, facilitating biomarker discovery.

Targeted Therapeutic Approaches

Molecular stratification enables moving beyond empirical hormonal suppression toward mechanism-based treatments. Current medical therapies, including progestins and GnRH analogs, show unpredictable individual responses, with 25-34% of patients exhibiting poor or no response [27]. Understanding the molecular basis of this variation could guide treatment selection.

Subtype-specific therapeutic strategies emerge from pathway analysis:

  • PI3K/Akt-driven lesions: Potential application of PI3K inhibitors, particularly in cases with PTEN alterations [73]
  • Immune-dominant subtypes: Immunomodulatory approaches targeting macrophage polarization or NK cell function [70] [51]
  • Estrogen signaling variants: Selective estrogen receptor modulators or aromatase inhibitors tailored to ERβ/ERα ratios [70]

Clinical trial design must evolve to incorporate molecular stratification, potentially enriching for populations most likely to respond to targeted agents based on their lesion molecular profile rather than solely on surgical stage.

Integration of molecular subtyping with detailed surgical and lesion characteristics represents a transformative approach to endometriosis classification. The established correlation between specific genetic alterations, transcriptional programs, and surgical phenotypes provides a biologically relevant framework that surpasses traditional anatomical staging alone. This refined understanding of endometriosis heterogeneity has profound implications for both diagnostic strategy and therapeutic development.

Future research priorities include validating molecular subtypes in prospective cohorts, developing standardized sampling protocols across centers, and establishing bioinformatic pipelines for clinical translation. The ongoing development of large-scale databases integrating multi-omics data with detailed clinical phenotypes will be essential to these efforts. Additionally, exploration of how molecular subtypes correspond to treatment responses across diverse patient populations will be critical for advancing personalized therapeutic approaches.

As our understanding of endometriosis sub-phenotypes matures, clinical practice must evolve to incorporate molecular characterization alongside traditional surgical assessment. This integration promises to finally address the longstanding challenges of delayed diagnosis, variable treatment response, and disease recurrence that have plagued endometriosis management for decades.

Conclusion

Sub-phenotype stratification represents a fundamental and necessary evolution in endometriosis genetic research, directly addressing the critical bottleneck of disease heterogeneity. By moving beyond a monolithic view of the disease, this approach has successfully increased the power of genetic association studies, leading to the discovery of novel, subtype-specific risk loci and revealing a shared genetic basis with comorbid conditions like rheumatoid arthritis and osteoarthritis. The methodological framework—from EHR-driven clustering to pathway analysis—provides a replicable blueprint for deconstructing other complex diseases. For the future, this refined understanding mandates the collection of deep, standardized phenotypic data in large biobanks. The ultimate translational impact lies in leveraging these insights to develop stratified medicine approaches, including non-invasive diagnostic biomarkers, polygenic risk scores for specific sub-phenotypes, and the repurposing of therapies targeting shared biological pathways across conditions.

References